var title_f15_58_16288="TEE color Doppler severe AR";
var content_f15_58_16288=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Color flow Doppler of severe aortic regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 291px; height: 220px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The color flow Doppler image is obtained from the transverse view of a transesophageal echocardiogram. The outflow tract is completely occupied by the aortic regurgitant color flow jet (AR jet); when the jet exceeds 65 percent of the left ventricular outflow tract (LVOT) width, the regurgiation is judged severe.",
"    <div class=\"footnotes\">",
"     Ao: aorta; LV: left ventricle.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_58_16288=[""].join("\n");
var outline_f15_58_16288=null;
var title_f15_58_16289="Hematocolpos";
var content_f15_58_16289=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diagram of agenesis of the lower vagina with normal uterus and cervix, and resulting blood-filled upper vagina",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 391px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"     </p>",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_58_16289=[""].join("\n");
var outline_f15_58_16289=null;
var title_f15_58_16290="Dibucaine: Pediatric drug information";
var content_f15_58_16290=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dibucaine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35410?source=see_link\">",
"    see \"Dibucaine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/23/2420?source=see_link\">",
"    see \"Dibucaine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F159194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nupercainal&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1057807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Topical",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Local Anesthetic, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1057804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35410?source=see_link\">",
"      see \"Dibucaine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rectal: Hemorrhoids: Administer each morning, evening, and after each bowel movement",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical: Apply gently to the affected areas; no more than 30 g for adults or 7.5 g for children should be used in any 24-hour period",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F159183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical: 1% [10 mg/g] (30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nupercainal&reg;: 1% [10 mg/g] (30 g, 60 g) [contains sodium bisulfite]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F159170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1057810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rectal: Insert ointment into rectum using a rectal applicator",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical: Apply gently to affected areas; do not use near the eyes or over denuded surfaces or blistered areas",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1057809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fast, temporary relief of pain and itching due to hemorrhoids, minor burns, other minor skin conditions",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F159206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema, contact dermatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Burning",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1057814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dibucaine, other amide-type anesthetics, or any component",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1057803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain sulfites which may cause allergic reactions in susceptible individuals",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F159177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14207761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dibucaine is not absorbed systemically following topical administration on intact skin. Systemic absorption would be required in order for dibucaine to cross the placenta and reach the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1057802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1057812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Within 15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 2-4 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1057813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Poor through intact skin, but well absorbed through mucous membranes and excoriated skin",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13225 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-5A6B11C91F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_58_16290=[""].join("\n");
var outline_f15_58_16290=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159194\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057807\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057804\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159183\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159170\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057810\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057809\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159206\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057814\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057803\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299181\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159177\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14207761\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057802\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057812\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057813\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13225\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13225|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35410?source=related_link\">",
"      Dibucaine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/23/2420?source=related_link\">",
"      Dibucaine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_58_16291="Bethanechol: Pediatric drug information";
var content_f15_58_16291=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"16\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bethanechol: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?24/56/25476?source=see_link\">",
"    see \"Bethanechol: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/14/15588?source=see_link\">",
"    see \"Bethanechol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F140932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Urecholine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F140933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Duvoid&reg;;",
"     </li>",
"     <li>",
"      PHL-Bethanechol;",
"     </li>",
"     <li>",
"      PMS-Bethanechol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1056843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Cholinergic Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1056838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/56/25476?source=see_link\">",
"      see \"Bethanechol: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Abdominal distention or urinary retention: 0.6 mg/kg/day divided 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastroesophageal reflux: 0.1-0.2 mg/kg/dose or 3 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose given 30 minutes to 1 hour before each meal to a maximum of 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 10-50 mg 2-4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F140915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as chloride: 5 mg, 10 mg, 25 mg, 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Urecholine&reg;: 5 mg, 10 mg, 25 mg, 50 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F140899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1056846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer on an empty stomach to reduce nausea and vomiting",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1056845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of nonobstructive urinary retention and retention due to neurogenic bladder; gastroesophageal reflux",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F140965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Bethanechol may be confused with betaxolol",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F140963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension, tachycardia, flushed skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache, malaise, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, belching, borborygmi, colicky pain, diarrhea, nausea, vomiting, salivation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary urgency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Lacrimation, miosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthmatic attacks, bronchial constriction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1056851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bethanechol chloride or any component; do not use in patients with mechanical obstruction of the GI or GU tract; do not use in patients with hyperthyroidism, peptic ulcer, bronchial asthma, or cardiac disease",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5540284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the adverse/toxic effect of Cholinergic Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction. Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F140911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5357780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1056837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates cholinergic receptors in the smooth muscle of the urinary bladder and GI tract resulting in increased peristalsis, increased GI and pancreatic secretions, bladder muscle contraction, and increased ureteral peristaltic waves",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1056849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Oral: 30-90 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Oral: Up to 6 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1056850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Variable",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolic fate and excretion have not been determined",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1056842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/14/15588?source=see_link\">",
"      see \"Bethanechol: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dizziness, lightheadedness, or fainting may occur especially when getting up from a lying position",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F11313499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 1 mg/mL solution may be made with tablets. Crush twelve 10 mg tablets in a mortar and reduce to a fine powder. Add small portions of sterile water and mix to a uniform paste; mix while adding sterile water in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     120 mL; transfer to a calibrated bottle, rinse mortar with sterile water, and add quantity of sterile water sufficient to make 120 mL. Label &ldquo;shake well&rdquo; and &ldquo;refrigerate&rdquo;. Stable for 30 days (Schlatter, 1997).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 5 mg/mL suspension may be made with tablets and either a 1:1 mixture of Ora-Plus&reg; and Ora-Sweet&reg; or Ora-Plus&reg; and Ora-Sweet&reg; SF or 1:4 concentrated cherry syrup and simple syrup, NF mixture. Crush twelve 50 mg tablets in a mortar and reduce to a fine powder. Add small portions of chosen vehicle and mix to a uniform paste; mix while  adding the vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label &ldquo;shake well&rdquo; and &ldquo;refrigerate&rdquo;. Stable for 60 days refrigerated (preferred) or at room temperature (Allen, 1998; Nahata, 2004).",
"    </p>",
"    <div class=\"reference\">",
"     Allen LV Jr and Erickson MA, \"Stability of Bethanechol Chloride, Pyrazinamide, Quinidine Sulfate, Rifampin, and Tetracycline Hydrochloride in Extemporaneously Compounded Oral Liquids,\"",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 1998, 55(17):1804-9.",
"     <span class=\"pubmed-id\">",
"      9775343",
"     </span>",
"    </div>",
"    <div class=\"reference\">",
"     Nahata MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"    <div class=\"reference\">",
"     Schlatter JL and Saulnier JL, \"Bethanechol Chloride Oral Solutions: Stability and Use in Infants,\"",
"     <i>",
"      Ann Pharmacother",
"     </i>",
"     , 1997, 31(3):294-6.",
"     <span class=\"pubmed-id\">",
"      9066934",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13061 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-90821EDB07-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_58_16291=[""].join("\n");
var outline_f15_58_16291=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140932\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140933\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056843\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056838\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140915\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140899\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056846\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056845\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140965\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140963\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056851\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298859\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5540284\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140911\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5357780\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056837\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056849\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056850\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056842\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11313499\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13061\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13061|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/56/25476?source=related_link\">",
"      Bethanechol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/14/15588?source=related_link\">",
"      Bethanechol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_58_16292="Carotid angiograms in ICNSV";
var content_f15_58_16292=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F52006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F52006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 504px\">",
"   <div class=\"ttl\">",
"    Carotid angiograms in primary angiitis of the central nervous system",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 484px; height: 254px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel: An anteroposterior view of a right carotid angiogram in a patient with primary angiitis of the central nervous system (PACNS) reveals focal narrowing of multiple vessels in both the anterior and posterior systems. Right panel: A lateral view of a right carotid angiogram in PACNS demonstrates beading and multiple irregularities both proximally and distally.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Leonard H Sigal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_58_16292=[""].join("\n");
var outline_f15_58_16292=null;
var title_f15_58_16293="Mitotane: Drug information";
var content_f15_58_16293=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mitotane: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?28/59/29620?source=see_link\">",
"    see \"Mitotane: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F197498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lysodren&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F197499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Lysodren&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F197517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F197502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Adrenocortical carcinoma:",
"     </b>",
"     Oral: Start at 2-6 g/day in 3-4 divided doses, then increase incrementally to 9-10 g/day in 3-4 divided doses (maximum tolerated range: 2-16 g/day, usually 9-10 g/day; maximum dose studied: 18-19 g/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cushing&rsquo;s syndrome (unlabeled use):",
"     </b>",
"     Oral: Initial dose: 500 mg 3 times/day; maximum dose: 3000 mg 3 times/day (Biller, 2008)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F197511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Adrenocortical carcinoma (unlabeled use):",
"     </b>",
"     Oral: 1-2 g/day in divided doses, increasing gradually to a maximum of 5-7 g/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F197503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F197504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose may need to be decreased in patients with liver disease.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F7310928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe side effects: Reduce dose until achieve a maximum tolerated dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Significant neuropsychiatric adverse effects: Withhold treatment for at least 1 week and restart at a lower dose (Allolio, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F197481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lysodren&reg;: 500 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F197467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7310929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer in 3-4 divided doses/day. Do not crush tablets; wear gloves when handling; avoid exposure to crushed or broken tablets.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F197482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of inoperable adrenocortical carcinoma",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F197514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of Cushing's syndrome",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F197524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Mitotane may be confused with mitoMYcin, mitoXANtrone",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F197515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The majority of adverse events are dose-dependent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: CNS depression (32%), lethargy/somnolence (25%), dizziness/vertigo (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Skin rash (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia (24%), nausea (39%), vomiting (37%), diarrhea (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (5%), confusion (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle tremor (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Aches (generalized), adrenal insufficiency, albuminuria, anemia, ataxia, autoimmune hepatitis, bleeding time prolonged, blurred vision, cataract, diplopia, flushing, GGT increased, gynecomastia, hematuria, hemorrhagic cystitis,  hormone binding globulins increased, hypercholesterolemia, hyperpyrexia, hypertension, hypertriglyceridemia, lens opacity, leukopenia, macular edema, memory decreased, mucositis, myalgia, neuropathy, orthostatic hypotension, primary hypogonadism, protein bound iodine decreased, thrombocytopenia, thyroid function tests altered, toxic retinopathy, transaminases increased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F197486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to mitotane or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F197471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal insufficiency:",
"     <b>",
"      [U.S. Boxed Warning]: Because the primary action of mitotane is through adrenal suppression, discontinue mitotane temporarily with onset of shock or severe trauma; administer appropriate steroid coverage.",
"     </b>",
"     Patients treated with mitotane may develop adrenal insufficiency; replacement therapy may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurotoxicity: Long-term (&gt;2 years) use may lead to brain damage or functional impairment; observe patients for neurotoxicity (behavioral and neurological). Other CNS adverse effects, including lethargy, sedation, and vertigo may occur; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; metabolism may be decreased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Metastatic masses: Surgically remove tumor tissues from metastatic masses prior to initiation of treatment; rapid cytotoxic effect may cause tumor hemorrhage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Corticosteroid replacement therapy: Steroid replacement with glucocorticoid, and sometimes mineralocorticoid, is necessary. It has been recommended that steroid replacement therapy be initiated at the start of therapy, rather than waiting for evidence of adrenal insufficiency. Because mitotane can increase the metabolism of exogenous steroids, higher than usual replacement steroid doses may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: The manufacturer recommends initiating treatment within a hospital environment until a stabilized dose is achieved. Continue treatment as long as clinical benefit (clinical status maintenance or slowed growth of metastatic lesion) is observed. Clinical benefit is usually observed within 3 months at maximum tolerated dose, although 10% of patients may require more than 3 months for benefit. Continuous treatment at the maximum tolerated dose is generally the best approach. Some patients have been treated intermittently, restarting when severe symptoms reappear, although often response is no longer observed after 3 or 4 courses of intermittent treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning] Should be administered under the supervision of an experienced cancer chemotherapy physician.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F197476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Mitotane may decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the therapeutic effect of Mitotane. Management: Consideration should be given to discontinuing spironolactone prior to initiating mitotane in order to eliminate the risk of therapeutic failure of the mitotane.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F197495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F197478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3030727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Animal reproduction studies have not been conducted. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F197507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3030729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F197487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Lysodren Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $512.58",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3030731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adrenal function; neurologic assessments (including behavioral) at regular intervals with chronic (&gt;2 years) use",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F197488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Lisodren (BR);",
"     </li>",
"     <li>",
"      Lysodren (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, IE, IT, KP, MT, NL, NO, PL, PT, RU, SE, SK, TR, TW);",
"     </li>",
"     <li>",
"      Opeprim (JP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F197470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adrenolytic agent which causes adrenal cortical atrophy; affects mitochondria in adrenal cortical cells and decreases production of cortisol; also alters the peripheral metabolism of steroids",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F197485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: ~5% to 40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Stored mainly in fat tissue but is found in all body tissues",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic and other tissues",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 18-159 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 3-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~10%, as metabolites); feces (1% to 17%, as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Allolio B and Fassnacht M, &ldquo;Clinical Review: Adrenocortical Carcinoma: Clinical Update,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2006, 91(6):2027-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/58/16293/abstract-text/16551738/pubmed\" id=\"16551738\" target=\"_blank\">",
"        16551738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Biller BM, Grossman AB, Stewart PM, et al, &ldquo;Treatment of Adrenocorticotropin-Dependent Cushing's Syndrome: A Consensus Statement,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2008, 93(7):2454-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/58/16293/abstract-text/18413427/pubmed\" id=\"18413427\" target=\"_blank\">",
"        18413427",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boscaro M, Barzon L, Fallo F, et al, &ldquo;Cushing's Syndrome,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2001, 357(9258):783-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/58/16293/abstract-text/11253984/pubmed\" id=\"11253984\" target=\"_blank\">",
"        11253984",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      De Leon DD, Lange BJ, Walterhouse D, et al, &ldquo;Long-Term (15 years) Outcome in an Infant with Metastatic Adrenocortical Carcinoma,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2002, 87(10):4452-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/58/16293/abstract-text/12364417/pubmed\" id=\"12364417\" target=\"_blank\">",
"        12364417",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kasperlik-Zaluska AA,  &ldquo;Clinical Results of the Use of Mitotane for Adrenocortical Carcinoma,&rdquo;",
"      <i>",
"       Braz J Med Biol Res",
"      </i>",
"      , 2000, 33(10):1191-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/58/16293/abstract-text/11004719/pubmed\" id=\"11004719\" target=\"_blank\">",
"        11004719",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Newell-Price J, Bertagna X, Grossman AB, et al, &ldquo;Cushing&rsquo;s Syndrome,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2006, 367(9522):1605-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/58/16293/abstract-text/16698415/pubmed\" id=\"16698415\" target=\"_blank\">",
"        16698415",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodriguez-Galindo C, Figueiredo BC, Zambetti GP, et al, &ldquo;Biology, Clinical Characteristics, and Management of Adrenocortical Tumors in Children,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2005, 45(3):265-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/58/16293/abstract-text/15747338/pubmed\" id=\"15747338\" target=\"_blank\">",
"        15747338",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Terzolo M, Angeli A, Fassnacht M, et al, &ldquo;Adjuvant Mitotane Treatment for Adrenal Carcinoma,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 356(23): 2372-80.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9659 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-9A4DD99832-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_58_16293=[""].join("\n");
var outline_f15_58_16293=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709093\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197498\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197499\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197517\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197502\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197511\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197503\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197504\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7310928\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197481\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197467\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7310929\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197482\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197514\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197524\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197515\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197486\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197471\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299722\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197476\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197495\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197478\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3030727\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197507\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3030729\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197487\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3030731\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197488\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197470\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197485\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9659\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9659|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/59/29620?source=related_link\">",
"      Mitotane: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_58_16294="Retinal layers";
var content_f15_58_16294=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68854&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68854&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 590px\">",
"   <div class=\"ttl\">",
"    Retinal layers",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 570px; height: 422px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGmAjoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK5z/AISy1/4WJ/wiHkT/AG7+yv7W87jy/L87ytvXO7PPTGKAOjorjh8QdFtYdRm1i8tbKO11R9LTZKZmlkVVONqrkN83KgHAGc1k6l8YfC+n6tpkc97D/Y9/ZTXcepByUzFJ5ZQIFyTnd9NpoA9HorjLP4k+HLzxpbeGbW7aa9ubJL+CZADDKj5KqrA53bRu6YweueK7OgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACijNFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUlAC0lLRQAUUUUAJRRS0AJS0UUAFee+KPAms33xEj8XeHfEsGkXY0oaU0U2mi6DJ5xlLZ8xcHJUdO3vXoVFAHivif4daxo16uu+F5J9R1oeILvV4Vjgh2wpcQLG8bLLMgfhBhgwIz93ipfh58KNQ03RNFk1q+jh1C30m/06a3jjEig3M7S7t+4A7QwBAGCe9ewzuY4ZHAyVUtj6Cm2cxuLSCYjaZEDYHbIzWftY8/s+tr/IfK7cx594U+Gtx4b17w9qNpriuNO0WPRLmJ7P8A4+Y0curqd/7s7jz97jjjrXo9FFaCCijNFABRRRQAUUUUAFFFFABRSUtACUtFFACUtJRQAtFFFABRRRQAUlLRQAlLSUtABRRSUAFLRRQAUUUUAFFFFABSUtFABRRRQAUUUUAFFFFABSUtFABRRSUALSUtFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACUtFJQAtFFFABRRRQAUUUUAFFFMmljhjLzOqIO7HAoAfRVJbqW4DfZISADgPNlQfcDqf0qO5lWJwLrUkhLdEG1CfpnJp2Ic1ui3ef8ek/+438qi0r/AJBdn/1xT+QqjK1p9nlAurlyVJz5jn+XFQWV1YpZQK2qGCTYoIeUDBx0AauJx/2xf4X+aL9pal037nQUVRLXXlLJayQXSn+8duR7MMj9KcmoRecIpw0EpO1RKMBz/snof5122I511LlFFFIsKKKKACiiigApKWigAopKWgAooooASlpKKACilFJQAtFJS0AFFFFABRRSUAFLRSUALRRSUALSUtFACUUtFABSUUUAFLRRQAlLRRQAlLRRQAUUUUAJS0UlABS0UUAJS0UUAFFFFABRRRQAUUUUAFFFFABRRQaAEopaSgBaKKKACiiigAoorH1LUT5j29qxBXiSUdj/AHV/2v5U0rmdSpGmryLdzekO0Nqqy3AxkE4VM92P9Bz/ADrOubiK2l/0gteXvDBOAI/fnhB+p96papqUOjQwWUbx295MplOefKXu59Tk45789q4C7+I8aebaaXafaY8kuYImuGZ/9puBk+54rWnRnUfLTV2cNfFRh8bt/X9f1t6hbyC6Obq9VcHPkQkoB7Fjy34YqzGdOtm3RpBG/wDeCjJ/GvE7fxH4h1AtJb6HDaADCmaYtuP4AY+h61bFr42vIlW2v7aBwW2/6LkM3ZSSxAz9K7P7Lr/baj6v/K5yLNYL4I3+R7Fc38DW8gRskof5VnpqVkun2tvdRrKfLVdjKGBOK8dlHiHTdVij1/xda2pZlxCsMfzcgbcckZzjOa0bn+35ry6Gja3Z3caTOHh2I8kGG+4B14AI59K45ZXNYyK5k7wb623XWxf9sJ0W0vtW/BnoM0Gm2+5rVp9PmzuCWLYH4r90/lVuDUbhgYtVs2kt8Ai4SPjH+2nP5jP4V5DH4h8SaG3n3mnWsyMDkfNGyj1PJx9P5Vs6P8SNO1Dyl1GSWylZsbGbKH6N/jXVUy7E048zjdd1r+RlSzGlN2Ts+2x6jHNLZlHif7TYuMjB3Mvup7jHbr6E9K1YZUmiWSJg0bDII71yFrqUNugezVprRzmWLPUH+Nff+f1rVjuPskkdxbESWtxh8DjeDjkejAdu/wBa4rXPSp1+Xfb8v+Ab1FR280dxCssLBkboakqDsTTV0FFFFAwooooASloooAKKKKACiiigBKKWigA70lFLQAUUlLQAUUUUAFFFFACUtFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABiiiigBKKWigAooooAKKKKACiiigAooooAKKKKACiiigAooooASloooAKKKKACikYhQSSAAMkntWJPPJqhMUaOLQ9MHBmHrkdE/U/Tq0iJzUSPU9W8+MrZylbbo1whBL88rH/Vu3bnozSLEtsnmXyoYxiONe3pUeqajo2gbW1e7iE2PkhXrjsFWuLv8A4pieRxZ6ddpZo213KhWwOpGeKxq4mFJW6lYbKsRi5e0a0/AvfEDw5p2t6nFHNqmoW928PlyQwBXWSPcSFIPPXPQ+1Yq6Z4O8LyLDqBihnB3/AOmzQ2/4hev6Uz4iu2veHbDVLK/8QWtgs/kyW+jyKJZDtJ3tIBuK4PK5x3rhdN+HUXiS5jg8PW81uqtuubzV1lcxoQfmVd22Rs9icdz6V00cZivZckJ2T7afja7O+OUYGKlVxMPh366/el+LPSv+E48I2asV1rRbdcYz/aQwfzH8q4fxR8WPEt/FPYeBfCmq3zTjy4dTa0mWEKQMOuQCevBbaO+DXo3gf4XeGPDsnmWll9pvkGTfXwEso/3cjCfRAOK7qOMbXMKKijjdIOT9BU88k7uTZ5NSNGScaVJKL+8+Q/A3wx8QP4pj1Xxjo19fSBxIWmlHByMEgHtyeuPauq+IPw200X174g8NnXNL8QPM9y7LE7xTMSWZlIBxuPbp7V9ISwlbaU+a7EITwAB0qO0jDabbDcMmJThlB7VzvEz+vRmt1F6/NGbwz9i1fr5W22PBfhx8ToNYso9D8Tj/AIqaBvLKSxKplXqChYjccdRjP1613GqeFrXUIt9xZqVYf8tdyjPvxitbxn8O/DniuM/21olrOOSJ4l2S5/31we3rXk0vwZl0K+a48N6teTaW4GYDdvFNDzyyOgwwGfusMjqCeh7/AK7iOfmpT5X6f5WM6eCwM1yYiLXmr/5/oaEuk+IfD10JvDFuktqJA01kLyPaw9VDHKn6ce1ev+Ejc3nhuJNaigjkmdmVYJRKIh2VnHBbOc44rxnwxoXiS58QtYaR4p1SEAbpLTxBatcAxqwDNG7AE89CNufWuwivbvQ76WDw+xjt/N3yCZDMshI5JAYbfpg49awxmZubXtoxv3V0366tP8z2KPD9KCcaE3fs9V+S/U7+IXOm3ZywO7g5OFk+voff863rW4S5j3pkEcMrDBU+hrjtG8YWt/H5OrwC2f7plRt8TH2PUfjXQCJojHPaSrIhwEcHIZf7rH09D2qY1I1FdM4ZYWtgnyzXumxRUNrOtzCJEyOSGU9VPcGpqDVNNXQUUUUDCikpaACiiigAoopKAFooooAKKKKACkpaKACiikoAWiiigAoopKAFooFJQAtFFJQAtFJS0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAJS0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFZ2oytLKlhbuRLKN0rKcGOPufYnoPxPagUnYjnzqbOgOLGM4Zs4ExHUf7o7+p46ZzxPifxpILqbR/C0fnXYXdNdM2yOId2Zzwo9z+AqbxxrgFvLpWlzR21pbxZu7kHiGNeCAO/oAOpwK8tu5llh8q5gKacDui09+fNPaW5/vyHrt6L0rkrVebROyW57+WZVdqpUjeT2T2Xm/0X3j3vZ75JTpqz6kd/z3yqlrA574nlDO491X8eaZd/bpVC3NxoozwVa4up+PTO4A/lVW6uri7Yea7NjhR2UegHaovIkI+7XHLFQWijf1PqYYCK1lLX+vl+A7xCdf1HRrLTtPbw0lvaS/aEESyLL5mMBwzk4OPTj1yK0PBPiy58M6nGdZsGsizMtxNFboYrkMesjxqORnhto989ay2ideoNTQ3c0IKhzsPVT0NaUsws7SWhFXK6c6bguv8AW+p9F21zb3tkt3pk8VzCwyGjYMP061Il7CZN75Rj8vqP/rV88aTNcaZdtd+Hb1tJvG5eNRut5j/tp/UYNdYvxL1G3TPiPwu1ymADe6VKHBPclDgj8zXfCpCorxZ8ZjMmxWHl7keZeX+X+Vz2W4ZGtJGRlI2Hn8KrWW5tLtVWQJ+5Tou49PSvKoPjJ4Vk8u2N7qsEspESxy2p4J4AJ57mqGsfGvQtJvZ9Kjs9c1G9tJWtmihjCJvQ7SASeRkda52l9bWq+F9V3RxujXUOR05Xvtyvt6Hs8arbw+SjF35OGOSSec8fWuC+IviWz8J6RKqFJ9VnBSKDeFVMjlnJ+6AO/WvOdX+JPjjWE8vQtIt/Dlm/W7upN8uP+BdPwBrlVis7a8N5qc02v6nnd596T5an/ZT/AB/Kt51Yw3Z6OCyGtiZJ11yxXTq/LsvnZ9kavgzxTr9jqt1qGj6bbXrXCyNMNjwW4LEHcZXJLHI6AAc8UXE2t3Eskl3ceFbCaQ/dijlnIHoSzn9BWXqWs32ovm5nYxjhYxwqj2A4rOPNefPExcr2uz7CGUwvzfD6X/r8DZKa4sDSRWWkXhU7i2j3jW0//fL5VvptNdx4M8dT2sdxcW0zXun26j7fZzwmG7t89WePkEf7a8eoFeYISrBlJDDoRxWvZ6m0l5bTzzeRqMHEGoBcsg/uSD+OM5OVPrxSVfm+HRk4jLnytfEuz/pv7vxPpSx1O1urSPV9Lk8+0kAEwByQB3x6j9R+FbysGUMpBUjIIPWvB/BevDw/fvdxRrBpMki2+o2StuW0mblXQ94nByp/CvZ9NkEEv2ZWDW7r5tsw6bO659s8ex9q9GhWVaN9mtz4XHYP6nU934JbeT7P+td+ppUUUVqcoUUUUAFJS0UAJS00uoOCwB+tJ5if31/OiwD6KbvT++v50b0/vr+dFguOpKb5if31/Ol8xP76/nTsFxaWm70/vr+dJ5if31/OizC4+im+Yn99fzpPMT++v50WYXHUtN8xP76/nSeYn99fzosxXH0UzzE/vr+dL5if31/OizC46imeYn99fzo3p/eX86LBcfRTd6f31/Ojen99fzpWC4tLTd6f31/Ojen95fzosO4tLTd6f31/Ojen99fzosFx1JSb0/vr+dG9P76/nRYLjqKaGVuFYH8adQAUUUUAFFFJQAtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACUtFFAEdxMlvBJNKwWONSzE9gOtcnr2qS6H4flvGw2q37fIAMEZ+6v/AVwPrk962tbD3M9lYKMxzSb5/+uac4/Fto/OuG8d6v9n1i+vipkj0iBWijB4kmb5UUjp94/wDjtc+KqOnT03Z15bRVfEe8rqOtu/l820vvOF8Q3itfvYBg0Vk6yXGRnzLvGR/wGMHp/eOe1YoV7iUnk0oiIADEu7Es7HqzE5Yn6kmt3TbULEDt5rxK9blXL2/M/QYJYeHmytaacxAzwa0ItLJ5PStS3t/lBFW0jxjP6V5U8Q2zkniG2YcmmDbjANZ11pWeVHOK7B4xjGPxqu8IPUUQrO+5VPFNHBTW8sDcqaZHcyxNlGZT6iu6e0hlUiRQawdS0gRNuT7tdtPEHZDEQqe6zKg1CRry2EgR90qAlkBP3h6ipPEeqzR65qcaPs23Mi/KAM/MfSm/Ytl7bEDjzUP/AI8Kq+J41/4SLVCRybmQ/wDjxpfWZfWVr9l/mi1QpyqKy6P80Y1xcSTNl2LE+tQbOeasyYzwBUJbI/wro9pc7VT5SLyxj29aTywelPVgyknseBRkc4PXmjmCzQ3Zj6U0rUrdOo96iLDPShyaKsma/h3V007UYpbyPzrQqba8Q/8ALS1b734xn5178MO9e6eBb2RIbvQLmTzbzSm32sjf8toSMqwx2IOPx9q+crgfuyy9QOgr1P4ea79o8P8Ah/W1dxPpMv8AZF8h/ij/AIGP0BH5muyhXUZxl30f6P8AQ+azvL1ODttL8JdH89vn5HusMiyxJIv3WAIp1VLNhHPLb5GB+8T6H/6/86tivYZ8DCXMrhS0U12VFZnYKqjJJOABQUOrjdQ1e+8R6jNpHhWYwWsDmLUNZChlhYcNDbg8PMOhYgpGeu5gUEMlzd+OpDDpc01n4TBxLfxMUl1L1SBhykPrKMFv4MDD12FhZ22n2UFnYQRW1rAgjihiUKiKBgAAdBT2FueS6foOiWp1C3XSrWURX06h51SWRvnJJZ5MuxJJJLEkk1b/ALH0XHOkaeB/1wg/wqxFtF3qvMIY6jcZ3bQfve9TboxwTAD6ZSvz3G1ZrE1Fd/E/zPYpQj7OOnRGcdH0cHjSNP8A+/EH/wATR/Y+kYydGsP+/EP/AMTV/KkHBiBH+5/hUTyx55eDPoWT/CuN1p/zM15F2KZ0nRgB/wASfT/+/EP+FIdJ0YddI078YIf/AImrBbJ4MR+hX/CopWUA5eMfin+FR7ef8zHyLsRf2Zof/QJ00Y/6Yw8/+O1KunaEDg6Tph/7ZQ/4UwbcAh4zk5/h/wDiaUyKucvGP++f/iaX1ia6sXIuxL/Z2g7cf2Rpg9P3UP8AhR/Zmgkj/iUaZ/36h/8AiagScMuVkQjrkFT/AOy1ItzGpAa4UZ4AOBn/AMdp/WZ/zMOSPYl/sjQmz/xKdM/79Q//ABNJ/Y+hkD/iU6Z/36i/+JqWKRnB2uDx2A/+JqUzCPAeUKx5C4H/AMTVKtJ/aBxj2Kx0bQweNJ0v6eVF/wDE1HJo+hgH/iU6V/36j/8AiavGZtpYudoHJ2//AGNR7nfkSZB6YH/2NP20v5g5V2M6TSdFz/yDNJGP+mcf/wATQmj6Lux/Zekf98J/8TWopfPDtx/sn/4mlV2b/lqx7dO//fNTzz/mFZdjNGjaKDzpOj/9+k/+Jpp0nRe2kaP/AN+U/wDia2HMgAJlYA9M9/0oAkPR5D+f+FPnn/MPlXYxP7G0djgaRpI/7Yr/APE09dG0YD/kE6SB/wBcV/8Aia13MsZG59uTgFsjn06UuLjHBY8dRu/wo55/zMOWPYxjpOjfw6VpOf8Ariv/AMRSDR9E3YOk6T+MK/8AxNaUj3KHaWx7fN/hQouyM8gevzf4VPtJ/wAzDlRQTSNCGSdI0jP/AFxX/wCJqUaToHX+yNJ9h5K//EVYD3LH/WAg+hb/AAqZLW9cnBY4P8LP/hVKpPuxcqKelWOnWvjzwy2n2VnbOxugzW6BSR5PQ4A4rrfiVYNceFL++tr28sdQ023lvLS4tpmQpIiFhuXO2RTjBRwQRn61zttDPF438LmfdgvdYyW/54+4rsPHn/Ij+Iv+wdcf+imr7nJG3hY37v8AM8rFJe0djS0u4a80y0uXAV5oUkIXoCVB4/OrVZ/h3/kX9M/69Yv/AEAVoV6pigooooASloooAKKBRQAUUUUAFFFFABRRRQAUUUUAFBoooAKKKSgDOt8ya3ezN9yGNIV9jyzfoV/KvF/Fs8kthbrk+ZqGoyzyHOQUiGAPpuYGvX5JfI03Wrjvvkb8kC/0rx3WH8y8sICzEQ2fmAEf89JGP8lFeZmM/ehH+v6uj3+Hqd25ea/C7/OxQ0y1E05JGcVvpFteNFxzzVfSodqk8nJzmtKGMBkc/wAbHHsMHFfO4iTbsfRYmrZ3JlUIpx0HenpkqM9aJI9zBT9wcsPX2qUj868+92cbZGc5zTW4GTipSufemEcVotBpldhj8KhuEDxEEVO55zUfVGzXTTd2bRfUxjAPPj9pFP6isXxNbbtb1AjnNw5P/fRro3XNxER03r/OqGuxhtUuz0/fOf1NJP8A2hf4X+aPSoVGpr0/yONlgYH2+lUHBBPFdNcwA55xWVcW/JwOa7Ez0ozuZAPXv7UwlsjB5xmrksQGRyeOarOuHAwDkVVzZCqxY9OMVFJnHH508gAEg8UMmV5HJq0xNBA28bTz2rqfg/OP7Z8TeHZfmj1Gy+1Rg9FkjOOP++gf+A1ycQwSTjr2rc8C3P2D4p+G7gkLHO8lq2e/mRkAf99AU5puErdjzszjzYaVt1r81qfRnhe+N7pei3hPzSQmGTJ/iAx/Na6auM8FqsWhyRqCBb6lIuCOnzj/AOKrotd1ix0LTnvtTm8mBSEAClnkdjhURRksxPAUAknoK+kpz54Rl3R+X4iCp4ipFbX0+ZY1C9tdNsZ73ULiK2tIEMks0rBURR1JJ6CuQFnd+OZRNq0E1n4VU5i0+VSkuoY6PcKeVi7iE8t/y0wMx1Pp+j3viLUINX8Vw+RbwOJbDRmYMsDD7s05BKyTdwBlY+25hvrsa02MtxAAqhVAAAwAO1LRRSGebG3iOoqWiDedqdyHznP+tx/I1v8A9h6Yj7hbHd6mVz/WsGViuo2+O2p3X/o4V1jE5P8ASvgsTb61W0+0ztu/Zw1Kv9mWGMeQD7Fm/wAa5qysbSXxRc2VxF5kcQcoCx4GVI5z2zXWnOf61zNmCPHl3weYn/klclZJuOnU0pN669DaGm2CfctwP+BN/jWdr1rbW2nmSKBUYyKpKk8gnGDW5t5HNZfiaLdo755xIh/WnUS5HZE05PmWolnp1mbO3cw5Zo1JO9ueBz1qHXLC3/sy5ljiCSxruVgT2IrR05f+Jbadj5SfyqLWkzo96PWJqTinDboVzPn36mT4csLSfTGM1ujlZpI8nPIDcVX8R2lraTaeLaBI1eT5lGcHDL/ifzrS8KIRowJ5JnlP/jxqp4wXabFz/CW/9CSsZRXsb27GqlerY2lsLOIkR2sSj2FZd+0UOtWUCxjY7L8p5HIYH+QreYfMa5vWD/xVOmKM53x/+z1rW0St3RnSetjZv4YEspWWJFKLkYqho1tbz6eplgR2SR1BPoGOK09SH+gT7umzrVDw4uNKXpzLIeP9805fxF6BF/un6lwWVqePIjx+NUdJjhnku1ljWQI643c9iP6VroBkVjeH2zcaljoJQB+tOXxRFF+7IfqlvBBNb+VEqxucOoHBwRjP51qrZWsZ+W3iX6LWdrp/49iP7+P1Wtkjk8U4/ExTb5Iv1MfXoUWKBlQDEgz6HHrWgLO2UnbBGPoKq64P9Fj/AN/+laf8VOPxP5ClJ8kde5iRW0R1ia3eKN4wu4Ky5APB4z9TUup2kMenzNDCiOMbSigEHI6U+MgeIZB/0z/otWtSwLGUnpx/MUoLR+rLlJ80fNIz9EtoHtX3wREiVxkoD3plmxj15oIyBCRIm3027SP51b0A77Wcj/n5kH/j1UoBjxQB/tTH/wAdSlFWjErmblNPsS6mMeMvCv8A11uf/RBrX8d/8iP4i/7B1x/6KasnVP8AkcfCn/XW5/8ARDVrePP+RH8Rf9g64/8ARTV9tlH+7R+f5nmT3Zc8O/8AIv6Z/wBesX/oAq/WdoDrH4b015GCotpGWYnAA2Dk1zXhf4i2fia5tzpOia/JpVzK8UGrNaqLWQrn5gd+8KSCAxQDPFeiSjt6K5vTvHfhPUobyaw8S6PPDZr5lzIl5GViXONzHOAue/SpbXxn4Zu7HUL218QaVNZ6eQLueO7Rkgz03sDgZ7etAzforj7j4ieHzNoi6XfW+rR6rfjT0lsJ45UikMZf5yDxwOnXkcVLa+PvD6+H9M1XWNT07SYtR3CBbm/gYMQ2DtdHZGxxkqxAzzigDq6KwdS8ZeGdMvlstR8Q6RbXrMiiCW8jWTLjK/KTnkdPWtHWdW07RLCS+1i+trGzj+9NcyiNAT0GT39qALtFc3J488JRxafLJ4l0ZY9QBNqzXkYEwDFTtOefmBH1GOtY/wDwszTf7f8A7K+xXnnf21/Ym/5dvm+V5u/r93HHrntQB3lFFFABRRRQAUUUUAFFFFABSUtFAGBroJ8MawoJVtsvK8mvG9Uw2vSGM5xY2o46Yw1e1atb7tI1mJero7D8UH+BrxmdCdYDf89rCIDH95GYEfqK8fMtKsH8vzf6H0vD8rU36/p/wDS08fumPfbWmyH7PGyDJTDADv8A5FVdMjHTGatQMJ9tp3jJEmOOB0/Ovn6z9656Vdc90SoA7l1yFbp/jTytJbIUuJkYHChdmf7uP8c1M4wO2K5nG0jlhU5lcrt15qNj1/WpWKnOPWq87EIADgsQtVY6I6kUjZGQTioWOEPNSzd+1VnbORWkHY6IIqlv9Jj/AN9f51V1kn+1L3jkTP8AzqZm/wBKi/31/nVXWpP+Jrer3858fnSvauv8L/NHdSXvr0/yMyUdc9RVCeMMKvOwO4mqshXHcDpXWmejAy7iPGeKzroGIiTjavBHrmtmZcofrisu6mi8xYjluckKucVp6nXTd3oRBCAAT25qOP548kjB/QUsweU7SjRp3B6mlUryAOnGKpMcthAuFJ96dAufFXhMjORqtt/6HTlUEAAHk1C7yHxn4Wgs41nvDqEEkcBbaCFbJJPOF464Ptk8V0Q+FnnY2SjTk32PpKyv4NM07VQweWeXUnEFvCMySv8AKdqjp7kkgKOSQBWhofh+6l1Vdd8USRXGsKGFtBES1vp6EYKxZALORw0pAJyQAq/LWb4J03y7PVL64b7RqdzetG9xtwNu5fkjX+FPbknqSTXd17mE0w8PRfkfluL1xEr+QUUlFbmQtAoooA81ueL2Ju/9pXX/AKPWuxYc1x9ypa9tgO+q3I/8jrXZMOa+ExEL4ut/iOtv91D5kYUVz1sg/wCE3nOf+WL/AMo66GeWO2gknnYJFGNzE+lcJNqk8OpLrC27lRIS8R+8YyAOPcAA/UVyV2oct+5pQTd/Sx3hFZviQD+x5f8AeX/0IVftriG7to7m2kWWGQZV16Gs/wATqW0SYjqGU/rWlSPuN+RnT0mk+5a09AdNtD/0yT+VRa0v/Ekvug/ctg/hVjTv+QbZ/wDXFP8A0EVi+NrphYpp9ux+03JDMAOkanJ/M4H51Mvdp8z7FL3qlvMn8ILjRQD1E0mfb5jVLxuAtvbMe2/+a1B4Ov8AyL+fTLlgpmPmw57tj5x+gP51a8cOI7a2ZueWGP8AvmsFaWHubJWr+p0hTLVxeq3hGozahGgeO1nRQRzlV4Yj82/Kt7xVqD2lvHbWrYurptinui/xN/h71Vm0xLWxSGNfkCgEGtKyb0j0/pE0Vb3mauolX0uaSNgytHuVhyCPWqfh5AdKXH/PST/0M1iWF4dOiuNOlctayROYc/wMBkr9CM4HbHvXQeHGD6WhBB/eSf8AoZohJTkmuw5R5KdvMtTSJbWsk0xwiKWaua8OXRivTHcDb9rG4EnjeMnb+IP6Vp3ky6jrSaeD/o0WGl/2n7D6Dr9ap+JdJVVza/I0eHQ56MOhoqKX8SOyYoJLR9S34jARbQ9zKM/mK3COa5bVtQW70XTrth5ZkO5geMEEZ/UGukv7lLO1kuHG4KOFB+8T0H4mrp2cpPpoTUTUIx66mX4hn2hIU+aRUaVh7Y4/Pn8q142EkaSKcq6hh9DWTa2LXEEl1K2ZnOWP9B7VLpMrRTNZSkkYLREjoO659s5Ht9KqCfPeWz2HUiuSy3QsY/4qF/8Arkf5LTfEd0sFmsAP72dgAO4UHJP04x+NKWEXiCWR+I1gZmPpjaax7e/tgVv9TOXnlCKMdPRfoBTUW7wju2wlZcs5bJIl0bVI7W+ktpsJb3Em5HP8LnsfY9j6/WpbYk+LWyON0qj/AL5T/CofEa2SQTSKoK7eQv8AnrVG2nvrW2tLyePzLlD5kmB97P3h+X61k26T9nPozRJSvNdUbmqjHjHwp/11uf8A0Q1bXjC2mvPCWt2ttGZJ5rGeONF6sxjYAD8TWHqE0dx4p8ITQsHjeS4ZWHcGBq3vFV5Np/hfWL21YLcW1nNNGSMgMqEg4+or7fLF/s8bHly3dyj4Uu9O8ReCLD7LOlzaT2SRSBG5GUAZGHVWHIIPIPBrzrw98I9d0jWPD7L4lhGnaEk0Nq8UMizyxMH8tJV3+WShckMF57j07vwrotjoXgcf2dAsdxcWYnubnH765mMeWllfq7kkkseea8OX4ra34Z+G3hVLC/tZtSGif2nOuoxCTz1ErLgyvPGSSRjaiu3sBiu8S2Ogh+COvSQ6t/aOv2dxcXmhPo4nPnuzMZo5BI3mO2BhCNqbVHGBWh4++F8/la/qmnhZWmi0wwWVraiQvJbSc70LKGQg8jOcDvgA2rX4meIrn4haf4UXTrBLm/ltr6GUxSFP7NaFnlYnf/rFddgPAJP3a5vQ/jP4pv7fVtQls9Hjgj0/ULhbOWSJZrWa3R2RGQXBlkB2HfmOPHUcc0DNTwP4F8SatfLr/iCKPTLn/hJzrX2d49rPELcRYCh22EnPBbPHbNS2fwb1bTvDmk2dhrGnG8h0a60K6a5tmkiMM8pcyRgMCHGcc8GvS/h9f61q3haz1LxD/ZwuL2OO5iSxR1VI3jRgrbySWyW5GBjH1PSUAeLar8FnudE8V6dBf2zjVNP0ywtJriIs8P2RNpZj6tgdK7v4i+FbjxPb6PLp93BbX+k6hHqNuLmIywyOgYbXUEHHzdQcgjiuuooA8T8R/CDVtc1GbUry/wBImuL+1+zX9ptu7e1OJXkVlWGdCw+YZV85YFsgmtWD4XXkXiSPUjqNuY08RDWtmxslBb+Vs5J5zzmvV6KACiiigAooooAKKKKACjvRRQAUUUUAV5FH2llbG2VMH8P/AKx/SvDbqJ4NRtw658i4mtJMcEbuQfzXH417hf4SJZ+f3DeYcDJx0P6E1518RdJEWom7hICagq4YdEmTlGz78frXn5jBciqfy/0/wuvmevklZQqypPrqvl/wLlPSgGT0ZTg/0p0KeX4gnUjiWFXX3xwah02QTwQXcPys6Z2N2P8AEp9wam1MlljvLYYubQ5eM9Sp6/h7189iaXLKzPfes2u+n9fMtysEu4l/vhh+WDTbphHsJ4UsBn3qOaeK4Syu4TmPeVPtkYx+dWplDqVblSMEdjXPOPKov+t3/wAA8+m3zzi9Gn+i/W5n3D7GMY+80gA+h/8A1Go77iEMD0ZT+tUxcMZjK6ZitXMDsRyeSM/gMfnV29AYJFn5nYHA7gcmoqLl0Z3UHzWmtn+m4yfn61RkwAauzHrkHJqhcnCYqabuzrpFHP8ApMR9ZF/mKqa9/wAhe+GP+W7/APoRq0QDPCO/mKf1FU9eI/ti+PT9+/8AM1N74j5fqjvpv94vT/Iz2I5GevFVyhe4Kr2U/wD1zUzcL3GOapOzxNdSEnyyoA/mf6V6WHSfM5dF+qX6nRUlK8Yx3bt+Df6EE+ZpWhiZhEnDMO59BUQijj4jUAVNbALbpngsNxPvTJeppc19Ttbt7q2Rl3zFGbH3mAC59c0RRqoIz8o6nqT/APXpLjElwB/DHkk+9UvtL3VwbTT227D+/uMAiL/ZUHhn/Qd+eK2pR5rvsTWqckVHq/6/r1uWbi5ZZPstkqvdYBct9yEHoX9/RRyfYc1f+G1qj/E7TVQtKbSKa9uZn5ZyqFQSfqwAA4HaqSrDZW/lwptQZY5OS57knuT3JrqPhRp8r6Zq+srFmfUpl0yxPQsmfnI9if8A0Gqqv3HGPXT79DzMwbVFqW709L/1ue8+D0P9h6dkYM8rzkA5wMk/4V1NUNNs0s44oIv9VbxLCuPYc/0q9X0sIqEVFdD80qz9pVnUXVsKWiiqICiiigDzDV7gWrLMTjydRuZD7D7Qv/167ph83FcU+kvewa1MxLg31wm0/wB3eeB+OaveC9WmuEfTNQJa7tlykh6yx5wCfccA/ga+Grz5cZVUlbmbt8jt5b0Y26C+IZDeanHZk4t4MSOv95jyM/QfzpLqa0u7NHVCsTMEjkxw1Qa8rW/iEsw/d3CKwPrgbT/T86o2Wj3VsEVr7fpcbb0hZPmHoM+lYwdOXtI1d+gSdRKHs1p1JvC0zab4gbTQT5FyrOFP8LqM5H1HX6V0Hid1j0koxGZZEjX8/wDAGuf0GE3/AIy+0J/q7GJix/2nGFH5bjVuZf8AhIdXkcSYtLJmjjA/ifozf0/CsKd/Y8q63SNZRvUT7Gv4YuUu9GttrDfCohkXurLxz+GD+NYdlLFc6xc3dwdyuxVCT0UHCgf571kNLcaBqz3aZaIjZOg6Onr9R1H5d6qxreXWnwNpUkbXdtIGUMcLJgY6+/WlCqpuEJ6WeoTi6alUirl7xBavHObuxYCeBxJGR2Yf5xWp4uvYrnTdJudu6OYGTA9NoJrnZnvrW1urnVY1SeXAESsG5/D1zTrnzbqzsrWL5orOExk/3nb7/wCA6A/U96xquNN1IR1X6l0m5qM5K39f8MdFrxH/AAlC+ZyPs6FM+m45/Wse4vdSurb7JJHLHqCTZR0UlXXPB3dMYrbsh/wkegxqWEeq2PyEkdWA7/7LAD6fhRb323RpTOpjmiYq6HqrDgg12Qq+ycppXUtTCdL2iUb2aOZ8RzGW6ht4cGZpBtx2x1/TNdl4TmDwXFoSBLDKX2+qscg/nkfhXO+FtM+3rLqcpzIx+RfRf/r9atX0c+nX8Wo2+TJHwyjgSJ3U/wBPeuKlzU2qslo/yOmS5o8gxGuRY6hParm+BdlAPJYMePrUFv4pGsXaQQW8wEcJNwWQgI3YEkdSe1a19F9luF1OzJNhebXbH/LN2xyR6H9D9ar+JtTa2skRRulk6Zrr9oqNKVKUb32ZhKnKpNTjKyW6KAK3OmW1shB2GdiPQFiB/I10N1cf2h4etJsYYSKJV/usMg/rVDwnojQaaZJ8O7dT61csIRHfXemySEQ3ce+P/ZcdSPfG0/8AAayoxkviXxI0m106GbDrFxY3uoW955uyVQbXapIIx0HvmtC2mdtT0oSDE5OWH/bNs5qrNqj6dFLDdKRNFw3HGfUfXrVSzE2I76ZjHc3mY4EzyqHln+uMAema2q4pTcYWs47/ACM6dFw5nzXvt8zbWaK71gkEeVP5kAbsRtA/9lNZMunRXVgLK4ZoJ4JMrIo5Rxx0PUEVs6rpCGxQWzeXIACjL2I6GqTyte6UL+SNVuoW8m6C8cg43D9Pz9qd6kJX2ktV89ymo1I2eqen+RkpagX6Wk1ybjYvnszDGWzhRj0HJrroDDPZIcqQPlY+/SuLntZYdb+3g4tYwlvIevzOcr+v8xW5a2T26OsVyFs3O9lIyc5zgGlQkqjnOtuyZxcIxjTWiIIAYfGHh+1zlI7m5ZB6BoGJH55P411Pjz/kR/EX/YOuP/RTVy1tul8WeHbth8s9zc7PdRAwz+JzXU+PP+RH8Rf9g64/9FNX1+TX+qQv5/mceItzyt/Whb8PAHw7pgYAg2sQIP8AuCpJNI02WKGOTT7N44VKRq0KkID1CjHAPtTPDv8AyL+mf9esX/oArQr0zJbGJD4Y02Lxa/iNY3OpmzWwVi3yRwht21F6DJ5NaDaZYPPNM1latNMpSVzEpZ1IwQxxyMdjVuigY2NEijWONVRFAVVUYAA6ACnUUlAC0UCigAooooAKKKKACiiigAooooAKDRRQAUUUlAC1g6ppiappN5pE5G8Luhdl6D+E/h0//XW9VW9ichJoBmeLJVc43juv4/zApNKS5WOM5U5KpDdHkehl7a8ms7xfKFxKVO44Ed0ONv8AwMDI98+tbctuk6bLhWBXOJEOGSrvjXSBLjWbCFpopUCXcKj5toPEg9GXH4Y9qpafd/bUALk3G3csoGPtC/3wP7395ex9q+fxFFr9y1qtvNdvWP5ejPpvbqtBV6btf8H2/rp8zAsraW0v7nSppARMgkhcdGI5BH+e1bkM4mgJYYdOHU9iKqapYyO8LK6rNG2+3kHAVu6n2NPVhfD7Ranyrtfllib+TD+tedKKcfZyduqf+fr+DXYitUlVf1mC95K016bNf1rr1sRw24bSNjDBkQs31bnNU9HSRrRJ7lt0jLtUY+6opZtRFjp7wXY8u4ClYwR9/sAPWr9vD5dlbof4UUZ/CuPFRnCpLm6v7/Q6cFWUsKuXyXmrLVfkVbn5QSfpWZIcsa1bsErjuaznTAIqafuxud9KSjG5nsP9Jh4/5aL/ADFUtebOr3w54nf/ANCNXZB/pMOOgkXn8RWf4gKrq+obm25uHxz1+asYv9+vT9UdNKfv38v8jOJ9az9SkItPLH3pX2gfp/SrkrEnDZVejPjGB/jWcZBeXTXCg/Z4fljHqfavajB0qTlPRy0S62vdvy2Vu/yOuhWVevFw1jDVvpezSS7vVt22truWH2ogGcBR+eBUE77Y2x94gkfQf1NIkkcUclxO6oiKZGkc4VR2yTxgVj33m6nbSSTB4LAqdkbAh7knoWHUJ7dT3wODpToP2fNbfq9kr/m7af1a54he29mndp7Ldv8AyV1d/wDDOlGZdTtVS2d4bQg+Zcg4aU55WM9h6v8AgvrV21ihsLZbW0jCKoxtXooqXzFjiSKNdzooQBQdq1WuZDa26qqPJcSvsjiRdzyMegA7kmtHOPKqdLb+v6X/AATojTlGUq1Z6v8AL+tX+tinfC41K9ttL07Ju7t/LTH8I/iY+wHNfR3w20aO2MHlBhp2jxC2t93/AC1lI5b9fzauC+HngyW0ujDw3iG6QG4kXlbOE/w59fX1Ne8aTaRW8MNtarttLUbBx99+7fz/AB+lbZfh3WqqvL4Y7eb7/ovmz5LP8xTXs4bvb06v9F/wxpRrtQZ5J5J9TTqKK94+RCkoooAKWkpaAPNE8R21gNftJ5I4pUvLhow/G7Lk1i2eo+cmk6zApjZnU4/vKW2ke4I5/KtyPSrDV5NUF9aQXBh1C4wXXJHz1Da2aapr1vbQqq2lkVlkCjC8fdUfiPyBr4TNKiqVnGK95Sf5s7cNCcLym/dOt1ewTULVoWO2RTujk/uN2/D1Fcxe6nL/AGPbwxwlruWUQLFnkPnBB+hz+ArtMZauLiG74heSeVimklX0BMK/1Y1lWhs++n3lUJbrtqdLoWnJpVksAYPMx3zSYxvc9T9OwHoK4zTXntdEb7OjSPG/72NPvMAx3D65r0E8Vzmo2q6fq6zqQtvdvgj+7J3/AD6/XNOSdNxlFfCRD95eLe5zizyaneXlytrLbWRjChZRjLCtGxtPs2g6VqEQABiVJR04zhG/kPyqxr8mNlrEd0s7CJB7mt+8tY4dDltUXMUVvtUH/ZHH8qyl++qzlaxoo+xjGN7nD6qr38l1cMzCOGRIY8fxStyT/wABXJ+pHpXR6HFaR2H2VdvmKm5gB0HaqMkXmeEo5lxmG7aWTHpuIJ/Iiqc+m31zKLrR75LaQqEmWRSwYD0x3pYaMVUTn1X5l1ZSUXyK9mDOdK1i31O2YGGRhFNg8OhOD+I6/hVvx7C26WO32pJdRqM9i27bn8iPyqrf2Q+zWelxMZJXcKT3JJ5PsOp/CtTxrGGudO68Hgj2kjrNq0JxWyZWvPG+5z639xYaXE9vC8saNtnROSAB/iK1rW8XUdPuJlVvs4UbWYYye+M1c1S1Om6oZgP9GuXJBA+456g+x6j8ai1VpLvyLK3OJJ2CnjOB3P4DJrZ1HCj9Xktnp8zOFK9T2ylo+hqeG4BL4Zhhm5SVHGP9kk4/SuPuQ159mlk5EFsJGGOnzqpP616RawpBFFFEu1I1CKPQAVyfhuCNtXMboGU2s0bZ7jzRxVVqN/Z036CpzvzzRT/ti406SZDBPLbSxgQ+WhYA45HHQ1YR7j7Vor3IK3XnLuUnkZBBB/A0+d5dBufs0pZo3yYX/vqOx9xxn86saBay6jfJqlzkQoD5CnuTwWPtjIH4mlOrKajQ5bNBGHJepzXT6B4tiV7lNy53xAflIP8A4qrHiODF9ps4UCNN8ZPoTgj/ANBNO8URhpLYk87GH/jyH+la2p2a31nJCTtY4KN/dYcg/nWkqHPOolvoJT5Ywb8zkRcam0sVgtpJ5Stu+05GzGc5q5ZJ5g8QIMGLYhwP72CT+mKqLqdxBZT/AGiIpLC3lsv+17f0re0uwew0Gdbgg3MyvJKR2Yjp+AwPwojOVeadrcqdylTVGLV73tYh0i2jvtN1KGQ4SaVkJ9PkXB/CsRUu5o47ORsSGXyJWA7g4Yj8AT+NdJ4aj8uwmHrO5z/n6VQkJXxBKMfKLqJhx0zHg1MqadKm2UnapND9URY/F3hJI1CoslyoUdABAeK1vHn/ACI/iL/sHXH/AKKaszWP+Ry8Kf8AXW5/9ENVz4jXUFn4A8ST3UqQwrp1xl2OBzGwA+pJAA7k4r7LLVagkeZPdml4d/5F7S/+vWL/ANAFaNUdCjeLRNOilVkkS3jVlYYIIUZBq9XcJAKKKKBhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABQaKKACikpaACiisjV9WeG4Gn6ZGtzqrruEZOEhU/8tJSOi8HA6sRgdCQAM1i+j0pwtvC11d3ZIjsoyN0pHVueFUZG5jx07kA8Re+Db3Tp21iDN7NMCZYYSV+yZ5xbjsM4yfvMRzxgL3+j6Smn+ZNLK11qE+PPupBhnx0UD+FBk4UcDJ6kkm7JG27dEwVu4I4b/PrWOIoQrx5Zff1Xoa4evPDyvHVPddDzWG+t761BuJFAb5fOC4XPo4/gb9PpWfrFjLA3nhpY5kGVuI+Wx/tgfeX3HNd3qWg21/M81v/AKBqLj52CgrL/vDo3161y86XejTpDcILeItxG48y3k/3T1Q+36V4GKw86V/bar+ZL80tn5q6fVI9ijVjVl7TDytJdOvp5r+tDkdX1YX9gbO6WFrtXWSGSIghsdSO4P8AnArU8OzsLK2t5pJJsxAxysclvUE+oOR+FbN7pOg62US+hWxvGOULngt6pKMYPsefauZuNJ13QNWjiuYXlgVy0c0eClyuMtkfwSADp0bGRzxWdLA+1pyjDVNXT3V1tZr8Vpu9NDqnX9rCEV7tRO9tlJOye/krrV6rfU2bkYbp9KyNQuooMgnLnHy56Zq14gvnsrGGZI2AuQTBIyHaRgEtnHPB6d65mKRFhNyRLcy5zyflVvXJ6t9M46Dis6OX2pe1rp26Lq3+iXVle2q1qv1fDLVfE+kf+C+iJx9pluoDhI081Tgk5PIrM8XzJa6ne4CtO9w5VBzuG7v3rb0NpL7U47e4jEKOhZGUsSrLyOoAI4I/GqXi60j07XTJaxtczyFp5md+Qzt8oHsF6fWualj5UcZ7GEVFuL2XT1vfpbe/lY64ZbRqVoxxDcmtdX/UUvkcnJaX98fMvSIYevkqxBPpmpL2a3sLJ5LkiOJQFVUHUnoB3JPoBk1JqWri2iV5rWTex2RxqwLSN1wo7n9AOTgVlWltqN7ei6uoQ9yP9TCmXWDP90D7zerfgMDr20r78if3tv721+B7koTqe652XZNJL7tfxuN4ukiuL+MQ28XzRWrHJz2eQ/xP6L0X3PIe26+cSSgpCOQCcFvc1ryeH7m0Ky600dmDgr9oYBuf7sYyxPtitTTvDdxdeY7q1pZ4BF3dKNzf7kPb6uf+A1tXjUbUsQ+VdF/lFa/cjOniMJgoP2Tu3u1rd+vV/j2RzWyR5IbSwt5JriY4hhixukHcj0X1Y8fyrufBvhKXTdRVI1jvvE8q/vJF+aGwjPZT2b1PU/odnw34fnujLF4aia2t5eLrV5jukfHoTyT+g9q9F8PaNb6da/ZNKj8uEj9/eH787d8d/wAfyz1rehgfb/Gmo/i/Xt6feeHmec8keV7v7P8A8l2Xlu+ttmaDo8emwNZ2DMZGbdd3h5Zm/ug/5wPeukiRY41SNQqKMADsKSGJIY1jiUKi8ACn17aSilGOyPkJznUk6lR3kwooopiCkpaSgBaKKKAPNLktYJqVxajDXN3dhxnALLJgH8uPwrqNA0lNJ01IA2+dvnml7u56n6dh7VgeU93/AGjCmd0dxduicfvCZTkfkDTpV1HS0t57K5uHtJI96xTfMEIGdjHsCOhFfF4mCji6kuW6u/z1PShTdSlGHNZv+kdcBXGwKF8etc7sxyzPEDnjPkqP5qRWxeT6hfrbxWJS2t5lxLPnLo3dAPX3rnoNJs5LaNZZJRsujHlWO4J0U59mwc+9Y1+ZuKitnf7h0KSSk5PXb09TumWsfxcMeH7hhgyIUaP13Bh0/WpdEubpprqzvmWSW1Kjzl48wHpkdjWbqUi6j81xIUhWYRbQceV6k+pIyB6c1rOPPB2WrM6VCXtLPpb/AIBX8LWpvtTn1Ockrb/uIUI4DEAs35ED866HVXEWlXsjdFhc/oaydOL6dFczW48y1+0FPKzyR2ZT347Gruok380dgoKwSoJXkz1XP3QPyrClTcKdralVYOVS72/y3KXg0h7G8gkUECXJVhnIZR/9eoLq3GkXLxQ5FtJGXQZ+7g8r9ORioYXOmW1vdxs3nxym3uYzkiQEkg59RxzVya2a61Cze5dSbkMDhsYQDIUfmazjRl7JRa1RsopVZSvp1+Sv/wAEPCumsu7VLsk3E4xEp6Rx/wCJ6/lTPGSlvJ2feWN2H4Mp/pT9OluNPS4WJvtFpBLsCNwUUjjae49qJbZ5p4JdUj5mYpIFbKIuDhfz7+tV7Bul7NInlcavPJ+n3di/4mkT/hHrx8bt0f7vHUufu4984qh4WjD3l3JP/wAfKqigeiH0+pH6VSu7CGwWJd01ykb4EsjDKYzwo6djz+FXriEx6jDPZymM7R5RzkSLnlCOvatHSlKam1sChBUnyy0d9fQ6MsEVmY4VRkn0rl9DUxazabvl8y3kJHTJLBsVqaxcKsiRTMVhZc7Rx5jdlPtVG5tp4YEcO/2kMPJZSDnI5/DHFVVjJzi0vhIo0/cab+L+v+HF8SKt/cxRLgi33k+7EYAH05rY0lkfTbZowABGBgdiBgisg2yOsyxyxv8AZ4MLt/vk5Y59f8asTTDTQk8DAwz4PlehP8Q/OnCElVdRrcc6alBU47keuo8+oxIgO2KB2OPUkY/lW1BIJoY5VxhlB4rIZY/t0aShpZmx5jDgKW6c/h0pltM9nK9vCjmZnwyN93cR94HPANaU1KNWUujJnT54KK6FbUYf+JrNJgeULy3ZuOOi5/pW5qzhLKRc4aTEaj1JOKzZIXazupLg7zHJ64DcjP8A+v2ohmkubeGeVz9rdzGqD7qnvVwpNKf979Ryjzcr/l0/D+rlvRDsS7iYgGOZm/4CeQf5/lWfNhpp7mP5mNxHLgDqq4HX6c/iKj8iRZmW6kdbksI2fOVIYcdOACR0wakXEaTvNkJBujBY5Lvwcj/x7rUOg3BRfQpQtJy7kms/8jj4U/663P8A6Iam/EzTpJdFXWLYWT3eh79RhivLVJ45GRS2Mkbo244dSCp5wehTVCx8V+ETINr+ZcZGeh8hq6LX7SG/0LUrO6m8iC4tpIpJcgbFZSC3PHAOa+nwGlFHly3aJYJmvtLjntmMLXEIeNmG7YWXIJHfGeleMeFfiV4hs/D97qGuCLXLiTxKPDlnbwRraYbcVDluQdxK8HGMda7v4b6vda34Ct5da057SFbYRrcBsR3sQTHnxrxIisBuCuFYAjr1qr4M8G+A7zQrPUvDWnrJptzcw6pBIZJ8NNGWKS7XOQQS3Uc988V2CRhWfxd1G8ubPTbfwmza9Pqd7pTWZ1FAiS20SysfN2YKlWHOBjB61Tk+Onm6Pos+meGLq61LULOe9ksvOY+UsUzQsqskb72LqccKOmSM16TbeDPD9rq8eqQabGl+l3PfLMHbInmQRyvjOMsqgY6ccVRn+G/hKbTbGxfRYRb2JkNtskdHi8xizgOGDYZmJIzigZn+FPiDc+JfFl1pNn4cu4bWzjtpbq7uJ0QwCe2E6K0R+bcCQhA6HJz2rP8AG/xRn8Narr9tBoBvrfQ7a3vLyb7YIj5UpI+RSp3MMdCRn1HGe30Pw3pGg3F1NpFjHayXSQxzFCfmWGMRxjBOBtQAcVzeo/DHRNX8b6h4i1yJdQFzFbxpaSqfLjMRJDEBsPkkcMMcUAch/wALWvNGl8SPfRSaq58RLpWl24XygiNAsnzMiM2B8x+6zcgY9Lt98ZX0zw/peq6t4W1C1TUHltI4mk2uLxSdkWHVTskAyJMcdwK7m+8D+G7+21CC80mCaO/uhe3AcsS04AUSA5yrADGVxVRvht4ReBYZtEgmiWGWBVnd5MLL/rCNzHDHA+f72ABmgDz74h/EPxFo9j48Glq0WpaUmlKFkeKSK0NySGaP92C5zgfOSMkEAAEHV0/4nXum3UGn6ppc91b2l/baNqGpSXMYlW8mVTxEkaq6KWClhtz1Cmu1n8CeG7i31GC40xZY9QS2jut8sjGZbc5h3Etn5cde/fNS3Pgrw5c+I016fSLZ9WR1lE5B5dRhXK52lgOAxGR2NAHFXHxbuIfDOv6+fC8503SrtrISfbY83EouUgwoxkD592SO2PeotO+Ll/Jrttp+p+FHskbWxoVxMuoJKIp2QvHtAUFgQOTxjturu5PBnh+TQrzRn02M6ZeXBu54N7YeUyCQtnOfvgHg9qH8G+H3ujcvpsZnOorqxfe3/H0q7Fl69QvGOntQB0FFFFABXN+LvG+geEbiwg168lgnvxKbaOK0muGkEYBc4jRiMBgTnt9DXSV5b8YPh9q3jfxH4VudL1JtMh06HUEmuoZSk0bTQqsZTA5G5cMMj5SfWgDvdO8Q6RqOiWmsWmo2z6ZdgGC4Z9ivnoPmxzweOvBqC48U6RFfapYpdefqGm2wup7SFS0gQqWG0fxEhTgA143qnwm8Q6h4a8IW89ppLNo1lNp9zpsV1shkD4AmjkeGTDkDLZTPJwani+EeqWcutfZ9O0SU6l4ZGlJcyTlprS4W3kiyGMQLhtyKX+U4HI4AoA9rh1Wzkt7aWSdIDOqFI5mCOC4yqlSfve1SDULI3psxd2/2sDPkeYu/H+7nNeDaz8FtS1LR/E4mttJl1a50zSbXS7mRstby28YWYh9uUBwMEdR1rS1f4aeJr/4p2/iB00k21vrkV8lzHIIpfsqptMZRYss/qzSHIAAAFAHquoancXd3JpuhlTcodtxdMN0dr3x/tSYOQnbgtgYDX9J0230u2MNuGZnbfLLId0kznq7t3P8AIAAYAAq4qqoIUBcnPA70ZwQDQKwtFFFAxksayoVkUMp7VWmgBheK4AuLZuGVxkgf1H61cooDZ3W55x4k0N9FcT2eJNJkIV4WG7y8/XtWTqF7caFpU8lo3+j74x5TfMEYuAGXJ4HPIH4civULuNLiyu7dgGXBTBGRyAR/OvH/ABFcpeTJpybPJjkjmmBGSzsf3Q+gCs59flryqOFUMzpKi7c2suzS3v8A1udONxkq2EcN5tqK7tv4fmn1NPTryTVoYU1GFY7aKN5ZWQbtoLEMFGOcuCAPc9hUNzGkk8ottJjjjLfuw12Fkx6Hg1fsYUg0eyKxkGcC4Kscn5siNT9EH5sTXRp4Rt5h5+qXdwcgfuYpPKjQde3J+pNKvVqYys6NO1o91/wUelUrqjUa5uRK+3V9X5tnASQS2U9tcroc7vHICWiv0YrzydpXJGM8VQkt59X1+5mbw6RAZNou7rUGjVwOBiNULdhXqUfhzw7yY42kJ7iV3P8AOnr4W0IHIsp2y2778h5/OsVlVRVPbe7zWt8L2vf+YtZth0t3fv8A1I8W8PWd3FqMV3ejw5/p8dyY3ktpXa3WORQsalpACvOTwCTyc8AdELoENBca7Nch8r5OnQJAD7fuwW9vvV1fh3wtoeka9cW39kSTTqsk1m87tIvkyOC6hXYqCr4HAztKeprs4YZYV22VnbWy/gP0Uf1rs+pVnpKs7do2j+Sv+Jyf2nStrFy9f+Dc8v0Tw/fRRldD8PC1D8tPdDYx9CS2Wb9a3bfwvaC4H9uXT6pdjkWduCEU++OcfXArtjZyTDF1cu4/uR/Iv+P61Yt7eG3TZBEka+ijGa2oYKhQbcI6vr1fq3qzGrmVep8Huee7+9lS2sR5MaTIkcKAbLaMYRPr6/yrQAA4HSiiuo4UrBRRRQMKKKKACkpaSgApaKKAOKskIgvp4gfPi1C5IAGdw8w5H86luHaRfJkjdLdpCxOM4BHOcfj+dLpMEc1vqYkTJ+3XWDk/3z6U3R7aB/PMkSNwmN2T2r5fEKTrStbdnRBVXFThb3f1IEdImeK3YuFYSRtg/exj+XB/A02zC2yxmNJVY7hJGVOeT1z0I6flV++tLZLSRlgRSMcjI70zTbC0lsI3mgR2bdkkn+8feseWV+g28S4yn7tpaPfXTcr2txNZ3d63lN5126shf5UHB6mq9zbTWQu4Z3E4ul8yOTHRweR9OetJp+nKdSu7aSWbaoO0iQjoRg46GkuEMVnJ5R3SxyGNYmPyB+mcemOcVm5OK1NZ4qrhZKM4qV0tV1ta2/6D7OfZBEl4pW2hBwAR+8J7knFOu9atZLiCaG5t4ZIjhvNnTaV7g4NWNK0u1NpHPcotzcyLueSX5+vYA8AfSrlxbwLZzqkESgxt0QelFptGU3iZ1LuSi/JXWu+5jW+qaaZmSfULO6i3GQpHIp+Zux5qpNqFvC6LDcxBIXaSJmlXcAR061reG40RLoiNMsyE4Uf3avXqo08AKjqMce4pKMmr3LjSr0KsoKad99PL1+RiC/tchIbyCKJo9s0ksoJJ9gOlSz6nbT6f9niu7fDYxMJS59sfh/OtzUmBsZuByAOnuKWxbFnCF6BcVThLa/4GMqdeaVR1Nb9jnoNQE1xZQQwCVItxCqGYsR1J+Xjt1q8v2i2liaSLyomL+WrMGKkjPT0OD/8AWqezUrqtye20/q1O1hwtqjnnZIp/pTSdm7nRGi1KNOUrrTTYhsd2o3U1zcEPAgMSLjGW/iP4dPzqCZmtxJHI75t/mRvVT3H8vqDWlpq+Xp9upwDsDH6nk/zqh4hUkREH7wKkZ6/Oh/xqmmzohPmq8q2/yJzaG0so2jK+agxISOG3dePQU2xg+1XDm4y8EI8tM9yRz+QP6+1XdSIFrcZ9D/Oo9J/48kboWZm/U0W1I55Ok5Pe/wDwSjIZYLpU2kmIoW/2lUnBH4E/lVi3gea1uL18efORIg/uqv3R/M/jUXiI7bYSIwEhBj/Ag/1rYj4CgdAAMU0rtodSp+7jJbv9DKspTfqIGBCtI00v+7ngZ9zTdXSS31JbiE7fl8wA9Cw4PHuCKn0EL5EpGOoX8AP/AK9SargyWxIySSP1FUr8t+pXPy1+VLTUfNbFNIuRKxeZkMjv/tAZ49MY4qnZW5vb8yzkGNFDlQMZY+v/AHzn8q0tRcCwuyT0if8AkapaG20vGx+Yxow/UH+lU90jKnOXspSW/wDwxFrJz4w8Kf8AXW5/9ENUnxN1Sy03wRrK3lwkct1aTW9tFnMk8roVWONersSQABzzUOr/API4eE/+utz/AOiGqf4iQ3sfh641fSL77JqOkxS3kO6FJI5tqEmOQMpYIwGCUKsM8GvfwTvSR5supq2tpMnhiGzZAs62YiK5HDbMYz06187+IvhX4xvfBfhrSF0i0lksNFaASRzQCaC78wsMvIGwmNuDHhs5ywGK+lNPuReWFtchdgmiWTbnONwBx+tWK6ho8A0/wzqsvxustJluZX0aO3tPEWox7mIS9jjaEJuzg7m2yEd8ZrK0X4VeLrBdb+1RTz6tcabqNo+ox30Kx3zTRv5ZcbRIx3FMbzhexxxX0pRQBzPw68OReF/CdhZLC8V20Ucl5vnaUtceWiudzE/3QOOOOK6aiigAooooAKKKKACiiigAooooAKKKKACiiigAoopKAFooooAKKKKACmyMERmPRRninVHL8zIuepyfoP8AIoBmTq7/AGDQ7hgSs02Seedzdfy/pXjl4ht9T1SR93mvdLEo5P8AywjA/wDQj+des+Ln3iKHsPmNefa1aCTxUANxU3MRIHYlIx/7LXjYHEe2zatFfZhy/e1f/I66NKMamGctue/3J2OunCvrscKjCeeEVe21QFH8q6f7OLm/kefDwxAIiHpu6kkd+o/WuYtAX8RKGOSs+f1JrrrHLJK5wN0rfocf0rHIantVVqPdy/QjGR96MX2LCqFACgAegpaKK985zJ8RWc01tFdWKhtQsn86AZx5nGGjJ9GUkexwewq9p95DqFjBd2zFoZkDqSMHB9R2PqO1WKwrTOk6/JZnIstRZp7f0Sf70if8CGZB7+Z7UxG7RRRSGFFFFABRRRQAUUUlABRRS0AJS0UUActoP+q1D31C5/8ARhqLQ2w7rnkxq2PpkH+lMsZGi03VGjP7w39yi/UyGs0vLp13byAnamAfdehBr5jFS5asvV/menhKTqUpR7/odBqg/wCJdPkdV/qKj0Q/8Sq3I6Hdj/vo0/WCBplwe23+oqlp8vkeGUccFImx9ckVD+IIRcqFl1l+hTS9ig1R7mV1S3Z3RpCcAD1/MfrUTpM2mveuj73m+0eXjB254X67eKpqIb6a2sMhkVsy++O354roRqUE9jc5CLbwkx5J+bI71j7GpWclH7OvzexxZpVi6qjF25V+IuiXCXOj2ksTbo2TgkYPBI6fhU2oSiPT7l2wAsbHn6VkaC5t9RubRD+4dPPUejZ5/PIqbxExlt4rNSQZmBb/AHQc/wA8Uo1OaHMdOEl9ZlGT6vX9SXQvlM6kYJVG4/EVPfOVvbMD+Jv6is2ydrbVIELfI4MZ+uMj9RV2/P8AxMrP0BH6mnF+6dlSH77m7r9LE+rPi3VR1ZgcfSk0mbzbZh/FG5U/zqG5dJNRKSkKiKAPqearaY5i1KSHI2Sgkc9x/wDWzTb965Cp3ouPVa/18i/b/wDH/dfQVBr0gWzRG/jY/oCf54qW2P8AxMrpf9kH9aq6pE91M5U5SJcbffv/AEoeiY6cV7VN7JL8jRtG3WduexjU/oKoa+xH2cqMn5v6Uvh+bzNPETHLwMYz9Oq/p/KmeIm2iAgdFc/+g076XFCm44jl8y9rEoS2Kk/NIwX9cmmaXKuJLfnKHcPdTz/PNZ2vaja2mpQm+kxGNqIv952z/QVNHOjavA8DcOCjD2xn+lUov4ugowTp8nW1/wCvkWdcjV7JgRznIP4GrjziO0Mp7R7v0qnqz5RY+5Vjj8Mf1qnrF+tto8EhGRsVyvTIAH+NCV5WW5CguSN9tW/6+RY0R/LYxMfmdA35f/rqfVyd1pjtJ+nFZOn6lb3uq2nkN84BJA9CprS1h9stp6gs34DFDi4Lll0NLKVaM11V/wAyfXpvLt1iC5adxGB7dSfyFRSuINTsWGBuzEfoR/iBWf4qedru1+zFg3luyleT1XOPfFZcF3Pe6vaRxmVoUdPndSCWByR+VW4trn7CoxjaNN9U3+a/Q39VOfGPhTj/AJa3P/og1q+PP+RH8Rf9g64/9FNWRqZ/4rDwpj/nrdf+iDWx44RpPBXiBEUs7afcAKBkk+W3Fe9gP4SPInuyxoUiQ+GdPlmdY4ktI2Z2OAoCAkk9hTdC8R6H4g8/+wdZ03U/I2+b9iukm8vdnbu2k4zg4z1waboEyN4S06eFftMZsY3VYiD5g8sEBcnBz25xzXhXh7wr4pfw3Lpo0PWNJa48ZR6jcPHcJAz2EjtvG+KTcNqjkdtw255x1iWx9GUV4FpPgLxG3iCw0m/GtL4Uh17VCQNTkU/YWtk8gF1k3lTIGwCc8nPWsW78G/EGbwr4WttSGtT21taXdvcQ21yHuYZjcP5MxBniD4i2BSWbbzleaBn0vRXlPw48Ma/H4z1TVPFNxrJWCCwFks18fKkk+xLHcM0SOULb92c5G7JBPWsX4n+DvEuua34zvLD+1/3en2jaJ9m1B4U+1KW3kIrgZAxyw78c0Ae4VT1jU7LRtMuNQ1S4S2srdd8s0n3UX1NeJalpvxCTU9RsY9O1SaC51+y1GPUI75BGlsPL8yLbvDDkNlQMdfbOb4k8HeJ77QvFdlfaDreoeI7t7sxaoupr9klgYnyo1iMvGBtAQoNpGc0AfRMbrJGroQyMAwI7g06vAfEHhPxtJ8Qvtv8AxOHslezfTprCVCluqIolikVp0CqWDbvkfcD+FZsnhrx+/jm91CHTNSsVn/tZJzBeZgkDwy/ZipadmJ3lD9xApwAABwAfSFFcn8LtDudC8F6VHqU2oSarNawSX3227e4ZZ/KUOoLE4AIPA4rrKACiiigAooooAKKKKAPN/jxqGo6d4PsXsLm6s7CXVLaHVbu1JWS3sWY+a6sOVx8o3DoDXmz+Nr3ws3jK48G6sNR8KWk+nx2t5fzveW8E0rhZlSVny6hTuI34U+mefdfE3ivQPDEcLeItWstOWdXMQuZQnmBcbtoPXG5eB6iuc8Xa78P9R0DTrTXda0xNMvTFeWoW5EYcJIGVwVPC7gOTgZ4NAHl2v+PvEt3ZWU8HijToNMs/FkWn/wBuQ25W2uYWiZtz/vApjRsq3zYb5eRjnTj8ealptvq620+nabb3HjGfTbjWJ0eSC2iEMbCRgz4DMcAchB6d69VvvGHhCxluNNvda0eGS2BM1q8yAoAockp6AEHOO9T3vinwxYwaibvVdNijtRG92GkX5fNGY9w7lx0HU9s0AT+Dr9tS8N2d02p2mrF94+3WkflxThXZQyrk46diRnOOMVd1HVbDTVU395Bb7vurI4DN9B1J9hVKwu9J8U6HDcaPqHn6a5+WWxnKZ2nBXcpBGOhHBq3p2j6fppZrGzghkbhpFX53/wB5jyfxNAin/bVxdHGlaTeTjtLcj7NH/wCP/P8Akhpgs9avJj9s1KKzj2/6uxiBYZ7GSTOenZVreqNf9c/pgf1phY4SXSrNNUmkWJ5boSbPtNzI00gRR82GYnGfQYq8NKQajZysBvnuWuXPoqIAB+Y/WrxtQbqQheWJz9Cc1o3cIjPmDqqeWn48k18dljqRq18XLs/zv+h3OpFONul/vasYuiwmXXWkKcAs+fwwK6Wz/wBQDjqzH/x41R09Ft4JJschfTr/AJ4rShUpEityQoBNevkNF0sInLeTbOfEVPaVL9lYfRRRXsmQVQ1vT/7S094Efyp1IkgmxkxSqcq2O+COR3GR3q/RQBQ0TUP7S05Jmj8qdSY54c5MUqnDLnvgg4PcYPQ1frBu86Tr8d4OLLUWWC49En+7G/8AwIYjPv5fvW9QJBRRRQMKKKKACiiigBKWiigAooooA4XbK+l6gsDiOQ6lcqrHoCXYA/ma5Od9bl1JPt9t9mt0TYSXVvMYkAYwfxzXZ2UbSafqoQZcX9yy/USEj+VZMCSanrVqM5gQiZ/oOR+uK+bxVVxlOFk7t/LU9fAU00qrlZR1fmb+usE0uYMR/Cv45FU7BVuPDZiQ5wHUgeoYn/Ck11mnu7azX7pBmc/TgD+Z/CodKzZ6i0A/1U4zg9nA/qP5VzOXvG1OnbD+d+b7v6uc/eWKWOoJrNn5u5uZYg3yuMYPHY9D+FXZ0095Gvnini8wh3A3hHJ6ErjGTV/ULY+c1sv3JCCv4nkVPrqGcW9opwud5A9F6fr/ACrNyqJuUZNaW9TmxOX0cTODWl739P8AMh8OqtxdXV8VaMj9ykZP3V6kn3Jx9AKi8VW891uitJViuXg/dMxwNwbOPx6fjVfTp303Vws7f6Pc4jPor/wn+lbetWrXFkzxj9/D+8T146j8RRSfLFOK1RusJDDSVKL92S39d/xOG8L22trrkcusARM0iIIwwbODktx7V2moSg3DyA5ETL+GDk1m6dIZr37Sfu28Rk+pPAq8Yito27nOSx+tOdV1W5237G3sY0eWF72/V3MzxNp1zfagfsVwIbiKRZU3g7GBXGDik8L2l7b6kE1CeOacl5WMYO1RjAAz1rWTMsVrcZy7IY2+q/5NZdtrEVtfX6W9vLeXSMEZYyAqcZwzHoeRxzW0ZVJpUltuTChdylFXla36G/A3/E2nGeWTj8CP8a5XxBqmp6feXRitp5rRwyjyIy5WTPQgc9Mc1Qu/El9p+sQXOpaYyW6yMXkhkLlUYYPBA9vyrqbuYLIl7ZypLaXiBldTkMcdfxH8qpc2HfPON0Ovg5pKN7XW/mun3FLwXPdySyLersma3SSRf7r5xz74q7rchuZJYozxCu0n/aPOP5VP4ZtSsVzeOPnmfC/7q/8A181RW9gi0+5lnIDb9zt7nn+tYKMprRbhKcIVnK/w2Xztr+TH+ItMtNWe2a6UtDMFKspwVccgg/iadothHb6kY4nkk8ldzO7ZJJ4H9aupH5nh0GMjC/NGx7YbirWiW4ELykfNLIcn2BwP61onK3LfR6nPNwhFz6q8f6+RAyC51CZjnbCvl/j1P86ryRC500HYJPszsjqRnK9xj6YNZupajd6dcTMIna2ZnDFFLEPuOAfwxWn4KkmuLa5lnTYzspZSMHOD/TFV7FqKk+pPtIx5rbxt/l+Nyvoek21trEj2sQjVI9xwSck5A6+2a0Z4vtOoy5zthj8sZ9Tyf6flU2jxeXd3KEfdG3PqAxxWRfTX1jqc8kVtLcwsWysQyQc5BI+mKqFJ1dL79yZ1Y05NrZJJfP8Ar8R0zvPpoYY8/T5Ruz3j6Z/L+VXLSBptUErfdgX/AMeP/wBaqOhLLcJqMkqGMvbEOv8AdY5IH1FbehgNbSP1LOCT/wABFQoXev8AVjavU5IyUf6vb/glHVRjxh4T/wCutz/6INdF4gv20rQdS1BEEjWltLOEJwGKIWx+lYGrj/ir/Cf/AF1uf/RDVp+PP+RH8Rf9g64/9FNX0GCVqSR4snq2Y3w/0GPwr4Ej+z3NxPPLbfapN7kQpIylyIoh8kUYLHCIAAMdetcRbfGhtH8AeGtW12x+33l9YG9ufs08MTKoYglYmbc3TsMe+a9Y0ONZvDOnxSDKPZxqw9igzXKXfwi8IXVjZ2j2d5HDbWJ00CG+miMlsWLeXIVYb1DEnDZ5rqYlsQxfFfSpfEEWiRWN62pzX1vaxQYUM8c0JmFx1/1YQHPcEYxWNpfx20PUnvng06+NlDZXV9BOrxsZkt1LOCgbMZIUld2Mj0rpLT4eWkHxOt/FpeHbZ6UmmWluIzuTBOZGcnk7SVHHSpYfhj4ZgjvYLeC/isruKeJ7JNQnFsgmVlkKQ79ikhm6DjPGKBmz4N8QN4m0SPU/7LvtNhm2tCl5s3SxsisJAEZsKdxAzg8dBW5VbTLKDTdNtLGzUpbWsSQRKSSQigADJ68AVZoAKKKKACiiigAooooAKKKKACiiigAooooA5XxB4VOr+OPC2vm4RYtGjvEaBo93neeiLwc8Y2+hzmvMYPgLNa6ZpUMOtWk8sGnHTLqO7t5jBPH5ryBgscyEEeYRtYsp64r3iigDgPD/AMOLWwfxYuoywXlvrypGyiHaY4xbiFlySeuCfx71ytn8EZI/AyaVdeIHn1uPUoNSXUjCwDGCMRRRsquGKiMY4YHJzmvaaKAOX+Hfhh/Cmhz2cz2bzT3Ul1IbSKRE3PjP+skkYk4ySW5zXUUUlAC0mPmJ9RilpKAKkMfIJXkvzxT7oF2RcEjv6VZornWHioOn0YFeJMRgAYy2T9P8irFFFbQioRUUAUUlLVAFFFFAFfULOHULGe0ul3QzIUcA4OD3B7H0PaqPh29lngms751bUrF/JuMYG/jKyY7B1wfY5HY1rVyHjENoWp2niuHIt7dBa6qoB+a0JyJTjvCxL+yNL3IprsJ6anX0UgwRkciikMWiiigAopKWgAooooAKKKKAOW0EZjv/APsIXP8A6MNVdChVbq8ZQOFRP5mrmhELa6kx6Lf3R/8AIhqLw4dxuCerLG3T2NfO4mH75+rO6hJqhN+n5mF4skvba9NxYxPMypGzRxjLMgLZwO/OOlZXh2+1PUrmKW8tJbVpLkGBJVKvsHJJB5Heu212DZ5F6o5hO18f3G/wODVXRYjcavcXMgP7qMImfVup/IfrWcmuT2XLrfc6aUrL6xzaJWt57f5EupJtvLP0LY/UVT1+2me6iNuwWR4mRcnABBz+ua09aUeZZuf4Xz+q1Pq8Ae18xB88LCRf6/pmo5Gm2uhnCrZQv1TR5wljrM+pBb5Y1kmljSKNH3AAHJc+nAr0sR7n9ie9ZuhQLJe3V22SVxEntxk/0rZYrHG8hHCgsfwFOKdRuo1a5OJq8qjQWvL+bOQ0gZ0zU5AMlAq8DsCTXN6trmrQ38th9kuGmllBhdYyYjEeh3dBx1zXb+FYh5N4rKMOVJH1WqV6ktuslnyzpgJ/tA8Kf6fhSpyVOHM43ujrq3q13GMrNNP5WRPp6SR+GxNjLqzSKB35PFcl4d1m20bRo7i8iZluGzK6ryHbkk/jXok0QtNJWJcARqq/jkVxmo6XLohN+i/adJuSHljbkws3t3Uk/hXbglGMlGW+g6NVV41IJ2cnp/kY9pK+owawZ28ywXb5LsO5zlQe+OKufDUPceCr5ZgXt7e+f7M7c/L8uce2S351P4u3Xuk21rbOttDKyxZQcRhmALY9s12Tabb6X4fFhYxiOCFAiKPqOT7k85961xri4tJf0i3UlQw8KU3eTl91n/SLVlEEtYF6AIOMe1c7qOh2U0cyTxuWjcAAOVEg/hz6+n4V09vzbxe6L/Kq14ge+hUjhgM/g2f61xNOK5ouzPKhJSk4zV1v939MbcW62uivDH0jjxxUumLtsYge+T+ZNSagM2Nx67DTdOObCE+x/nTULSt5EublSbff9ChqMRt7h5I+I5lLMPRh3/EVY0O2NvYKX/1kp8xvx6D8qTWWAjhUjlmIrRPXFKFNc7LqVZOjGPf9DOsuNTulx8uP/ZjUWsZtn+0Jn50ZXH0GQf51at8fb5seh/8AQqreJAfsMe3rvP5bGocb038/zLpyvXiu6/QlsbQWmkMh/wBY6M8h/wBojmo/DhH2BgOgfH/jq1euW/4l8r9vKJ/8dqhoKeQs0OQfuOP++QD/AOg1bXLKKRPM50pylvcraz/yN/hP/rtc/wDog1p+PP8AkR/EX/YOuP8A0U1Zmsf8jf4T/wCu1z/6INQ/FeeVPDjW8l5cafpF1uh1K9gszcPBbkYcghh5fGR5hVwvUgYyPawv8NHA+p0vh3/kX9M/69Yv/QBWhUVtFHBbxRQALDGoRADnCgYH6Vy+k/Efwnq2tR6Vp+sRy3crvHCfKkWKdk+8scpUJIR6KxrcpHW0VHcTR21vLPO4SKJS7seiqBkmq9hqljqGl2+pWd1FLYXCLJFOGwrq3Qgn1oAuUUU13SMAyMqgkDLHHJ6UAOorJsPEOm3+s6zpdvOTeaQYheKylVj8xPMX5jwfl546VqoyuqsjBlYZBByCKAForD17xTpmgQ6hPrDXFraWFuLqe5e2k8kKTgBXAwz5/hGTyOOavaVqkGp2NtdRJcQC4BZIrqFoJcA4OY3AYfiOmKAL1FFRiaIsAJUyWKY3D7w7fX2oAkooooAKKKKACg0UUAFFFFABRSUUALRRRQAUUUUAFFFJQAUtFFACUtFFABRRRQAlNljjmieKZFeN1KsjDIYHqCO4p1LQByXgmR9KuLvwpdsS+mqslg7HmayYkR+5aMgxt3+VGP3xXWVzPjixuvItNb0mJ5tV0hmmjhj+9cwkATQe+9QCo6b0jJ6VvabfW2p6da39hKs1pcxLNDKvR0YZUj6gim+4lpoWaKKKQwoopKAFoooFACUtFFAHGR3At9E1bBHmSX10i59TIRn8BT9OuIrWeIknb5Yidh0U9Rk/gazNJ1C1h1TVUufNk2XtyAyIXWNi5wpHqQc+lW7PUrQabb3jLNHbSu0Ew2f6th0z69uRnpXmVsBiJ1PaKLt0/rzOmli8NGk6blr1/ry/M6C/2/2fclsbPKYk+2K57Tdcs7V7gzO7hwu0xoWHAIPI4qpd6k9za20EizJb4Z5E8pskjkJjnIxzn7oyPTFTaFLB/aNnELF4pJlKuJFDljjJYew4Ga2/s6pZVJRYU8VhYQdOU737f1pcNZ8Q2dzFstfPMgXK5hb72Qcfp+ta11rmmyWcwE7bmQgDy2zyPpXM69cW00ckFpCwcki7eWDbtUnBGf147DHer1vpVnaWVk8sCJYtPu894/3hGOC3cA849OPYUfUZRXM4O76aGyxOBnFJS+H+uxPoWv6bBDNFcXOyQyZUeW2SNoGeBTta8TaYbJ4YLomWTAOI24XPPUemaxJJFn1dLaC1kkg3eZDCkYO7jkkcYHbJOP1rX8QaGmm+HLy6t7WKS+bazMFHyjI3EcenGf6Unl8octLkd2u6/wAiniME5+35r7f09PvItL8Q2UF2z7Zvs8iYLiPgEHj+ZpuoeKLK4v4Bb20zvGw5JVd3IOOvtWbp1sZhHFBA8+rGTzY7hv8AVlSOTtI+UDgdOcfhV7XrJ7W7tbK6ZVsFAmZgDtlfByCB16AD0zmnHLuV+ycHbff9EaLF4GU/a83lu/6ZLqPiZLyzaOOAxBmUeYxLL14HAxz9ajS3vdftPJmvY47GFQflTCnHQ46t065x9aZAh8T6tb20ZxYQRrLLkY34ONo+v5DnFb3iCFrGSOVcJaS/JIBxt9B+PGPf6054adJpwh7z6dfLfqOOMw1OC9k0ut97M5iPQ5GniilvpNtwCpDAMoyOMr6Z4/Go5ZNU0nfp4vJvMBUJCU+0K4OSCufmA4PGeMVtfaLWKbyvs8pmuZkWFYwGKnnP4AckiobmWW31O6M8Be+uH8tWP3Y0QcZ9zjPpUUsLiFGUZq73Q3m1GTvKSa9Ov9fkJZeK5bUW1rqNnscjYpyYyxHHAYYJ9t1XD4isri+TaJUeMDKEKWzkdgT2qSeC4bSArWjzWczfPGoG5Rj7wz264/CodDlMI+wzWZuoGf8Act5a8huSGz6HJz9accG6kWnC1jnqYrCJ8y3fm+pbvtfsjBJGvnb2GMFNv8yKr6d4ltWhWFIJXdc5w8fr/vVDqug2+n3xZhI1jIjeXEq7iJewye38+PSrejwfa5BDHE5hKMl15g27WPI2+p6c+2e9N4Rp8yhdd7h7bBqPs1q+xn3/AIggvJIjEIl8snAedASePr6VeHiiMoH8hFVhuUmQ/MPUfLzUU+nPaxC3u4YriGF2dtx270J+XHXkHHPsB6VoaZpE9vpbxXyi8iBJSArj5T2IP4n/ACAGsJy3ly7+YSxOEkuVR+H1MlL7VXuc20MMbS7lXKFjyc5wWH+TVRptY1FIWknIj3uuVdIipHBDKFJHXpnvViztbqCW6QQl7PzAkQdsyp06fjj8Ku2mlzWdzez3ibrmVMJsywZixO4jp3xn2+lL6rUjFx5V5Gn1/DayjbTyf6/1oULe2vZ4FQ6rKzN8hiWZm46Z6Dg06C01awvFeC6FwwOwrPyDkn5c9eoHNa0EIgvGukhDtCAkmDnA6HJ/vdDj0p05L3dw0ahrdiFUscYbvxjnJOPqKn6piHq0rr0IlmlK9ls/Izpb1b/xN4UlCGORJ7pJIz1RxAcit3xyrP4K8QKqlmOn3AAAySfLaubt9Jl0nXfCsdzJ5s8lzcvI24tkmBu56nqT9a7DxDftpeganqEaLI9payzqjHAYohbB/Ku2EFBWRw1eXnlybFTRY4dU8F2Mcc2YLrT41WWJs/K0Ywyn6HINeVaF8O/FP2DwR4b1SHTLfSfCupJqA1K3uGaS8EZcxosW0bM7/myx6cZruvAOgL4X8ARrb3U81zLa/aZGZz5Sysm4+VF9yJMk4RAABivN7T4watovw78N3s1rBrmpSaSdTvlaSVJjEHKl8RwuiLwRucqM8DPNUyFsQaT8LvFTJ4a0TV7DSjo+jNq8ZuhdFzcLdxy7GMRQbQGkA6k9eB3rzfCLX5fBvhKx/sqwhGkieK+0+C5hIvHdEUXIMsEke/5T95cgdGBruYPi2Z/GFt4ai0Nv7Uuru3WCNrrG+zlgMzXP3P4ApUpzzxurJ0b42Xup2N/qsfhK8OiR2F7e290BOozbqzCOV2hEal9jYKO+0jB5oGWfhz8MJdK8WjVNes0kjtdOsoLBpbv7RJDJEHBywVAxCsoDbR3wKw/i74X1DxR8VtRsbHQbPUmuvCi20Vxev5cdnK1zKBMrbWy6ZzgYNeveBta1DxD4et9U1LSk0v7SqSwRLdCctEyKwYkKMHLEbeemc84G/QB4F4i+FHie9HiJYLuGZbi70m4XzZVH29LW18qVH3o6jL4Yb1ZSVGQRVe++E/iGfwbp+kaNbjSL+K7vLlb6XUFke2iljIMCeTHEAkjE5VV2oORk8D6FooA+f/GXwq1fXdN1qOx0bT7FbjQLKxtLMTqy29xFMWYBsdApOG6nPPNXvFnwp1O58U3r6JZaYlncNp39nagZfLl0SO2YF0hTaeHwSNpAyxz2r3KigDxHUPhVeXPhz4kt9itW1/W7+6fT5jN/y7yCIhT2XJQ54zwKzZvg3eWuvX15pGnWVukeraXeaeyS7TCkaILor/dLMuT/AHsCvoCigAooooAKKKKACg0UGgAooooASloooAKKKKACiiigAooooAKKKSgBaKKSgBaKSloAKKKKACuQ0L/inPFF1oMhC6dqBkv9MzwEfObiAfRm8xR3DuBxHXX1ieL9Hl1jSNtjIkGqWsgurCd84jnTO3OOdpBKMB1R2HemhM26Ky/DWsRa7oltqEUbwtICssDn54JVJWSJv9pXVlPuK1KQwpKWigAooooAKKKKAPM7pfIi1RoGZJbq7uE4b+LzguR6cEV2P2C3XSf7MRAtuI/KUY6cdfrnnPrXFXjg3oVui6pNn8bhf8K7cSfP+NejUT9lD+vQ8mLXtJ/cYnhpjd3/AJszZ8i1WIqf7zE5P5LUfhdU/tS6cj57eHyEz/CvmN0/IflUXhV2TUtQUnsuB/wN6PD8h/tjUvTGM/8AbR63qQ1qLyRlTn8D9R3jK2Dqvlna128UcmO+JFz+hxXS34WeyuIGUFGjZduPbiuX8XSlRY4J/wBYp/8AH0rpJHO5h71jUi+SD9f0NISXNNIwPB8m/UbuRwPNW1gAbHQHOf1ArqPMzweV5BFcd4SYDULzHJ+zwj9Wrp1Ocd6MXD96/l+Q8PP92vn+Zm+HI0gvr9I+FhxEvsu5iB/L8qt6+om0uUkAtFiUZHTBGf0yKyfDcxfUNZJOQZwR9MtWve/PYXS5+9C4/wDHTRWjatd+X5IVKV6Nl5lbwwiCK8nAH7y4Kj2VOAPzzWxcRR3ltLbXKh4ZV2sDWN4XbOiRf775P/AjWnLcLbwSTSHCxqWNY1ot1Hbua05JQSe1jmvB8bHWrt58O1nEIUbrgljkj8FFX/FxANqy8PLmIkd+Rj+Zqr4PkDSalkYkYxsR65B/rT/F8uz7Bz0k3fqtdTi/rSX9bHPGX+z/ANdzqwSvAOAOPpWTpcKtrd2d3EHCqOgLEn+Q/Wr9xOkEckkpwicmsHwxf+ZrF+spAlnRZVX6Eg/lkVx04S9nOSOudRe0imdJqkCXOm3MUoyrRn8Djg1S8K/NpCSEDdI7M31zj+QFXL6ULY3LDtGx/Ss7wkwGhxjptZs5+ualJ+xfqv1NeZe3T8v1IfFEjC8sETklgSP+BrXR1wepXbaheT3ERIQfJFjsAeG/Pmul8N6qdT0/fMuy5iby5VHTcO49iOa1r0JRpRfbf5kUK0ZVJee3yILqML4ptimR5ibnHY7Q2DVnxDK1tbx3Mf34yR+BU/1AqteuB4qsTnrGR+jU/wAWNnSwqn5mfj/vkmkledNPt/mDaUKlu/8AkXLGz8rSRAR88iEyH1Zhyf1rH0BHuJYXuGDfZo8lfVzxn8MGt61uBLZwS5HzorfmKxNGfbd6mmeRIDj2JaphKTjO+/8ASCpyqULbf1Yi1593i/wn6edc/wDohqX4j3c0fhW/sbLT73UL/UoJLO2htoiw3uhUNI/3Y0GclmI4HGTgGtqzbvGPhP8A67XX/og1N8TNLtdQ8H6nczoVvNPtpbuzuoyUltpkQlXRhyDkDI6EcEEEisGrNHRTlzRbN/T7MW+kW1lNtk8uBYXx0bC4Nc9e/DfwdfWtnb3fh3T5obOA20CtH9yInOz6ZJIB6HkV0WkTvdaTZXEuPMlgSRsDAyVBP86t1BqjlLbwRp8Hj5PFW4m4g01dLtoNgCQRBixIPUk5xz0GR3pR8PfCIvLy6Tw9p6T3iSxzskW3esilZOBwCwJBI5OTXVUCgCGztobKzgtbWNYreCNYo416KqjAA+gFTUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACUUtFACUtFFACUtFFACUtFFABRSUtABRRRQAUUUUAFFFJQAUtFFAHISD/hGvGgmGV0nxA4ST+7DfKuFb2EqLtPbfGg6yGuvrO8Q6Rb69ot1pt4XWKdcCSM4eJgQVkQ9mVgGB7FQao+DNXn1PTJIdS2LrOnymzv0QYXzVAO9R2R1KyL/suM8g0xbG/SUUUhi0UUUAJSikpaAPHdTkaa61yOMndBeTMuP7wk3/4V38EyzJHNGQVkAdSOcg8/1rjLOCIal4hkYgsdQnO0n/aFaHgm+jubCS3jYsts+Ez1CEnA/Ahh+Ar3Jw5sPFr7KX4o8FS5a0k+rf4Mk8NvnWNUGR/D/wChvTvDjq2pajjjB/8Aaj1S8KNnW9TYdNq/+htR4cuEifVLnG8CIzYHcBnNaVYaz+RnTlpD5h4zuczwRx/M8KeawH+8D/Ja61JUmVZYiGjkG9SDwQeRXlK6+o03VLuUxefE3z+c33zjP4D0rsPAuoJd+EYLkMREoYqW/hTG4D8AcfhVYrCSp0YtrZ2+/UKFZSm/NXE8Ikf2letnk28Q/wDHmrd1nUl0zTZrg8yEbI1zyzngD/PpXJeDroJrTwuMGe0UoSOpViSPybNWfH880NtYyJGZUWVmKAclscfjjdUVKHPilF9f8hwq8tDmX9ajPCk5sNWWzmBxcxBVY/31ycfjk11t+2ywujkcQuf/AB015BqmunUdRS608zRxWibnLIVAccr175Fer6vN5ei3csny5gPGehIx/Wqx+HlCUZy3luPDVE4yitkV/CLbtEXuRI/88/1qPxNeBHtbR3CxyHe/vzhR+efypfChT+z5kQhgkp79MgVneOLCS68lo5fIfA8uUjIV1JOD7EGsacIvEtS0LlJqirE1pci012FIyMTfupF9Afun8/50vjmQrFa5OB834crWHoFpcya9byX88c1yOT5QIVUXnv74rZ8ejdawcdBJz+ANbuEY4mCTvp/mZc7dGTL3jHUUsrCJpTiIyAt79MfqRWA2qG08Q6U7LGS8mwMgwdp4YH8wfwre8UW63ehmbYsixgSlWGQyEfMPyOfwrntC0qzn1S3NvHIyxqJWeSQvtUHhQT0ycflU4ZUlQbktrjrOftLLyO71uUx6LqDbukL/AJ4rKsJ2j8MalsY74y4yO3yj/GqvjS6k+yWthCfnu5MufRF5/nik8KvsvL2wmYSJLGsozyG/hYf+g1ywo8tDmfe/yX9M3lUvV5V2t+pzkupNb6ayq7RXMT4VP74zxgdwa7Hwb5ggvppF2iWYYHuFGf14/CsHVydKjuo5AGEA3xsRkle3+FdP4ejaDQ7FH++Yldj6s3zH+ddGMnF0fdW7/wCCZ4dNVNXsv+AM1OXb4i05vov5kioPENy02ox26crEuT/vH/6386qa5ck6hLNF85tdnA9VO4j9cVkeJNaGka09w6FrWZxulA4QFFKknsDzWdDDubjZa2/r8yqlVJNN6X/r8jpvDVy0cUlhKxLRkvGT3Qnp+BplhMF1nUo/UK3H+81cr4V1SfU9YMtuZHtVuNscjD7ylSXAPcDj863bWXb4jkywxMHQH3Bz/jVVsO6c5p7tX/UUKvMotdCa/bd4x8Kf9dbr/wBEGtrx5/yI/iL/ALB1x/6KasO9JPjHwp/11uv/AEQa3PHn/Ij+Iv8AsHXH/opq8ir8R6tD4GW/Dv8AyL+l/wDXrF/6AK0az/Dn/IvaX/16xf8AoAqxFe2kt3JaxXMD3MQy8KyAug916jqKyN1sWKKKKBhRRRQAUd6KjuJ4raCWe5lSGCJS8kkjBVRQMkkngADnNAElFMhljnhjlhkSSKRQyOhyrA8ggjqKfQAUUUUAFFFFABRRRQAUUUGgAopKWgBKWkpaACiiigAooooAKKKKACiiigAooooASilooAKKKKACiiigArkPE5/4R7X7XxMmFsZQljqw7CMt+6nP/XN2IP8AsSMT9wV19Q3lrBe2k9pdxJNbTo0UsTjKujDBUjuCCRQhMmNFct4IuZ7UXnhvUJHkvdI2rFNISWuLRs+TKT3bCsjHu8bHoRXU0AncKKKSgYtFJS0AeMX9uk+p6wj3NxbSLfznfDjJUtxweDyDV3wwkelaHe3NqJMTN5NuG5LFc5bP1LflUWugg6ky8OLq65/7a8f1rV1tl037FBHGPItolwo+uCf0r6WnNyoQp9H+h81UilWnLs3+JS0O7i01NZklJWSO3EoB6kAHP6kfnVXwjM9pqVtb3AzDcwGEsehYc4P15Fc9rd3/AGjrLBSJLRXUCQdiTyh9R0Na2s6laQ6Arw482OQKMHDKwbg/XNdcsO9razt8tNDCNTqto/j3M/UvD1hBql1Y6vZ+cseJYJNxUTR9twHUjp+FdQyf2f4Gt4wVjF243Y4Co3JH/fIAqp4zk+3T2bxEeallukx23kEfyNbniyGOLQbFSoMKSRKfTBUisalaVRUlN7vb0/z3LhTUOfl6fqc5q8sdhd2U0JYSRlZkYdx3H4jNdjrliuq6RLFG212USwv/AHWHKn+n4muG1LSY45bcLcz3DzSJDEkhGEDHGBjrwe9eiarcJp+nXE54WKMhR6noo/PFYYp8rpum7v8A4Y2oq6mpaI840e5/t+90m3lyUkPnSKe6pyR+YArsvFkryix06FwrXcm6Qn+4vOPxOK5PwlDHpWvaaspCieJ7cMf755A/HGK2PiHZXLXumXNnL5cy8Rlj8pZTu2n2IJ/Ktq8YyxMILRWdvxIptqi5Pe+v9f1uW9CdLDX/ALIrjbPHsKg9HXkfmMitfxTGG0SYdW3Jt+u4f/XrktGtdQvfGFlcXqRRBAWKI+4kKMknHuQBXT+KXJltYcnZ98j1PQf1rlrwtXhZ62TfyN6cr0pK3WxQ8E2zC+1V5OWXy419gQSf1x+VT+J/9JuFtUBPlxMWx6tj+g/WoNHuDZeLY7f/AJZ3sRU/7yjcD/MVBr73Nvqt48VrNcq+UKRAEqTjBx6YquVyxHN3Sa/L/MlNKly+bv8AmX9K1AT+C7ozg+bawvbyg9yFwPzBFRfD2IR6fdo5zKjRgn1XYMfrmuL066vYriXTZwy+aqzTKWyVKscA/gR+VdP4WvPJ8SR26DC3UTh89ynK/wBfzrTEYZ06dRLrr92v+f4EU6qlOLfTQueNLOe5ubT7KVEyoWj3HAYhhkZ7cYrK8Mw6gvjGKS6hECujAxhwx27eSce+K7HxLAH0eaVR++g/eRsOoOQD+YNZnh4lU1S/JVriGLYvfHBP6kD8q56OIf1Zxt3X3ms6Vq1/mVPGCR3T3gX5vLiERx65JI/UV0NpdI+iQXcf3PswkA9ML0rmbeEvYS7zukZdxPqTya1vBbLcaBJauDtikeFh7Hn+pqa8EqS68rKpt8780YMGr28OhPdqBJh2WQMfmJzz+Oat2u19Js79cvDva3cOMgruO0ke2cflWNd6LY2LXct1E7yxOQUVzskfsSvcniuxu7JbHwr9kI5VVz7uWBP6muivKnHl5L+8/wAP6ZlTUpX5uiKVnKBd3t0qqI7KDaigYG5ueg9gPzrIv1ENtDKlyI7lHGx2OAX64z79Pxrb0eETaVrESAmVpGyM8n5Rj+Vcdqun31zaLHLdRNp6kSBs/OQORx608OoyqNN2tb8v+HFUbUdv6udWLlbzxJ4PuFG3zJLolf7p8g5H55ro/Hf/ACI/iL/sHXH/AKKauS0mN01fwc0gx5k15IB7GEkV3eu3cWn6JqN5cRedBb28k0kfHzqqklefUDFeHiUo1Wl/Wp7OFd6V3/WhV0xJpfCFpHaSCK4exRYpDyFYxjB/PFeA+EfDGop/wgFhZ+F9S0zxXpOrG41vV5rYoksGX84G56TeZuXABb8K9f8AhvpV/wCHPANuL3UZLxhaieK3I/c2i7dwgiY5kZFBCguzNhRyOlc/Z/GOxsPAfh7X/E9ldRHUrX7RI1nEGii+YgjLMCfXAycVzs6VscbY3/jzWbTw/wCHtQs/FEFyv9sW+rXUlqUhm3RTG2xKRtI5QBumeMms62h8aaf8OvBVjpY8V2ljFHLDqgFpMLm3nEaCNVRE8wwg7sFQQT1JFeyr8TPDr6iLCOa4e8a/g09YRCdzPNH5kbgf88ygLbugxWZZfGfwjeT3iQzXflQWtzeRzmD5LmOAEymLnJIAJwQMjpmgZjfDmHxjqfi0N4i1XX4bCy06ykUNai3ivJsOJN4dCQeFLKpU5IzjpSfFO28WX3ivXI9FvvENnp1p4Xa9tBpqkJPfpLJtj3bTuYgLlFIJGK9J8J+I7TxRpX9o6dBfxWrMBG15avbmUFFYOgcAshDDDDgkHGa2aAPnjW/EXxDt9P8AEVuNP8TSahe2+jz6dNbWLNHCdkP2tSQPkYt5mVxnrwBzVjxYniS+Hjy01ePxhLqEy6hDpltY2zPp0tobZxCGIUqWPfnfvwAK9/ooA+bdc/4WFZS6Rb2T67p9lb6PYfYPsVjLOgmVB5yToin5sjGJMKB3BrRv9R8df8LWL2Vt4lt9PXVJbaSF4ZpraS28ttsyvt8pVJAwBlgepz1+gaKAOE+DNprieCbC+8U6hq9zq95Ajz2+ooqG2YZG1VCKwzxndk13dFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACUUUtABRRRQAUUUUAJRS0UAFJS0UAFFFFABRRSUALSUtFAHKeOLaWza08TafE8l5pO4zRRrlrizbHnRgd2AVZFHdowP4jXS2lxDeWsNzaSpNbzIJI5EOVdSMhge4IOalrkfC5/4R/XbrwxIcWbq19pJ7CEsPNgH/AFzdgQP7kiAfcNPcWzOvpKWkpDFooooA8ivYvtc+uIpwftlxGp9Pmz/M1sXcxv8ARrTU4gpe2+W4jI5HQH8iM/Q1StQDqmq7hwdRuB/49Utk4s/FEdmV/wBH1GNoHXtnaSD+h/OvoKetKNuiv8ra/gfPVFapLzdvnfQik0228Q6vFaFAtrHGZpPL+XDYwvT/AGiD+FZs+jQy/ZrVLVH1NpjE0pH3cfeb8ga6XwAiIupqzZmR0Vs9lC8H6ZzWTHqUUXiJ9VyfsSXEgZhz8jDbu/Pn6VtGrUjOUIbRWnrb9f0M3CDipS+1+X/AFv7QPf6kgGFBESj0VVAFaXh3f4h8FS212v76Jnttx7sn3G/lTZmjl1jUApVl8zgg8H5QaZ4GuvsvhbWpxgmC9mCj1O1cD8yKyqtuimt042NIJc7T2adzH0ISXmvaKJRgoWkZT6qp/rXT+Nh/xL7ZD917gZH0Vj/MCuS0dv7L1rTLmd/3Yl8p27LvyM/ma63xx/x72K8j/SD1/wCubVWIT+sU2trfqyaf8CV97r9DifFsfleHo7jOGQh0YdQQc5/Su68XWovvDMkjNslhVLhG/wBodvxBI/GuL8bMF8JjHZa6jxhK72VhZrkLLhmx3wBx+dXUvL2TX80v0CNl7ReS/Uq+C5EXWpkmP76S2HlZ7gHLD69K1/EGP7RsQe6n+dc9fQi0fSryPKyx3Ua5BxkEgEfka6HxBxq9lx0X/wBmNc9VJ1lUXVP8DWGkOR9H+ZiuceNdFGOd7/8AoBrc8SxiO7tpVO1yrbvoMf41zk7EfELQl5wXk/8ARbVsaxKbnWJlJ/dwgQqPcjLH9cfhROL9pB/3f1YoP3ZL+9+iMKPTkj02LUGbdNes759FBAA/mfxqfRIwniTSGI+ZvMA/74as77b5TJpJYlreSZgPVG2kfkc1pafJt8SeHx/eaTp/1zauqopKEubqpfdZ2/Axjy3Vu6/NXOj8VagLW2S1AzJcdf8AZUEVhWdz9h1SS3wNt7ayKe3zKpYH+f51o+JV8zWrcHoIM/8Aj1ZGtMkeu6bHjDvHKFPv5TVy4aEfZqFt03/X3GteTu5dnY0NMUtYkn/nkD+lWvAa5ttSbPAnyc9B8oqtpODp45/5d1/kKo6TcPF4b1kK20NeJGT3wQuRRUi5xnFdWvzKjJRlGT7MsajcxXEzXQUNB9qR+eMoGXn9M1seKpcNp9uAcSz7j77Rn+ZFZMUSy23lYypTBFZ+nXU1xYaSlxIzvb3VxAGPUqoGM/gafsk2mvs3/LT8hc9k0+tvzX+Zt6ZMtn4j8tvlW7TaOwLrkj8xmsLXIlM8wVwIJLraPQKXwf5mrPjGRoEtZ4W2OjKysOxzUGvRKugyOvBUZz9K1oxs41P5tPuIqvSUe36m9qOB4y8Jqowqy3QA9AIDW148/wCRH8Rf9g64/wDRTVhXZLeLfCLHqz3J/wDJet3x5/yI/iL/ALB1x/6KavAq/Ee1Q+Bk+ixLP4XsIXJCyWcaEjrgoBXn998D/Dt3p2n2Y1HWoEtNMbSN8csRaW3LF8NujIDZY8qFz0ORxXovh3/kX9M/69Yv/QBWhWRutjzWx+GiQfF208Vt9n+xWGkR2NsocmaSZdy+bINoXiNiowe/aksvg3oFjbX9nZX2qw6bd29zbCzV4dkKToytsYx7+A5wGZgPSvS6KBlPRtPi0nSLHTrZnaCzgjt42kILFUUKCcADOB6VcoooAKKKKACiiigAooooAKKKKACiiigAooooAKSlNFABRRSUALRSUtABRRRQAUUlLQAUUUUAFFFFABRRSUALRRRQAUlFLQAUlLRQAVz/AIz0m41LTYrjTBGNZ06UXlgznCmVQQY2PZXUtGx7ByRyBXQUUAZ+gatb67o1pqVlvENwm7ZIMPG3RkcdmVgVYdiCO1X65GDHhnxm1sfl0nX5Glh/uw3wUs6ewlRS47bo5CeXFdfQxIKKSloGeWW5/wCJpqY/6iVx/wChVS8U3kun6/otxEB5ouAoz7ow/rV21GdX1L/sJXH/AKEKyfiA+zVtDHreJ29jX0uDSk4Rf8r/ACPnMTdKTX836jdTuLmy1q2S2do47xDDOV/iXGf8n3NaSwKPD86BeCmMYqn4hUHVdDOcEynPv8prajUHSJh221rOXuwf9bmcI6yX9bHM/DS4kuNLkaRyzLIyZPXAAArX8Luf+EH8S46/2nJg/jFWR8No/LsrsZyPtEgrX8NJs8HeIwBwdQc4/wC/dPF255esfzJoXUF/hkV9Vt1utJvUY4wDyOMVqXN3LqHhHw5dXD755FDO/wDeby2BP44qnqMZfTNQUHHBpmlAjwB4VVjkgMMn6PUyScYvtL/21l7Nrul+ZQ8cgjwqmCAeMV1/igBZdNJ67D/SuQ8bvjwrEeDyB1966nxfIFl0zP8AdI/lUyTfs/WX5IpPWf8A27+pneJXIstM2HrfQZ+m9a6DXz/xOLY56L/7PXO+ID/xLrA4zi6iP/j4rc16T/iaQY6Bf/Z6wa+D/t79DVOzfyMe7XZ8Q9EPGN7/APotqs2sm+W5c9WuZP8A0I1W1Eq3j7QznGHc/wDkNqfYN++uVIwRdzD/AMfNaNXjF/3V+bIjpKS83+SOdvMDxjMc9YnP6itq1fHiXw1k4+aT8f3bVzerPjxxLg9Ld+PxWtqN9viPwwOzSOP/ACG1dlaPuR/wv8mYQer/AMS/M6nXmH9rQk/88P8A2asLxIoHiDSpD/Ckjf8AkJq1tdf/AImcRP8Azw/9nrF8UN/xOdM5/wCWcnP/AGyauHCx+H0f5G9d+6/VfmbGmH/iXKR3tlP6Csa2k8vwvqrdjqMf/staekyAaUnp9kT/ANBFYVtN5nhPVskcajGB/wCOVpCPvP1X5hUdkvRnQ6fJuUZ/uVj6Sc21k2Bzf3X/AKCtX9HfKj/c5rL0mQG1tcE8X9z/AOgrRGNnL+ujFJ7f11RY8etixtvTep/UVP4kUDwvcegjb+VUvH7qNNg3dmT/ANCFXvFHHhS7A4xG3b2pw0hS9WKe9T0NSQ58TeDCOhNwf/Jeug8ef8iP4i/7B1x/6KaubR9/iDwS3qJz/wCS1avxP1ay0zwVq0d5Oq3F5azWtpbjmW5mdCqRxJ1dySAAK+frr95Y9vD/AMM2vDv/ACL2mf8AXrF/6AK0ap6NBJbaRYwTDEsUEaMM5wQoBrD8OeOdD13wNB4uS5+xaJKrsZr4rFsCyNGd3JA+ZTjnnIrA6EdQKKxNL8W+HdVhtZdN13TLlLqVoIDFdI3myKMsijPLAYJA5xzUF7448K2VpaXV34k0eK1u2ZLeZr2PZKVO1trZwcEYPoetAzoqKzF8Q6K+rDSk1fTm1MkD7GLlPOyU8wDZnd9z5unTnpUd/wCJ9C07WbbSb/WNPttUuceTaS3CLLJk4GFJycngevagDXorjvDPj/TPEvjDW9B0mN5v7JylxdiaLYZAVBRUD+YRyRu27cqwznGexoAKKKKACiiigAooooAKKKKACiiigApKKWgAooooAKKKKACiiigAoopKAClopKAFooooASilooASiiigApaKKAEpaSigBaKKKAMvxLo8eu6LcWDytA74eG4QZaCVSGjlX3VwrAdOOeKg8IazJrWjiS8iWDUraRrW+gXOIrhOHAzztPDKT1VlPetuuQ1wjw34pttcQBdN1Jo7HUugCSZ2285/E+Ux6kPHnhKa7Cemp19AoopDPKbOVV1zU1LDP9p3HGf9oVh/EByda0b5cAXacg+xrRhl8rxJqobbg6nPjOB3FYPxEcf2xpBjIB+1Jnb+NfV4CHvw/wAP6Hy+KlpL/F+pu+I3C6hoRxn96f8A0E1p20udLuOB93pWDr0w8zRW3H/W5wB/sn2q9ZXKtp11w2QP7h/+Jpypv2cf66ijO05f10Rl/DdwljdrnJW4kB/StrRj/wAUj4gHGTeM36R1zfw3kULqQyc/anPQ+g9q3NLcf8Il4j4wBdNwe/EdXiofvH6xJoy/dr0ZplUksb7JyfmyPaqNgfL8EeGwTjAb2/heq8V4sdpeSKckA5G7/wCvTLWYnwL4cfJO4kA/hJ71n7Npf9vL/wBJZbmnr5fqjO8b3APhaJVPO7+tdN49OINNl3fdYr+grivF0xPhpSy/Kr9c+/1ru/GMRufDkrAnfCqzLj2xn9Ca0mlB0vWX42Ji3JVPRfhcytblL6NZg4x50fP/AAIVv6sVfVYt/wB1Yix/Bq4fU5z/AGFZyM54nReR710vied4r6NUB+aJs4H+0PY1nOk7xS/vfoaKpo2/Ir6hKP8AhN9FJ672x+KGpLaVlvbvbyPtkvGP9qsa8kYeN9CG3AZ+/H8B9qulsane/MeLx+Mj29qt09Ir+7+rIU9W/N/oc9qcznxzMOv7hz+orbMhXxP4ZBP/AC2I/wDIbVy2pTonjWRsfMIXGMjuRW2kwfxX4bG5f9e2MHOf3ZrsrQ9yP+F/kzCE/e/7eX5nV+Ipymo2/THkk8/79ZPiaUtqujMCMO7IcH/pm/SrPigkanbHeoH2c/ebH8Y9xWTrk4Gq6KnyvumB+90OxveuLDwVovyZvWn8S80a+kTSHTFzgD7IpPP+yKzNAjkvfDOvxQth0vFlGfRVVj+gNTaKrPpaYyN1mnHzegqX4brsttYV8f8AH2Mj22DinU9yM5Lo1+YRvOUYvqmTaJdpJGiRMCNvJBrH0WYmyh+bgajcDP8AwBasadbPZa3dWv8ABG5UFh1HUfoRWbpG1dPUPjA1ObkgAf6ta1UI3k11t+TIc20r/wBao1viAWXTFJJO0KR/30Ku+KHP/CLXBYn7j5/I+1ZfxCdWsBjYSFRu2cZFXvEUu/w3L8p6sM7QPWsoR92l6/5DnLWp6Gzpz79Z8CMDkNHMf/JYV0fj19TstFl1fRri3S40uOS6aC4hDpcIqEmPdwyEgcMOh6hhxXLaJ/yEvAHOf3Mv/pMK7Lx2CfBHiEDknTrjp/1yavm8WrVmv63PosN/DNayuFu7OC5jBCTRrIobqARnn868b8NfDXxvo3w3bwbF4i0e3soIybW6tbeZLgSG4EpDvv4UguuUCsMqQeDn1HSLjy/B9lcQlX22CSIeoOIwR+FeAXfxV8Q6/wCC75ZL3SZWv/DN1qLjSkeKXTJU+VQ7eYx+bPH3SD+vKdKNTxH8K9d0j4e60mmSC78ST63BqmnNY+Z/o8nyRsWaVmYgLvySxz+lbmvfBXzF0YaNeW/k2ejDRLi0unuY4p49xYuTBLGxJYtuVsqc+wrHf4l+LfDdpd6fqf8AZF1LHp+m3NveiKRY7ZLiQRs0+XJcL1JBXJ9M4EWvfETxPc6RpM9rrOj2yWvi5dIm1WOFhaXsXlllkI8ziPOQ6hjkgYYcigD0jwL4BXw34n1vV7g2c73sVlFblIjugEFsIWwzFmAbGepOOpNY/jD4XXuu+ItcuLfVbaHS9elsZr9JLdmuIjakFRC4YABgozkHHJHWsux+KGtTeOotPZtIkt3199E/suONvtgiWMuL3dv/ANWcZxsxtI+YnmsuT4reME+Hmk+JLi20RItW1E6fE8MTAWoWWZGkk82ZEOfLUAF1GSSW6CgD1HwT4Tbw7q/im9klhl/tjUTexhEwY1KKu0nvypP411leF2nxQ8RXaeH7G+vfDWhXF4LtrjVbh0uLY+Sy7UTy59gdgwLAyHbg4qJfi14km8cR6dBHohsYLmzgmV5YoftEUyIWniaS4Vzkt8irE+RgFs8UAe80V896J8VvE+vQadHBdaC9zqllqhe2tLeTzdNa23+XLJ+9JIfaBgheSMZqHSfij4it/Bnhfzdd8PfaLrS7i+l1O8iZ0Z4UQi1YCUfvjuJY5HBGFoA+iqK8q8LeOfE3iXxdpun29npdjZPo1lq92lzHI0y+aWDxoQwHbgkcdweg9VoAKKKKACiiigAooooAKKKKACiiigBKKWigAooooASloooASlpKWgBKWiigAoopKAClopKAClpKWgAooooAKKKKACqup2Ftqmm3VhfxLNZ3UTQzRtnDowwRxz0NWaWgDmfA9/dNb3Wi6vK8uraQ4gllfg3MRGYZ/wDgajntvWQDpXTVyPjZX0e4tPFdqpP9nqYtQRRky2TEFzgDJMZAkHfAkUffrrI3SWNZI3V0cBlZTkEHoQab7iXY8Ve4WLxXqyEru/tKYgEH29qwfiPcs2p6USVGLlD0I/pW3OU/4TDVT5rKRqEvC7cZ49VP865f4q3KfbNMjZzIPtCE5wfX2r7TLY3nS0+z+h8nim/fX95/mbuvXB/4kzqgDeYAMg88H2/pVvTppm0y84GQvp/9asXUmR00MPIAhlUEMRxwea3NNEKWF4FnLAg4+YH+VVOKjTWn9XM4tubt/Whz/wAO3YDUFcAZuGPPUZAro9IyPCPiYjA/0luR0HypXJ+Dbr7PJqLSMRvnO3POcKBXQ6bqMEXg/wAQx3DFJpJ9yIVOWUhORVYum3N2XWP6F0E+T5MRJFFhqQMhIwx4cH+tT2ThfAHhlg38RGR9JKzRfRLYX213O4HHX/GrNhdwS+AvDqqSzxykMu0jHEtTUg+Vafa/9tYQ1T9P1RkeM5wfCrA54bP05+teqvGs9qIpOY5YgrfQrg/zrx/xtMsfhqQKrb+TyDx+OK9XfVbWGO2EizjfGuD5RPO3pWGOhL2cOVdZfob4Rc0p/L9TzPWGaDRTauD5lverGTjPRsZ6V13jZ0TULcyRGT902CFzj5x7GuZ8cxQpPczRwsI7hknG5ApznDdvUVteJtSs9QuYCgdWELfLKu3qw9Tz+Fbv3pU5Jd/xSMLOMZp7q36mNJMJfHGgMIgmJRnjr8p9hWnMB/bWplguReH/ANBWsRrq3g8V6NJIQFSQFtg3N0PQAmth7iGbUtRljHDXZ4fCt90dQTVzVmtPs/qRG7Tfn+hyOqu8fjmXysKTEec4yD+dblvO3/CQeFSxdj9oKklsjlWrndSlD+NpSrAZh5Oc9vrWjczy2+peHJoSss0dyCsZzg5B7/pXXUheEV/d/RmdO/P8/wBTsvF0m3VLb7v/AB7nGf8AfH+0Ky9VZ31zRBhdgmUkqR0Knr8x9am1S8nvbuKSe3WH9wQoSQnPz+1Q+ILpF1DRkwd3mqR8zcnB/wDr159FNKMfJm9Ze9L1Rc0OV/sMSrAD/oij76/3R71Z+Gzk2+sBl2EXQyAQf4B6VT0W5CWMGMkC1UZLH+6PeqPg7U7uxl1Zbe3imRplY7mOQcY60q0HKnUS8vzNKP8AEh8ze8UI9prVtcwop+0JtfcehXp2PY/pWF4f3tbYZF41KYgAnH+pT0FbuuSX97p8cs0EKmGYN8gyQCCD1rmtFmnEohMCMi3ryGTeASTEBjGPY0UE3Rt1X/BFWhyVWn6/kX/iG0psowVUKyLn5n9R2xitbXXlbwuwJQMCQ2GbH+Nc98Qp/wDiXxZjA+UDO4HuPatbxBd+V4dnHJAbqE4P604wfJS9TOUtanobnh5t998P29YZj/5LCvQtfvv7L0LUdQ8vzfsttJP5ZON21S2PxxXl3g17r+1vA0d0ysnkzGPC4wPs+P8ACu/+Ic0dv4B8SSzyLHEum3BZmOAP3bV8vj48teS8/wBT6XC/wzO+G3hldF8IRW8t9dXQvYhM8bv+5t965Mdun/LOIZwqc4AFVPB1x8P9H8O3Wl6HquhyafpkQivGa6ifYgJA85s9Ooy3Haun0+z+0eFbayn8yLzLJYXx8rLmMA/QivJ4PgrfzaNcafqWt2eyHQn0Kxe1tGQmNpBIJJssdxyo4GByT1riOlHfeLfF3hDwtp95e6vd6cvkpDFNFGY2m8uRsRgpnJU/MR2wrHoDU0/iPwUqadpM+q6B5d8qvZ2pniKTKT8pRc4IJ6EdT0rz7UfhLr+taf4mGt61pT6hq1pYQRPb2jrHE1rJvGVLEkNgAkEdTx2qTXvhFqOreIrzVZr3TJRqaWpvrRzdxwRywKArRpFOgYcAgSA4IyDyRQM9NsNU8PX2tzQ6ffaTcaxCrxypBNG86BGCurAHcArEAg9CQDVWPX/CR1OTwxHqWi/bgH36YJY93QswMfrjLEY6ZNU/h/4NXwtP4huJjbTXWqavdags0ceHWOZwwjLdTjH0rjJfhHqVx4q1q7/txLDRdTa9ae1sfOHnm4jZN7o8jRrIob76AE47ZoA7ez8QeCNT0i9W01Pw/daXp3z3KpLE0NuOfmYdFHXnp1pU8UeCL22j1ca34dmggdYUvDdQkROwyqbyflY8kLwa8n1H4OahYeDtTinmhv7uOzt7W3ktUubiadYZ0kRXjnuDGE+XlExjJx/dNnw14D8R+J2v9U8SW0OmSXHiax1fyJYdvmw26BWXYHfbu6Dce2SBnFAHffDqfwHpVraaN4R1bSriWSOWeJY7lJJ5UMjMxJHJAYt9Me1XbXxH4DurG8W31bw3JZWMge4xPD5cDs21WbnAJYgA9zxXF2PwceG906SS+tkigvtWuJTBEVdo7yJo1VT2KbvpxxWMnwM1D/hHrvTJtS06WU2MGnw3jG7eRoo7mGYBkkmeNFxERtRQMtxgZBAPRdT+I3gjTbFdaOtaXPDJdJpzXVtNHJhychWYH7o5Y84A56Vsp4y8Mvq9vpSa/pT6lcKrw2y3aGSQMNy4Gecjkeo5rgfEnwnuNQ1DxPd6fd2Fs2o6jp2o2kT25McbWyAMrgEcMQTx61JZ/DXWofiDF4gTWLSwtWuFury3sFmVbxhGF2vG8jR9ejhQ2AO/NAHrFFFFABRRRQAUUUGgBKWiigBKKWigBKWikoAWiiigAooooAKSlpKAFopKKACiiloAKKKKACiiigAooooAKKSloASlpKWgBCAwIYAg8EGuS8HM2iald+E5+IbVPtOlsf47MnHljnkwsdnshizyTXXVznjbTrq4srfU9Ij8zWdKkN1apkL54xiSAk9pEJXngNsb+EU0J9zzLWka017U7x4isD3037wRbskNjk4rDutMn8T+ItNe3jmktrecSSSCLaigA9zjvjivQdM1kXuhz6jpTvNa3F7NKropzsL88dQQeCOoIIPStrT76S5t9zrKFzhd4OTX0mHxs6VFNR1Ste/l2t+p4ssFGVZvm632/r8jgtQ0VotMW5iTcYJwSUUkqoY56Vlfb5hbTIEuC0mRjYw/rXfw6lLZk+ZG/ks7YYKeuTWjHMz39tOQw+RsDB7kVpHFypq043+YVMGqs24yt8v+Ccb4W8KXUmiQG4geGZmZwJfvKCxIyPcetad74cYWs9qg8yd7YAKPl3lSp/UitO+1ma1v5jIXAQgJGFOXzV03BfUY3KMCY89PpWE8RX5/aPrr+p006dPk9kumn6Hl8ul6qwuIE07UDIzY2iA4J+uMfrXTWnhiaXwpa2CwoL20RGMTnA3HcSM9M4bFbaeIZFvpY5zg7wiRBeeuK0LS6H225IyR8vY+9aV8XXaXupW1OehgqWqve+h5dqngHxDqsX2UWCQI52tI8qbVHc8HmvSNXsFN7p8a9PmQfgmKpf8ACTOmqm1m8zzWlKLEFPA9f/r1Z1W8Zb23dFZ2QSMoweTt4pV62IquKqJJJO1vM1w1GjSUnTbfe5neNvCd1q2l2i6bs+0QyfMrtjKE5P5HmsTxRoeo3llp76bbC4AjZHKHbtO7jv0rsLDWhNtXqdvzEDoaoadfTRabC4RmXzG3hVJIXJxSo1q9KyaXuvT53Crh6VRSeutvwOB0bwdrY1UX19ZpFaWqNIWeTknaQAozycn6V1Oq+FdW/tS6utPt4J4538wfvNrA4Gc547V0FxqDy6Pel43VSpCAjBIpLnULmJgYo3kVlG0gcA1pPG4ipPnsr7eXfuZLBUY0+W77+Z5pdfDrxFJrK3jT2ZvPLZ1sw5Hy5A/1nTd7dPer+leBNek8Q6bd6lDFaWNm/msxnVy57AKpPf1xXetcyNq0LNxL9kcf8C3LT4tQuGjKSxOoVeWYd60lmWKceXTa221+2v8AmCwFCMlLX+vkc/qegXep6bp91phBkjEiMhODtLkgjP8AKufv/Cety6lZXl6qxWdm3mu5ddzYHAABJ6nvXZWd3JDpFoY1dkXO4ICT1qbVb57nRJmdGTcOFI5xkVFPE16T5Va12vPUqeEo1J8zvffyMJvBesIuy2uLRo9u0PnbkdsjscVa0zwm/h/RJzdXKXE80yuSi4VRkAAZ61r3Gp3UFwESJ3idRtZVJx6g0/VrtpdMCyg5LITx/tCsZYjETtGTVm0XSw1CEnKKd0aS6XBcWbQyE7ZEZSfrmuB0/wAIX9jHJaNdwPeCb7SjDO1k+7gnsT19sCupt9QuIwIjFLu3cyY+UjNQ31xK2oOYQd4txjjvuPFTQnWpNxT0ZpUpUqvvNao5bxB4K1O/tyZpbeIKNxLPuyBzgAVZ1HwdqOo2v2d54IEbB3lg+PoAOfxxXQXF/LNaXG+KRFEZADDBzihHu45meNDIkoUgk42cfyroWKxCS1Sttp6HL9Sob6u4yK0i0/xh4LsoCSkKXKAnqQIQM1s/EeBk0231b+x7LWIdJdr2S2uGIfaik7ouqmRcZUMMZAwVPNYzSed4/wDCpHOz7UrEdiYun6V2/iPUF0jw/qmpSIrpZ2stwyu20MEQsQSeg4618/ir8+u56tJJRaRbs7mG8tILm2cSQTIskbjoykZB/I15XoHxu0vWLKK4/sfULCO7sLu/sJbySJYrlbbd5oLIzGPBU8svQE+mes+GHh1/Dvhe3ilv7u5e4RJzDK/7m1JUHyYEPMcS9FUk4AAzXK+FPgpo/h7wBe6Gk0c+s3enXWnNrDQNuVJi/wB2MuQoG8ZCkbtvJ5rmNUdPefEjwvpkFkdZ1e0s7i4s470xhmkEcbgYYsowAScAnGe1P1b4k+D9I1eTS9T8QWNrfxP5ckUjEFG27gGOMDI6ZPPQZNeSfED4X+KG+26P4Vjeez1fTLCwv7qZYFiJtvlVwTL5icDJUI+c9fTv9R+F323XrvUv7Y2faPEFjrvl/Zc7fsyhfKzv53Y+9jj0NAzck+JHhGPQ7PV21y2NheM6QOoZmkKffwgG75e/HHemat8TfBmkiA6h4isYhPBHcxYYtvif7rjAPyn16DvXHXvwTSZLaWHW1W+t7++u0eazLwsly4Zo3jEik7cDDBh7jtVsfCBRYaxbLq8Ua6hoK6IBFY7Ehwzt5irv6fP93Pb7xoA6LT/id4XvfEHiDSRfiCXREElxPMVWFk2hmZGzyFyAScc9Mjmpo/iT4Qk0mfUl1y3FpBMlvJuV1cSOMovlkbyWHIwOQCR0Nc1c/CMXQ8T20+uOdM1+xtba4gW1AkSW3iWNJFk3fd+TJQqc/wB6qVt8G7m3Ed1Hr1lHrFve217BdxaUQpaFZFxKhmJkyJT0ZcY4AoA7r4e+LoPGmi3Gp2tu0EMV5PaKGbO8Rtt39BjPXHaunrlvhz4Uk8H6Jc2M+oDUJri9nvXnEHkjdK+4jbuboT611NABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAYooooAKKKKACiiigAooooAKKKKADFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc7L4K8PSzzTNpkSvNI0snluyBnYks2AQMkkknuSTTP+EG8Of9A4f9/pP/iq6Wiq55LqLlXY5lfAnhtBhdMVRnOBLJ1/76oPgXw4WDHTQWHQ+dJn/wBCrpqKftJdxcq7HMN4D8NOwZtLRiOhMshI/wDHqU+BPDZIJ0xcjv5sn/xVdNRR7SfcOWPY5U/D7wsZvOOjwmbpv3vu/PNOXwF4ZViy6UgY9SJZOf8Ax6uooo9pPuwUIrocufAPhgtvOkxl8Y3GR8/nupD8P/C5YMdIiLDoTI+R/wCPV1NFHtJ92HLHscsPh/4XXONIiGeTiR+f/HqI/h94XjGI9IiQeiyOP/Zq6mij2k+7Dkj2OWk+H/heRSsmkxsp6hpHIP8A49Tx4E8NgEDTFA/66yf/ABVdNRR7SfcOVdjlm8AeF2kDtpMRcDAYyPnH13Up8BeGSpU6WhU9jLJj/wBCrqKKPaT7sOVdjlk8AeF0XCaTGo9BI4/9mof4f+F3GH0mJh6GRz/7NXU0Ue0n3YcsexzA8BeGQMDS0A9PNk/+Kpj/AA+8LOu19IiZeuGkcj/0Kuqoo9pPuw5V2OW/4V/4X4/4lMfHT94//wAVSf8ACvfCu/d/Y8O713vn/wBCrqqKPaT7sOVdjlW+HvhVhhtHiP1d/wD4qgfD7wt20iL/AL+P/wDFV1VFHtJ92HLHsYGleD9A0m9ju9P0yGG5j3bJAWJXcMHGScEjjNWfEHh/TfEEdvFrEDXNvDIJRbmVxFIwII8xAQsgBAO1gRnnFa1FS227sdlsQ30ksNlcS28RmmSNmSIHG9gOF/E8V81aV8XPGL6Br+oXOoaW9zb6VJdGyMSrNZXCyKNpjHzBMMRiTnIBBr6brP1/R7DxBo13pWrwfaNPu08uaLeyb19MqQR+BpDPA5PHerarq1nA97Y69pMfiTRooNQS18tEklLGWJcHDFMLg5JGcHOaxbrU9duvtOnXnih7jVLb4hW8EUU8RZrZDMwjk2l8+U3BWPIXCnB5r6jijSGJI4xhEUKo9AKfQB876l8SPGOnaNPbXF9bFrTxJdaPda39lSNY444keMspyiFmcrk8AD15rA1bxRqt8msazqclheXv/CD738gl7aZl1GVA4HGchQeOPTjFfU9FAHgfjH4sal4cl8X6d9oggvrQaU2jxPbE+ZFKIhO2cYIBZxkng8daLjxt40u/FUlvZa1Y2tlJ4pufDscTacJDGiwiRZS28ZYZ4HAzycjivfKKAOL+DfiDUPFPw40nVtYeOS/lM8crxpsDmOaSMNt7EhASBxk12lFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Laminar organization of the retina.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bear, MF, Connors, BW, and Parasido, MA. Neuroscience - Exploring the Brain, 2nd ed. Philadelphia: Lippincott Williams &amp; Wilkins, 2001. Copyright &copy;2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_58_16294=[""].join("\n");
var outline_f15_58_16294=null;
var title_f15_58_16295="Overview of hepatitis A virus infection in children";
var content_f15_58_16295=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of hepatitis A virus infection in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/58/16295/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/58/16295/contributors\">",
"     Rub&eacute;n E Quir&oacute;s-Tejeira, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/58/16295/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/58/16295/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/58/16295/contributors\">",
"     Elizabeth B Rand, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/58/16295/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/58/16295/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/58/16295/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis A virus infection is one of the most frequently reported diseases in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/1\">",
"     1",
"    </a>",
"    ]. The hepatitis A virus (HAV) is a 27 nm single-stranded, icosahedral, nonenveloped RNA virus that belongs to the Heparnavirus genus of the Picornaviridae. Four well-defined genotypes of HAV have been described in humans, yet they belong to a single serotype [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/2\">",
"     2",
"    </a>",
"    ]. The virus is stable at low pH and moderate temperature, but it is inactivated by high temperature, chlorine, and formalin. These characteristics are relevant for preventive measures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis A virus infection occurs worldwide (",
"    <a class=\"graphic graphic_figure graphicRef69392 \" href=\"UTD.htm?8/14/8424\">",
"     figure 1",
"    </a>",
"    ). Although it remains one of the most commonly reported vaccine-preventable diseases in the United States and among American travelers [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/1,3\">",
"     1,3",
"    </a>",
"    ], the incidence in the United States has declined substantially since vaccination was recommended for persons at increased risk (in 1996) and children living in states with the highest incidence of HAV (in 1999) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/4\">",
"     4",
"    </a>",
"    ]. The incidence of acute HAV infection in the United States has declined from 12 cases per 100,000 in 1995 to about 1 case per 100,000 in 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/5\">",
"     5",
"    </a>",
"    ]. Declines were greatest in states in which routine vaccination of children for HAV was initiated in 1999. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7591?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of hepatitis A virus infection in adults\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A similar decline in the incidence of hepatitis A infection was seen in Israel following a universal immunization program for toddlers that was initiated in 1999 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. The incidence declined from 50.4 cases per 100,000 in 1993 to 1998 to 2.2 to 2.5 cases per 100,000 in 2002 to 2004, and outbreaks in school and day care settings were essentially eliminated.",
"   </p>",
"   <p>",
"    To what extent the observed reductions in the incidence of hepatitis A infection in these reports can be attributed to improved environmental and hygienic conditions or variation in the epidemic cycle is difficult to evaluate [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/9\">",
"     9",
"    </a>",
"    ]. Nonetheless, the above reports highlight the potential for \"herd protection\" through the immunization of toddlers or children [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/4,6,8\">",
"     4,6,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HAV is spread via the fecal-oral route. The majority of patients who acquire the illness have had personal contact with an infected person (",
"    <a class=\"graphic graphic_figure graphicRef66917 \" href=\"UTD.htm?12/49/13086\">",
"     figure 2",
"    </a>",
"    ). In the childcare setting, spread of HAV usually takes place before the index case has been recognized. Outbreaks are usually recognized only after childcare staff members develop symptoms, such as jaundice, since most of the children are asymptomatic or have nonspecific symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/3,10\">",
"     3,10",
"    </a>",
"    ]. The potential for broad exposure is compounded in childcare centers that include children who have not yet been toilet-trained [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical manifestations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Community, restaurant, and school outbreaks due to contaminated water or food have been described. In the United States, clusters of cases have been seen around international adoptions, more than half of which occurred in nontravelling contacts of adoptees [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/12\">",
"     12",
"    </a>",
"    ]. In a report of 288 international adoptees, 1 percent had acute HAV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nosocomial spread of HAV is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Among these reports include outbreaks in neonatal intensive care units where newborns were infected through blood-product transfusions and later transmitted the virus to other neonates and the units' staff members [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incubation period for HAV is 15 to 50 days. HAV RNA can be detected in stools at least one week before the onset of histological and biochemical evidence of hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/17\">",
"     17",
"    </a>",
"    ], and it can be detected for at least 33 days after the onset of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/18\">",
"     18",
"    </a>",
"    ]. In neonates and younger children, HAV RNA can be detected in stools for several months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/16\">",
"     16",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of hepatic injury during HAV infection depends upon the host's immune response. HAV infection traditionally has been considered a biphasic process [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/19\">",
"     19",
"    </a>",
"    ]. In the first phase, a noncytopathic stage, viral replication occurs exclusively within the cytoplasm of the hepatocyte. This phase is followed by a second phase, a cytopathic stage, with florid portal zone infiltration, necrosis, and erosion of the limiting plate. Hepatocellular damage and destruction is not the result of a direct cytopathic effect by HAV but a process mediated by HLA-restricted, HAV-specific, CD8 lymphocytes, and natural killer cells [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interferon gamma appears to have a central role in promoting clearance of infected hepatocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/20\">",
"     20",
"    </a>",
"    ]. An excessive host response, reflected by a marked reduction in HAV RNA during acute infection, is associated with severe hepatitis and a possible fulminant course [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis A infection in children is typically an acute, self-limited illness associated with general, nonspecific symptoms, such as fever, malaise, anorexia, vomiting, nausea, abdominal pain or discomfort, and diarrhea. During the prodromal period, aminotransferases are typically elevated. Jaundice (conjugated hyperbilirubinemia) usually occurs one week after onset of symptoms, along with choluria (bilirubin in the urine) and mild hepatomegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptomatic hepatitis occurs in approximately 30 percent of infected children younger than six years, some of whom become jaundiced. When it does occur, jaundice usually lasts for less than two weeks. Conjugated bilirubin and aminotransferases return to normal within two to three months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, older children and adults with HAV infection are usually symptomatic for several weeks. Approximately 70 percent are jaundiced, and 80 percent have hepatomegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/1,19,24\">",
"     1,19,24",
"    </a>",
"    ]. Symptoms lasting for up to six months have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute liver failure is rare, occurring in fewer than 1 percent of cases. However, the case-fatality for HAV infection varies with age. In 2001, the case fatality rate was 0.3 percent in children younger than 14 years, 0.1 percent in adolescents and young adults (15 to 39 years), 0.4 percent in older adults (40 to 59 years), and 1.7 percent in people older than 60 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/1\">",
"     1",
"    </a>",
"    ]. Acute liver failure secondary to HAV infection is more common in those with underlying liver disease such as hepatitis C [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/27\">",
"     27",
"    </a>",
"    ]. HAV is responsible for no more than one percent of acute liver failure in children in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/28\">",
"     28",
"    </a>",
"    ], and up to 60 percent of liver failure in Latin America [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/29,30\">",
"     29,30",
"    </a>",
"    ] or other countries in which HAV infection is endemic [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2330?source=see_link\">",
"     \"Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common extrahepatic manifestations of HAV infection include an evanescent rash (11 percent) and arthralgias (14 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/32\">",
"     32",
"    </a>",
"    ]. Much less common extrahepatic manifestations include vasculitis, arthritis, optic neuritis, transverse myelitis, encephalitis, and bone marrow suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HAV rarely is associated with a relapsing pattern. It may also trigger autoimmune hepatitis in genetically predisposed hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32980?source=see_link\">",
"     \"Atypical manifestations of hepatitis A virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of acute HAV infection is made by the detection of anti-HAV IgM in a patient with the typical clinical presentation. Serum IgM anti-HAV is the gold standard for the detection of acute illness. This antibody is positive at the onset of symptoms, peaks during the acute or early convalescent phase of the disease, and remains positive for approximately four to six months (",
"    <a class=\"graphic graphic_figure graphicRef57931 \" href=\"UTD.htm?16/1/16414\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The serologic detection of antibodies is simpler, easier, and less expensive than other techniques, such as HAV detection in stool and body fluids by electron microscopy and HAV RNA detection in stool, body fluids, serum, and liver tissue. IgG anti-HAV appears early in the convalescent phase of the disease, and remains detectable for decades.",
"   </p>",
"   <p>",
"    There may be special considerations when assessing anti-HAV antibodies. In adults, antibodies become detectable two weeks after HAV vaccination, but titers are 10- to 100-fold lower than levels induced by wild-type infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Similar data are not available in children. Anti-HAV IgM may persist at a low titer for 12 to 14 months in patients with a relapsing or protracted course [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32980?source=see_link\">",
"     \"Atypical manifestations of hepatitis A virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PREVENTION AND PROPHYLAXIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     General measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since hepatitis A is transmitted predominantly by the fecal-oral route, prevention can be aided by improved sanitary conditions, adherence to sanitary practices (eg, handwashing), heating foods appropriately, and avoidance of water and foods from endemic areas. Handwashing is highly effective in preventing the transmission of the virus, since hepatitis A virus may survive for up to four hours on the fingertips. Chlorination and certain disinfecting solutions (household bleach 1:100 dilution) are sufficient to inactivate the virus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7591?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of hepatitis A virus infection in adults\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;In January, 2006,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/43/38581?source=see_link\">",
"     Hepatitis A vaccine",
"    </a>",
"    was added to the recommended childhood and adolescent immunization schedule in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/3\">",
"     3",
"    </a>",
"    ]. Hepatitis A vaccine is administered in a two-dose schedule and is recommended for all children at one year of age (ie, 12 to 23 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/3\">",
"     3",
"    </a>",
"    ]. It also is recommended for specific high-risk groups, such as international travelers, close contacts of newly arriving international adoptees, persons with clotting factor disorders, patients with chronic liver disease, males with homosexual activity,",
"    <span class=\"nowrap\">",
"     injecting/noninjecting",
"    </span>",
"    drug users, and people living in communities with HAV outbreaks [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/3,40,41\">",
"     3,40,41",
"    </a>",
"    ]. By 2009, 74 percent of adolescents in states that have been practicing universal hepatitis A vaccination since 1999 had received at least one dose of the vaccine; in states practicing hepatitis A vaccination since 2006, coverage for adolescents was only 28 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link&amp;anchor=H53#H53\">",
"     \"Standard immunizations for children and adolescents\", section on 'Hepatitis A vaccine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/38/1641?source=see_link\">",
"     \"Hepatitis A virus vaccination and postexposure prophylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A compelling argument for universal vaccination of children is the observation that the disease tends to be more severe when acquired at older ages. In a report from the Centers of Disease Control and Prevention, for example, hospitalization was required in 13 percent of children younger than five years compared to 31 percent of older children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/1\">",
"     1",
"    </a>",
"    ]. Because humans are the only known reservoir for HAV, universal immunization strategies could hypothetically eradicate HAV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyclonal serum immune globulin (IgG) pre- and post-HAV exposure has been available since the 1940s and can decrease the incidence of HAV infection by more than 90 percent. Passive immunity lasts for up to six months depending upon the IgG dose used but is only effective if administered within two weeks post-exposure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/38/1641?source=see_link\">",
"     \"Hepatitis A virus vaccination and postexposure prophylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Post-exposure prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for and detailed recommendations about postexposure prophylaxis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/38/1641?source=see_link\">",
"     \"Hepatitis A virus vaccination and postexposure prophylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is supportive. HAV infection in children is usually a minor and self-limited infection; as mentioned above, HAV is often asymptomatic or associated only with symptoms indistinguishable from nonspecific viral gastrointestinal infections. The usual supportive measures for fever and diarrhea may be undertaken. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9912?source=see_link\">",
"     \"Prevention and treatment of viral gastroenteritis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18570?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathophysiology and management of fever in infants and children\", section on 'Management of fever'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No particular diet has had a major impact on outcomes of patients with acute hepatitis A. As a result, no specific diet is recommended unless patient has severely compromised hepatic function (ie, fulminant hepatic failure).",
"   </p>",
"   <p>",
"    Patients rarely require hospitalization except for those who develop fulminant hepatic failure. The following criteria were proposed by the Pediatric Acute Liver Failure Study Group (PALF SG) to identify such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/28,43\">",
"     28,43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Absence of known chronic liver disease",
"     </li>",
"     <li>",
"      Evidence of hepatic injury",
"     </li>",
"     <li>",
"      PT&gt;15",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      INR&gt;1.5 with encephalopathy",
"     </li>",
"     <li>",
"      PT&gt;20",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      INR&gt;2.0 with or without encephalopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These criteria should be fulfilled within eight weeks from the onset of illness, and the above-described coagulopathy (prolonged prothrombin time",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    INR) should be unresponsive to vitamin K therapy.",
"   </p>",
"   <p>",
"    These patients require aggressive supportive therapy, and should be transferred to a center capable of performing liver transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2330?source=see_link\">",
"     \"Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Return to school or daycare",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children should not return to school or daycare until one week after onset of the illness [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/44\">",
"     44",
"    </a>",
"    ], the prophylaxis program for contacts is completed, or directed by the responsible health department. In addition, adherence to universal precautions is crucial, since HAV may be present in stool for several months after the initial onset of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16295/abstract/16,18\">",
"     16,18",
"    </a>",
"    ]. Post-exposure prophylaxis and universal precautions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/38/1641?source=see_link\">",
"     \"Hepatitis A virus vaccination and postexposure prophylaxis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link\">",
"     \"General principles of infection control\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25267267\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatitis A virus (HAV) infection occurs worldwide (",
"      <a class=\"graphic graphic_figure graphicRef69392 \" href=\"UTD.htm?8/14/8424\">",
"       figure 1",
"      </a>",
"      ). HAV is spread via the fecal-oral route. The majority of patients who acquire the illness have had personal contact with an infected person (",
"      <a class=\"graphic graphic_figure graphicRef66917 \" href=\"UTD.htm?12/49/13086\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incubation period for HAV is 15 to 50 days. HAV RNA can be detected in stools at least one week before the onset of histological and biochemical evidence of hepatitis, and it can be detected for at least 33 days after the onset of disease. In neonates and younger children, HAV RNA can be detected in stools for several months. In the childcare setting, spread of HAV usually takes place before the index case has been recognized. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HAV infection in children is typically an acute, self-limited illness associated with nonspecific symptoms, such as fever, malaise, anorexia, vomiting, nausea, abdominal pain or discomfort, and diarrhea. During the prodromal period, aminotransferases are typically elevated. Jaundice (conjugated hyperbilirubinemia) usually occurs one week after onset of symptoms, along with choluria (bilirubin in the urine) and mild hepatomegaly. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HAV disease tends to be more severe when acquired at older ages. Among younger children (under six years of age) with HAV infection, only one third develop symptomatic hepatitis, and this often lasts less than two weeks. In contrast, most older children and adults with HAV infection are jaundiced and have hepatomegaly, and they are usually symptomatic for several weeks. Acute liver failure is rare, occurring in less than 1 percent of cases. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of acute HAV infection is made by the detection of anti-HAV IgM in a patient with the typical clinical presentation. Serum IgM anti-HAV is the gold standard for the detection of acute illness. This antibody is positive at the onset of symptoms, peaks during the acute or early convalescent phase of the disease, and remains positive for approximately four to six months (",
"      <a class=\"graphic graphic_figure graphicRef57931 \" href=\"UTD.htm?16/1/16414\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/43/38581?source=see_link\">",
"       Hepatitis A vaccine",
"      </a>",
"      is part of the recommended childhood and adolescent immunization schedule in the United States. It is recommended for all children at one year of age (ie, 12 to 23 months), and also for specific high-risk groups, including international travelers and patients with chronic liver disease. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Vaccination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Post-exposure prophylaxis for individuals with recent exposure to HAV may be accomplished with the HAV vaccine or immune globulin. Indications for and detailed recommendations about postexposure prophylaxis are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/38/1641?source=see_link\">",
"       \"Hepatitis A virus vaccination and postexposure prophylaxis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      HAV infection in children is usually a minor and self-limited infection requiring no specific therapy. The usual supportive measures for fever and diarrhea may be undertaken. Patients rarely require hospitalization except for those who develop fulminant hepatic failure. Children with HAV-related hepatic failure are candidates for liver transplantation. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Centers for Disease Control and Prevention. Hepatitis Surveillance Report No. 58. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention 2003. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/2\">",
"      Lemon SM, Jansen RW, Brown EA. Genetic, antigenic and biological differences between strains of hepatitis A virus. Vaccine 1992; 10 Suppl 1:S40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/3\">",
"      Advisory Committee on Immunization Practices (ACIP), Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/4\">",
"      Wasley A, Samandari T, Bell BP. Incidence of hepatitis A in the United States in the era of vaccination. JAMA 2005; 294:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/5\">",
"      Daniels D, Grytdal S, Wasley A, Centers for Disease Control and Prevention (CDC). Surveillance for acute viral hepatitis - United States, 2007. MMWR Surveill Summ 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/6\">",
"      Dagan R, Leventhal A, Anis E, et al. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA 2005; 294:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/7\">",
"      Belmaker I, Dukhan L, Yosef Y, et al. Elimination of hepatitis a infection outbreaks in day care and school settings in southern Israel after introduction of the national universal toddler hepatitis a immunization program. Pediatr Infect Dis J 2007; 26:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/8\">",
"      Barkai G, Belmaker I, Givon-Lavi N, Dagan R. The effect of universal toddlers-only hepatitis A virus vaccination program on seropositivity rate in unvaccinated toddlers: evidence for reduced virus circulation in the community. Pediatr Infect Dis J 2009; 28:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/9\">",
"      Van Damme P, Van Herck K. Effect of hepatitis A vaccination programs. JAMA 2005; 294:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/10\">",
"      Hadler SC, Webster HM, Erben JJ, et al. Hepatitis A in day-care centers. A community-wide assessment. N Engl J Med 1980; 302:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/11\">",
"      Vernon AA, Schable C, Francis D. A large outbreak of hepatitis A in a day-care center: association with non-toilet-trained children and persistence of IgM antibody to hepatitis A virus. Am J Epidemiol 1982; 115:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/12\">",
"      Fischer GE, Teshale EH, Miller C, et al. Hepatitis A among international adoptees and their contacts. Clin Infect Dis 2008; 47:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/13\">",
"      Abdulla RY, Rice MA, Donauer S, et al. Hepatitis A in internationally adopted children: screening for acute and previous infections. Pediatrics 2010; 126:e1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/14\">",
"      Noble RC, Kane MA, Reeves SA, Roeckel I. Posttransfusion hepatitis A in a neonatal intensive care unit. JAMA 1984; 252:2711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/15\">",
"      Klein BS, Michaels JA, Rytel MW, et al. Nosocomial hepatitis A. A multinursery outbreak in Wisconsin. JAMA 1984; 252:2716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/16\">",
"      Rosenblum LS, Villarino ME, Nainan OV, et al. Hepatitis A outbreak in a neonatal intensive care unit: risk factors for transmission and evidence of prolonged viral excretion among preterm infants. J Infect Dis 1991; 164:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/17\">",
"      Pinto MA, Marchevsky RS, Baptista ML, et al. Experimental hepatitis A virus (HAV) infection in Callithrix jacchus: early detection of HAV antigen and viral fate. Exp Toxicol Pathol 2002; 53:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/18\">",
"      Bruisten SM, van Steenbergen JE, Pijl AS, et al. Molecular epidemiology of hepatitis A virus in Amsterdam, the Netherlands. J Med Virol 2001; 63:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/19\">",
"      Lemon SM. Type A viral hepatitis. New developments in an old disease. N Engl J Med 1985; 313:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/20\">",
"      Vallbracht A, Fleischer B, Busch FW. Hepatitis A: hepatotropism and influence on myelopoiesis. Intervirology 1993; 35:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/21\">",
"      Fleischer B, Fleischer S, Maier K, et al. Clonal analysis of infiltrating T lymphocytes in liver tissue in viral hepatitis A. Immunology 1990; 69:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/22\">",
"      Baba M, Hasegawa H, Nakayabu M, et al. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts. J Clin Lab Immunol 1993; 40:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/23\">",
"      Rezende G, Roque-Afonso AM, Samuel D, et al. Viral and clinical factors associated with the fulminant course of hepatitis A infection. Hepatology 2003; 38:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/24\">",
"      Lednar WM, Lemon SM, Kirkpatrick JW, et al. Frequency of illness associated with epidemic hepatitis A virus infections in adults. Am J Epidemiol 1985; 122:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/25\">",
"      Tong MJ, el-Farra NS, Grew MI. Clinical manifestations of hepatitis A: recent experience in a community teaching hospital. J Infect Dis 1995; 171 Suppl 1:S15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/26\">",
"      Gordon SC, Reddy KR, Schiff L, Schiff ER. Prolonged intrahepatic cholestasis secondary to acute hepatitis A. Ann Intern Med 1984; 101:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/27\">",
"      Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/28\">",
"      Squires RH Jr, Shneider BL, Bucuvalas J, et al. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr 2006; 148:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/29\">",
"      Ciocca M, Moreira-Silva SF, Alegr&iacute;a S, et al. Hepatitis A as an etiologic agent of acute liver failure in Latin America. Pediatr Infect Dis J 2007; 26:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/30\">",
"      Ciocca M, Ramonet M, Cuarterolo M, et al. Prognostic factors in paediatric acute liver failure. Arch Dis Child 2008; 93:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/31\">",
"      Shah U, Habib Z, Kleinman RE. Liver failure attributable to hepatitis A virus infection in a developing country. Pediatrics 2000; 105:436.",
"     </a>",
"    </li>",
"    <li>",
"     Terrault NA, Wright TL. Viral hepatitis A through G. In: Gastrointestinal and Liver Disease, Feldman M, Scharschmidt BF, Sleisenger MH (Eds), WB Saunders, Philadelphia 1998. p.1129.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/33\">",
"      Schiff ER. Atypical clinical manifestations of hepatitis A. Vaccine 1992; 10 Suppl 1:S18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/34\">",
"      Vento S, Garofano T, Di Perri G, et al. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet 1991; 337:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/35\">",
"      Skoog SM, Rivard RE, Batts KP, Smith CI. Autoimmune hepatitis preceded by acute hepatitis A infection. Am J Gastroenterol 2002; 97:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/36\">",
"      Vento S, Cainelli F. Is there a role for viruses in triggering autoimmune hepatitis? Autoimmun Rev 2004; 3:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/37\">",
"      Ashur Y, Adler R, Rowe M, Shouval D. Comparison of immunogenicity of two hepatitis A vaccines--VAQTA and HAVRIX--in young adults. Vaccine 1999; 17:2290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/38\">",
"      Jilg W, Bittner R, Bock HL, et al. Vaccination against hepatitis A: comparison of different short-term immunization schedules. Vaccine 1992; 10 Suppl 1:S126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/39\">",
"      Kao HW, Ashcavai M, Redeker AG. The persistence of hepatitis A IgM antibody after acute clinical hepatitis A. Hepatology 1984; 4:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/40\">",
"      Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices. Updated recommendations from the Advisory Committee on Immunization Practices (ACIP) for use of hepatitis A vaccine in close contacts of newly arriving international adoptees. MMWR Morb Mortal Wkly Rep 2009; 58:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/41\">",
"      American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for administering hepatitis A vaccine to contacts of international adoptees. Pediatrics 2011; 128:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/42\">",
"      Dorell CG, Yankey D, Byrd KK, Murphy TV. Hepatitis a vaccination coverage among adolescents in the United States. Pediatrics 2012; 129:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16295/abstract/43\">",
"      Narkewicz MR, Dell Olio D, Karpen SJ, et al. Pattern of diagnostic evaluation for the causes of pediatric acute liver failure: an opportunity for quality improvement. J Pediatr 2009; 155:801.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Hepatitis A. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.361.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5942 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-190.92.87.113-B93B22F26D-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_58_16295=[""].join("\n");
var outline_f15_58_16295=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25267267\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PREVENTION AND PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      General measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Vaccination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Immune globulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Post-exposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Return to school or daycare",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25267267\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5942\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5942|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/14/8424\" title=\"figure 1\">",
"      Geography hepatitis A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/49/13086\" title=\"figure 2\">",
"      Risk factors for acquiring HAV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/1/16414\" title=\"figure 3\">",
"      Clinical course HAV infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2330?source=related_link\">",
"      Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32980?source=related_link\">",
"      Atypical manifestations of hepatitis A virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/38/1641?source=related_link\">",
"      Hepatitis A virus vaccination and postexposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7591?source=related_link\">",
"      Overview of hepatitis A virus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18570?source=related_link\">",
"      Pathophysiology and management of fever in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9912?source=related_link\">",
"      Prevention and treatment of viral gastroenteritis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_58_16296="Prenatal diagnosis of renal agenesis";
var content_f15_58_16296=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prenatal diagnosis of renal agenesis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/58/16296/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/58/16296/contributors\">",
"     Tulin Ozcan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/58/16296/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/58/16296/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/58/16296/contributors\">",
"     Laurence S Baskin, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/58/16296/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/58/16296/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/58/16296/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Development renal defects include: (1)",
"    <span class=\"nowrap\">",
"     bilateral/unilateral",
"    </span>",
"    renal agenesis, (2) renal hypodysplasia characterized by a reduction in the number of nephrons leading to a small overall kidney size and frequent dysplasia with or without cysts, and (3) multicystic dysplastic kidney.",
"   </p>",
"   <p>",
"    A kidney may be absent because it never developed (agenesis) or because of complete regression of a dysplastic kidney (aplasia). In the following topic review, the term renal agenesis will be used to refer to absent kidneys resulting from either of these etiologies (",
"    <a class=\"graphic graphic_figure graphicRef80784 \" href=\"UTD.htm?23/2/23588\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Renal agenesis may be either unilateral or bilateral. Bilateral renal agenesis is incompatible with extrauterine life because prolonged absence of amniotic fluid results in pulmonary hypoplasia leading to severe respiratory insufficiency at birth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the widespread use of prenatal ultrasonography and availability of legalized pregnancy termination in the United States, the incidence of bilateral renal agenesis was about 1 in 4000 births and about 1 in 250 autopsies of stillbirths and infant deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It is 2.5 times more common in males than in females [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of unilateral renal agenesis is about 1 in 1300 births [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/4\">",
"     4",
"    </a>",
"    ]. This is probably an underestimate because many cases remain asymptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EMBRYOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;True renal agenesis results from a lack of induction of the metanephric blastema by the ureteral bud. Most cases represent true renal agenesis; however, some absent kidneys may be secondary to involution of multicystic dysplastic kidneys (or dysplastic kidneys) (",
"    <a class=\"graphic graphic_figure graphicRef80784 \" href=\"UTD.htm?23/2/23588\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Normal development",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal urinary system develops in three stages:",
"   </p>",
"   <p>",
"    &nbsp;(1) The pronephros, a transient nonfunctioning structure, develops from the intermediate mesoderm in the cervical region and then regresses at about four weeks embryonic age. It is replaced at about five weeks by the mesonephros, which develops from the paravertebral mesoderm of the upper thoracic to lumbar region and is also not functional (",
"    <a class=\"graphic graphic_figure graphicRef53054 \" href=\"UTD.htm?33/60/34759\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    &nbsp;(2) The mesonephros disappears by the end of the second month of gestation. The few remaining caudal tubules adjacent to the testis and ovaries develop into the vas deferens in males and remnant tissue in females.",
"   </p>",
"   <p>",
"    &nbsp;(3) The ureteric bud is an outgrowth of the dorsomedial wall of the mesonephric duct. The ureteric bud invades a cord of mesenchymal cells called the metanephric blastema at 5 weeks of gestation (",
"    <a class=\"graphic graphic_figure graphicRef68255 \" href=\"UTD.htm?27/52/28482\">",
"     figure 3",
"    </a>",
"    ). Invasion of the metanephric blastema by the ureteric bud leads to the formation of the metanephric, or definitive kidney. While growing into the metanephric blastema, the ureteric bud forms the major and minor caliceal system of the renal pelvis and collecting ducts of the kidney. The advancing ureteric bud induces the mesenchymal cells of the metanephric blastema to differentiate into the epithelial cells to form the glomeruli and renal tubules. Foci of the metanephric blastema become condensed adjacent to the branching ureteric bud to form comma-shaped bodies that then elongate to form S-shaped bodies. The lower portion of the S-shaped body becomes associated with a tuft of capillaries to form the glomerulus, while the upper portion forms the tubular elements of the nephron&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef80344 \" href=\"UTD.htm?6/55/7031\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The development of a connection between the nephrons and the collecting system marks the beginning of the functioning renal unit. This metanephric tissue, called the metanephros, forms the permanent kidney. It contains glomeruli and tubules that begin to function at 6 to 10 weeks of gestation and begin to produce urine at approximately 11 weeks. The definitive kidney then migrates from its caudal position to its permanent location in the lumbar region.",
"   </p>",
"   <p>",
"    The bladder develops from a separate, but contiguous, structure termed the urogenital sinus. The bladder is present in fetuses with renal agenesis, but is empty since no urine is produced.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Abnormal development",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal agenesis (and many other renal malformations) occur when the ureteric bud fails to develop and thus fails to induce differentiation of the metanephrogenic mesenchyme to renal tubular epithelium. In vitro models reveal that when the ureteric bud and metanephrogenic mesenchyme meet, the ureteric bud branches and nephrons form within three to seven days of culture; however, if they remain apart, nephrons do not form and the mesenchymal tissue undergoes apoptosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral renal agenesis has been associated with a maternal body mass index of greater than 30",
"    <span class=\"nowrap\">",
"     kg/m(2)",
"    </span>",
"    prior to pregnancy (adjusted odds ratio (OR) = 1.92, 95% confidence interval (CI): 1.00, 3.67), smoking during the periconceptional period (aOR = 2.09, 95% CI: 1.08, 4.03), and binge drinking during the second month of pregnancy (aOR = 3.64, 95% CI: 1.19, 11.1) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal kidneys can be seen on transvaginal ultrasound as early as 10 to 12 weeks of gestation. Transverse and coronal views can be used for assessing the presence of fetal kidneys; the addition of color Doppler flow on the coronal view is useful for visualization of the renal arteries. A small amount of fluid in the renal pelvis is physiologic and is helpful in identifying the renal tissue (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77510 \" href=\"UTD.htm?26/57/27536\">",
"     image 1A",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64756 \" href=\"UTD.htm?40/3/41008\">",
"     image 1B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75147 \" href=\"UTD.htm?40/46/41711\">",
"     image 2A",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The diagnosis of bilateral renal agenesis is based upon sonographic nonvisualization of the fetal kidneys, ureters, and bladder, accompanied by oligohydramnios (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58911 \" href=\"UTD.htm?35/1/35856\">",
"     image 3",
"    </a>",
"    ). Unilateral renal agenesis is more difficult to diagnose and depends upon accurately excluding the presence of a second kidney in the renal fossa or an ectopic location (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54132 \" href=\"UTD.htm?7/1/7185\">",
"     image 4",
"    </a>",
"    ). The adrenal gland or bowel may mimic renal tissue if appropriate care is not taken. The adrenal gland appears flattened or lying down; the normally \"V\" shaped adrenal gland assumes a discoid shape and moves laterally and inferiorly (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69784 \" href=\"UTD.htm?33/42/34464\">",
"     image 1C",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77621 \" href=\"UTD.htm?30/14/30959\">",
"     image 1D",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77040 \" href=\"UTD.htm?2/13/2257\">",
"     image 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An empty renal fossa warrants a detailed search for an ectopic kidney location or a dysplastic kidney. In one study, for example, renal agenesis accounted for only 42 percent of empty renal fossae; 47 percent of the cases had an ectopic kidney in the pelvis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73564 \" href=\"UTD.htm?43/13/44240\">",
"     image 6",
"    </a>",
"    ) or, less commonly, fused to the contralateral kidney and even in the thorax secondary to a diaphragmatic hernia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/8\">",
"     8",
"    </a>",
"    ]. The remaining 10 percent originally thought to be absent were subsequently located, with the majority being dysplastic. The kidney can be located in thorax without evidence of a diaphragmatic hernia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major nonspecific marker of bilateral renal agenesis is severely reduced or absent amniotic fluid. In early pregnancy, the movement of fluid across the amnion, fetal membranes, and chorionic plate is thought to be the dominant source of amniotic fluid. Fetal urine becomes the main source after about 16 weeks of gestation. Therefore, amniotic fluid volume in pregnancies complicated by renal agenesis might appear normal in early pregnancy (before 16 weeks), even though sharply reduced or absent amniotic fluid volume is the most prominent ultrasonic feature of this disorder by the midtrimester [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/888?source=see_link\">",
"     \"Physiology of amniotic fluid volume regulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Ultrasound diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fetal kidneys and adrenal glands can be visualized by transabdominal ultrasound between the 12th and 15th week of gestation. Medulla and cortex can be differentiated well by the 20th to 25th week of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In two studies, the prenatal detection rate for bilateral renal",
"    <span class=\"nowrap\">",
"     agenesis/dysgenesis",
"    </span>",
"    by ultrasound was reported to be 84 and 91 percent; the detection rate for unilateral renal agenesis was 59 and 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The absence of an amniotic fluid sharply diminishes the ultrasonographer's ability to examine the fetus for the presence and structure of kidneys. Impaired visualization is further exacerbated by crowding of the fetal extremities adjacent to the torso. A systematic approach to evaluating the genitourinary tract is of utmost importance in making the correct diagnosis. The components of this examination include:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Amniotic fluid volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, transmembranous flow may result in normal or near normal amniotic fluid volume prior to about 16 weeks of gestation. After that, oligohydramnios or anhydramnios results from lack of fetal urine production and is immediately obvious when the obstetrical ultrasound examination is performed. The absence of fluid is not pathognomonic of bilateral renal agenesis; it can also be associated with severe intrauterine growth restriction, fetal demise, transient fetal anuria, urinary outflow obstruction, and premature rupture of membranes.",
"   </p>",
"   <p>",
"    Unilateral renal agenesis is associated with a normal volume of amniotic fluid, if the contralateral kidney is normal or not completely obstructed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Fetal bladder",
"    </span>",
"    &nbsp;&mdash;&nbsp;A full fetal bladder is the best indicator of fetal urine production. Nonvisualization of the fetal bladder combined with oligohydramnios indicates severe pathology. In one series of 29 pregnancies with a nonvisualized fetal bladder at 16 to 24 weeks of gestation, the following severe anatomic malformations were present: bilateral renal agenesis (11), bilateral multicystic dysplastic kidneys (9), bilateral polycystic kidneys (3), unilateral absent kidney with unilateral multicystic dysplastic kidney (3), and normal kidneys, but ectopic ureters and cone-shaped bladder (1) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/15\">",
"     15",
"    </a>",
"    ]. Although the remaining two infants had anatomically normal urinary tracts at autopsy, one had Turner syndrome with cystic hygroma and the other had severe intrauterine growth restriction, entities that can be associated with a functional derangement of the urinary system.",
"   </p>",
"   <p>",
"    Filling and emptying of the fetal bladder occurs approximately once per hour. Therefore, the bladder should be observed for accumulation of urine over one to two hours before concluding that urine is not being produced. It had been common practice to administer intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    to the mother to stimulate fetal diuresis and bladder filling [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/16\">",
"     16",
"    </a>",
"    ]. This practice has largely been abandoned since absence of bladder filling after furosemide does not prove absence of normal functional kidneys [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Color flow Doppler imaging of the pelvic umbilical arteries can be useful for demarcating the location of the bladder (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78040 \" href=\"UTD.htm?6/31/6643\">",
"     image 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Retrograde filling of the bladder, such as in urogenital sinus anomalies, and midline urachal cysts may be misdiagnosed as normal renal urine production [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Fetal kidney",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification of the fetal kidneys requires stricter criteria than mere presence of tissue or a mass in the area of the renal fossa. Presence of a kidney should be based upon visualization of an echogenic reniform mass containing hypoechoic medullary pyramids having the appearance of sonolucent circles circumferentially arranged beneath the renal cortical tissue (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77510 graphicRef64756 graphicRef69784 graphicRef77621 \" href=\"UTD.htm?32/15/33017\">",
"     image 1A-D",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Renal agenesis or dysplasia causes compensatory hypertrophy of the contralateral kidney. Thus, an enlarged kidney contralateral to an empty renal fossa supports the diagnosis of unilateral renal agenesis or in utero dysplasia of the other kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/18\">",
"     18",
"    </a>",
"    ]. In one study, the compensatory hypertrophy of the contralateral kidney was defined as anteroposterior to transverse diameter more than 0.9; this cut-off differentiated all cases of true renal agenesis from renal ectopy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Fetal adrenal glands",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fetal adrenal glands must be distinguished from the fetal kidneys. The adrenal glands may migrate ventrally to fill the renal fossa when the kidneys are absent. The normal adrenals have an inverted \"V\" or boomerang shape that may change with renal agenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/7\">",
"     7",
"    </a>",
"    ]. The \"laying down\" sign refers to a flattened appearance of these organs on parasagittal imaging of the abdomen, with a hypoechoic layer sandwiched between two hyperechoic areas (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77040 \" href=\"UTD.htm?2/13/2257\">",
"     image 5",
"    </a>",
"    ). The hyperechogenic layer represents the adrenal cortex on either side of the medulla. An autopsy study found this adrenal flattening in 4 of 11 cases of bilateral renal agenesis, with no evidence of adrenal hypertrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Renal arteries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Color flow Doppler imaging of the renal arteries should be performed when the kidneys are not visualized. Failure to image renal vessels with color flow Doppler using appropriately low gain settings is suggestive, although not definitive evidence, of renal agenesis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75147 graphicRef73646 \" href=\"UTD.htm?4/55/4982\">",
"     image 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. By comparison, color flow Doppler demonstration of renal vessels confirmed by waveform analysis verifies the presence of renal tissue.",
"   </p>",
"   <p>",
"    The renal arteries can normally be seen on coronal views to exit from either side of the aorta cranial to its bifurcation into the common iliac vessels. Pattern recognition of the renal artery and vein waveforms using pulsed Doppler should enable the observer to distinguish these vessels from other abdominal vessels. In a study that correlated prenatal color imaging with postnatal evaluation, absent renal blood flow was noted in seven of eight fetuses with bilateral renal agenesis and in one of eight fetuses with unilateral agenesis with contralateral atrophic multicystic kidney on postmortem examination [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/23\">",
"     23",
"    </a>",
"    ]. Three fetuses had only one renal artery imaged; two of these had unilateral agenesis and one had a multicystic dysplastic kidney on postnatal evaluation. The presence of both kidneys was confirmed postnatally in all 22 fetuses in whom both renal arteries were identified prenatally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Amnioinfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poor visualization of fetal anatomy due to absence of amniotic fluid is the main obstacle to accurate diagnosis of bilateral renal agenesis. Diagnostic amnioinfusion has been used in an attempt to surmount this limitation. As an example, one study reported successful fluid replacement was possible in 95 percent of diagnostic procedures and suspected fetal anomalies were confirmed in",
"    <span class=\"nowrap\">",
"     27/30",
"    </span>",
"    patients; the diagnosis of bilateral renal agenesis was excluded in three fetuses after amnioinfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/24\">",
"     24",
"    </a>",
"    ]. However, it is not clear whether amnioinfusion improves the diagnostic accuracy for bilateral agenesis when a careful color Doppler examination of the renal artery has been performed (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Renal arteries'",
"    </a>",
"    above). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5252?source=see_link\">",
"     \"Amnioinfusion: Indications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43203?source=see_link&amp;anchor=H4#H4\">",
"     \"Amnioinfusion: Technique\", section on 'Transabdominal approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signal void in a contracted bladder on T2-weighted magnetic resonance imaging (MRI) indicates an empty bladder, which is one sign of a severe renal anomaly such as renal agenesis. The contribution of this technique to diagnosis of renal agenesis remains unclear at this time [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;True renal agenesis, severe renal hypoplasia, and cystic dysplasia with subsequent atrophy (renal dysplasia defined as a renal remnant and ureter without normal renal histology) all lead to the same clinical presentation, but distinguishing these entities can be difficult both on ultrasound examination and at autopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/26\">",
"     26",
"    </a>",
"    ]. With true agenesis, the kidney and ureter are absent with no detectable rudiment. In contrast, atrophy of a previously hypoplastic, dysplastic, or multicystic kidney leaves a rudimentary kidney and ureter. Ultrasound examination can only distinguish between renal agenesis and atrophy if serial studies were performed and the early studies show the presence of the now atrophic kidney.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ASSOCIATED ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral renal agenesis is associated with other structural abnormalities in over 50 percent of cases. The types of structural anomalies are similar to those in patients with congenital solitary kidney, although the frequency is lower. These abnormalities include a variety of syndromes associated with chromosomal anomalies, caudal dysgenesis, VACTERL (",
"    <strong>",
"     V",
"    </strong>",
"    ertebral anomalies,",
"    <strong>",
"     A",
"    </strong>",
"    nal atresia,",
"    <strong>",
"     C",
"    </strong>",
"    ardiac defects,",
"    <strong>",
"     TE",
"    </strong>",
"    fistula [tracheoesophageal fistula],",
"    <strong>",
"     R",
"    </strong>",
"    enal defects, Limb defects), and isolated anomalies of the cardiovascular, skeletal, and central nervous systems [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Caudal dysplasia syndrome (CDS) is associated with hypoplastic lower extremities, caudal vertebrae, sacrum, neural tube, and urogenital organs. Sirenomelia is characterized by a single lower extremity, absent sacrum, urogenital anomalies, and imperforate anus. Abnormally formed lower limbs with varying degrees of fusion are the major feature of sirenomelia, whereas maldeveloped lower limbs without fusion are found in association with caudal dysgenesis. A review of nine CDS and six sirenomelia cases revealed that 22 percent of the CDS and 66 percent of the sirenomelia cases were associated with bilateral renal agenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among cases of unilateral renal agenesis, urological anomalies occur in 48 to 65 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/4,29,30\">",
"     4,29,30",
"    </a>",
"    ]. The most common anomalies are vesicoureteral reflux (28 to 41 percent), ureterovesical junction obstruction (11 to 18 percent), and ureteropelvic junction obstruction (6 to 7 percent). The remaining 50 percent of cases have structural malformations of the heart (eg, septal defects), gastrointestinal tract (eg, anal atresia), genital, or skeletal systems.",
"   </p>",
"   <p>",
"    The incidence of a single umbilical artery is increased with unilateral renal agenesis.",
"   </p>",
"   <p>",
"    With true unilateral agenesis, the ureter and the ipsilateral bladder hemitrigone are absent. The embryonic insult that results in unilateral renal agenesis may involve, not only the ureteral bud, but also other mesonephric duct derivatives, including the seminal vesicles, vas deferens, and epididymis. The absence of the vas deferens is the most frequent genital anomaly in males with renal agenesis, and can be bilateral even if the renal agenesis is unilateral. One third of men with bilateral congenital absence of the vas deferens have unilateral renal agenesis.",
"   </p>",
"   <p>",
"    Since the wolffian and m&uuml;llerian ducts are contiguous, m&uuml;llerian abnormalities are common in girls with renal agenesis. Septate uterus is relatively common and can be associated with renal agenesis. The Mayer-Rokitansky-K&uuml;ster-Hauser (MRKH) syndrome affects at least 1 of 4500 women and had been considered a sporadic anomaly. Congenital absence of the upper vagina and uterus is the prime feature of the disease. The most common anomalies that coexist with MRKH are urinary tract anomalies, including unilateral renal agenesis (21 percent), pelvic kidney, horseshoe kidney, and ureteric duplication, which are reported in 40 percent of cases. Spinal anomalies have been reported in 10 to 12 percent of cases and include wedge, supernumerary, or asymmetric and rudimentary vertebral bodies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of chromosomal anomalies (trisomies 13 and 18 and Turner syndrome 45,X) and Mendelian disorders are associated with renal agenesis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of 682 fetuses with renal defects who were karyotyped, the overall incidence of chromosomal abnormalities was 13 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/32\">",
"       32",
"      </a>",
"      ]. The incidence of aneuploidy was 5 percent in isolated bilateral renal agenesis, but there were no cases of aneuploidy in the three fetuses with isolated unilateral renal agenesis. The incidence of karyotypic abnormalities with unilateral or bilateral renal agenesis and multiple anomalies was 33 and 40 percent, respectively. The pattern of chromosomal abnormalities, but not the frequency, was related to the type of renal defect; the risk of chromosomal anomalies was similar for unilateral or bilateral involvement, mild or moderate or severe hydronephrosis, renal agenesis, oligohydramnios or normal amniotic fluid volume. In",
"      <span class=\"nowrap\">",
"       moderate/severe",
"      </span>",
"      hydronephrosis, renal agenesis and multicystic dysplasia, trisomy 13 and 18 were the most common abnormalities.",
"     </li>",
"     <li>",
"      Another study included 95 cases of bilateral renal agenesis, of which 91 percent were diagnosed prenatally [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/13\">",
"       13",
"      </a>",
"      ]. Chromosomal abnormalities were present in 8.1 percent of cases. The prenatal detection rate for unilateral renal agenesis was 62 percent and 25 percent had chromosomal abnormalities; however, 94 percent of these cases had multiple malformations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Potter sequence or syndrome is a historical term that was used to define the typical appearance of a fetus or neonate exposed to severely decreased or absent amniotic fluid secondary to renal disease. Typically, this syndrome is characterized at birth by pulmonary hypoplasia, limb deformations (altered positioning of hands and feet, clubbed feet, hip dislocation), and flattened facies. It results from external compression of the fetus, limitation of fetal movement, and alteration in the dynamics of lung liquid movement due to severe oligohydramnios. Potter syndrome can also be seen in infants with normal kidneys with prolonged leakage of amniotic fluid or rarely with severe fetal growth restriction; thus, it is not pathognomonic of renal anomalies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     OBSTETRICAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral renal agenesis is incompatible with extrauterine life because prolonged absence of amniotic fluid results in pulmonary hypoplasia leading to severe respiratory insufficiency at birth. Fetuses are able to survive in utero since the placenta is responsible for fetal oxygenation and excretion of wastes; however, there is a higher rate of fetal loss that is probably related to cord compression. As many as 33 percent of fetuses with bilateral renal agenesis die in utero [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/20\">",
"     20",
"    </a>",
"    ]. Patients who opt for pregnancy termination should be encouraged to consent to autopsy for definitive diagnosis. A nondestructive method of pregnancy termination is desirable for this reason. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28409?source=see_link\">",
"     \"Termination of pregnancy: Second trimester\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In unilateral renal agenesis, a thorough sonographic examination should be performed to look for additional structural defects, especially of the vertebrae, heart, or limbs. Many reproductive tract anomalies are difficult or impossible to detect with prenatal ultrasound. Fetal karyotype should be offered as there is an increased frequency of chromosomal abnormalities in the setting of multiple structural anomalies.",
"   </p>",
"   <p>",
"    There are no fetal indications for early delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     COUNSELING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Bilateral renal agenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of bilateral agenesis are sporadic. However, genetic factors play a role in the pathogenesis, and multifactorial inheritance is a likely explanation, although the precise method of genetic inheritance is unknown. X linked, autosomal recessive, autosomal dominant inheritance have also been described. In one series of 199 cases, seven siblings were known to be affected [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/33\">",
"     33",
"    </a>",
"    ]. Twenty to 36 percent of bilateral renal agenesis is associated with familial inheritance; the genetic mechanism may be autosomal dominant inheritance with incomplete penetrance and variable expression. The risk of recurrence is reported as 3 to 6 percent, but may reach 8 percent in cases associated with multiple congenital abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Fetal ultrasound evaluation as early as 12 to 14 weeks of gestation, but traditionally at 16 to 20 weeks of a subsequent pregnancy, is the only way to determine whether the fetus is affected.",
"   </p>",
"   <p>",
"    Approximately 9 to 14 percent of first degree relatives of patients with bilateral renal agenesis, bilateral severe dysgenesis, or agenesis of one kidney and dysgenesis of the other have renal abnormalities, most often unilateral renal agenesis, but also duplicated collecting systems [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. It is probably worthwhile to evaluate for the presence of both kidneys and the absence of gross renal defects in the mother at the time of prenatal ultrasound, as this can be accomplished quickly and without additional expense. The value of screening other asymptomatic family members should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Unilateral renal agenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some cases of unilateral renal agenesis result from in utero regression of multicystic dysplastic kidneys [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/5,37\">",
"     5,37",
"    </a>",
"    ]. These patients have an ipsilateral blind ending ureter. Because renal agenesis, hypoplasia, and cystic dysplasia have been reported in the same syndromes, the same families, and occasionally even the same individual, they can, when unilateral, be included together under the heading of congenital solitary kidney.",
"   </p>",
"   <p>",
"    The minimal estimate of empiric risk to offspring of individuals with congenital solitary kidney is 7 percent for congenital solitary kidney and 1 percent for bilateral renal agenesis. Ultrasound examination is recommended to check for urogenital anomalies in first-degree relatives. Prenatal diagnosis by ultrasound is recommended for pregnancies in which the patient or her partner has a congenital solitary kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis for patients with one normal kidney is excellent, with a survival rate similar to that of age and sex-matched controls from United States life tables [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/27\">",
"     27",
"    </a>",
"    ]. However, proteinuria, hypertension, and renal insufficiency appear to be more common later in life. One study followed 157 patients with unilateral renal agenesis and a normal contralateral kidney diagnosed at a mean age of 37 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/38\">",
"     38",
"    </a>",
"    ]. The types and frequencies of abnormalities in this population included proteinuria (&gt;150",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    19 percent), hypertension (47 percent), and decreased renal function (adjusted for age and sex, 13 percent). On renal biopsy, these patients typically have focal segmental glomerulosclerosis, presumably reflecting chronic glomerular injury resulting from the compensatory glomerular hypertrophy and associated increase in glomerular perfusion pressure (intraglomerular hypertension). Furthermore, patients with solitary kidney have a probability of nearly 50 percent of requiring dialysis by 30 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. This has been attributed to reduced nephron number in the solitary kidney mediated by whatever factors led to absence of the contralateral kidney, including mutations, epigenetic factors, or teratogens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=see_link&amp;anchor=H13#H13\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Secondary FSGS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Historically, most pediatric urologists recommended that children with a solitary kidney avoid contact sports. However, since the risk of kidney loss resulting from trauma is less than 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/41\">",
"     41",
"    </a>",
"    ], this recommendation does not appear to be evidenced based and needs reevaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16296/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/13/36058?source=see_link&amp;anchor=H35#H35\">",
"     \"The preparticipation sports examination in children and adolescents\", section on 'Abdomen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal agenesis refers to congenital absence of the kidney and ureter, which may be either unilateral or bilateral. Renal hypoplasia can also lead to absence of the kidney and is commonly referred to as renal agenesis. Bilateral renal agenesis is always fatal in the newborn period. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of bilateral renal agenesis is based upon sonographic nonvisualization of the fetal kidneys, ureters, and bladder, accompanied by oligohydramnios, usually after 16 weeks of gestation. Unilateral renal agenesis is more difficult to diagnose and depends upon accurately excluding the presence of a second kidney in the renal fossa or in an ectopic location. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal agenesis is associated with an increased risk of other structural abnormalities and chromosomal abnormalities. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Associated abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For pregnancies with unilateral renal agenesis, a thorough examination for other structural defects (especially of the reproductive tract) should be performed. If additional anomalies are detected, there is an increased risk of chromosomal abnormality; amniocentesis to determine the fetal karyotype should be offered. There are no fetal indications for early delivery. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Obstetrical management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most cases of bilateral renal agenesis are sporadic. The risk of recurrence of bilateral renal agenesis is 3 to 6 percent, but may reach 8 percent in cases associated with multiple congenital abnormalities. Approximately 9 to 14 percent of first degree relatives of patients with bilateral renal agenesis or dysgenesis have renal abnormalities. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Bilateral renal agenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest sonographic screening of parents and siblings of infants born with agenesis or dysgenesis of both kidneys or with agenesis of one kidney and dysgenesis of the other, given the heritable nature of these defects (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Counseling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prognosis for patients with unilateral renal agenesis is reported as excellent, with a survival rate similar to that of age and sex-matched controls; however, some data suggest an increased risk of renal dysfunction, proteinuria, and hypertension, and a high risk for dialysis. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Unilateral renal agenesis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/1\">",
"      Whitehouse W, Mountrose U. Renal agenesis in nontwin siblings. Am J Obstet Gynecol 1973; 116:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/2\">",
"      POTTER EL. BILATERAL ABSENCE OF URETERS AND KIDNEYS: A REPORT OF 50 CASES. Obstet Gynecol 1965; 25:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/3\">",
"      Cardwell MS. Bilateral renal agenesis: clinical implications. South Med J 1988; 81:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/4\">",
"      Cascio S, Paran S, Puri P. Associated urological anomalies in children with unilateral renal agenesis. J Urol 1999; 162:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/5\">",
"      Mesrobian HG, Rushton HG, Bulas D. Unilateral renal agenesis may result from in utero regression of multicystic renal dysplasia. J Urol 1993; 150:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/6\">",
"      Slickers JE, Olshan AF, Siega-Riz AM, et al. Maternal body mass index and lifestyle exposures and the risk of bilateral renal agenesis or hypoplasia: the National Birth Defects Prevention Study. Am J Epidemiol 2008; 168:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/7\">",
"      Hoffman CK, Filly RA, Callen PW. The \"lying down\" adrenal sign: a sonographic indicator of renal agenesis or ectopia in fetuses and neonates. J Ultrasound Med 1992; 11:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/8\">",
"      Chow JS, Benson CB, Lebowitz RL. The clinical significance of an empty renal fossa on prenatal sonography. J Ultrasound Med 2005; 24:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/9\">",
"      Hahn H, Park SY, Eom JH, Park SW. Quiz page. Congenital intrathoracic kidney after regression of an adrenal mass. Am J Kidney Dis 2009; 53:A27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/10\">",
"      Bronshtein M, Amit A, Achiron R, et al. The early prenatal sonographic diagnosis of renal agenesis: techniques and possible pitfalls. Prenat Diagn 1994; 14:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/11\">",
"      Dugoff L. Ultrasound diagnosis of structural abnormalities in the first trimester. Prenat Diagn 2002; 22:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/12\">",
"      Rouse GA, Kaminsky CK, Saaty HP, et al. Current concepts in sonographic diagnosis of fetal renal disease. Radiographics 1988; 8:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/13\">",
"      Wiesel A, Queisser-Luft A, Clementi M, et al. Prenatal detection of congenital renal malformations by fetal ultrasonographic examination: an analysis of 709,030 births in 12 European countries. Eur J Med Genet 2005; 48:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/14\">",
"      Stoll C, Tenconi R, Clementi M. Detection of Congenital Anomalies by Fetal Ultrasonographic Examination across Europe. Community Genet 2001; 4:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/15\">",
"      Brumfield CG, Guinn D, Davis R, et al. The significance of non-visualization of the fetal bladder during an ultrasound examination to evaluate second-trimester oligohydramnios. Ultrasound Obstet Gynecol 1996; 8:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/16\">",
"      Wladimiroff, JW. Effect of furosemide on fetal urine production. Br J Obstet Gynecol 1975; 82:2221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/17\">",
"      Raghavendra BN, Young BK, Greco MA, et al. Use of furosemide in pregnancies complicated by oligohydramnios. Radiology 1987; 165:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/18\">",
"      Hill LM, Nowak A, Hartle R, Tush B. Fetal compensatory renal hypertrophy with a unilateral functioning kidney. Ultrasound Obstet Gynecol 2000; 15:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/19\">",
"      Cho JY, Moon MH, Lee YH, et al. Measurement of compensatory hyperplasia of the contralateral kidney: usefulness for differential diagnosis of fetal unilateral empty renal fossa. Ultrasound Obstet Gynecol 2009; 34:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/20\">",
"      Droste S, Fitzsimmons J, Pascoe-Mason J, et al. Size of the fetal adrenal in bilateral renal agenesis. Obstet Gynecol 1990; 76:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/21\">",
"      Wladimiroff JW, Heydanus R, Stewart PA, et al. Fetal renal artery flow velocity waveforms in the presence of congenital renal tract anomalies. Prenat Diagn 1993; 13:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/22\">",
"      DeVore GR. The value of color Doppler sonography in the diagnosis of renal agenesis. J Ultrasound Med 1995; 14:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/23\">",
"      Sepulveda W, Stagiannis KD, Flack NJ, Fisk NM. Accuracy of prenatal diagnosis of renal agenesis with color flow imaging in severe second-trimester oligohydramnios. Am J Obstet Gynecol 1995; 173:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/24\">",
"      Fisk NM, Ronderos-Dumit D, Soliani A, et al. Diagnostic and therapeutic transabdominal amnioinfusion in oligohydramnios. Obstet Gynecol 1991; 78:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/25\">",
"      Hawkins JS, Dashe JS, Twickler DM. Magnetic resonance imaging diagnosis of severe fetal renal anomalies. Am J Obstet Gynecol 2008; 198:328.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/26\">",
"      McPherson E. Renal anomalies in families of individuals with congenital solitary kidney. Genet Med 2007; 9:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/27\">",
"      Robson WL, Leung AK, Rogers RC. Unilateral renal agenesis. Adv Pediatr 1995; 42:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/28\">",
"      Bruce JH, Romaguera RL, Rodriguez MM, et al. Caudal dysplasia syndrome and sirenomelia: are they part of a spectrum? Fetal Pediatr Pathol 2009; 28:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/29\">",
"      Dursun H, Bayazit AK, B&uuml;y&uuml;k&ccedil;elik M, et al. Associated anomalies in children with congenital solitary functioning kidney. Pediatr Surg Int 2005; 21:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/30\">",
"      Kaneyama K, Yamataka A, Satake S, et al. Associated urologic anomalies in children with solitary kidney. J Pediatr Surg 2004; 39:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/31\">",
"      Kimberley N, Hutson JM, Southwell BR, Grover SR. Vaginal agenesis, the hymen, and associated anomalies. J Pediatr Adolesc Gynecol 2012; 25:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/32\">",
"      Nicolaides KH, Cheng HH, Abbas A, et al. Fetal renal defects: associated malformations and chromosomal defects. Fetal Diagn Ther 1992; 7:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/33\">",
"      Carter CO, Evans K, Pescia G. A family study of renal agenesis. J Med Genet 1979; 16:176.",
"     </a>",
"    </li>",
"    <li>",
"     Holmes, LB. Prevalence, phenotypic heterogeneity and familial aspects of bilateral renal agenesis/ dysgeneis. In: Genetics of kidney disorders, Bartsocas, CS (Ed), Liss, New York 1989. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/35\">",
"      Schwaderer AL, Bates CM, McHugh KM, McBride KL. Renal anomalies in family members of infants with bilateral renal agenesis/adysplasia. Pediatr Nephrol 2007; 22:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/36\">",
"      Roodhooft AM, Birnholz JC, Holmes LB. Familial nature of congenital absence and severe dysgenesis of both kidneys. N Engl J Med 1984; 310:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/37\">",
"      Hitchcock R, Burge DM. Renal agenesis: an acquired condition? J Pediatr Surg 1994; 29:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/38\">",
"      Argueso LR, Ritchey ML, Boyle ET Jr, et al. Prognosis of patients with unilateral renal agenesis. Pediatr Nephrol 1992; 6:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/39\">",
"      Chevalier RL. When is one kidney not enough? Kidney Int 2009; 76:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/40\">",
"      Sanna-Cherchi S, Ravani P, Corbani V, et al. Renal outcome in patients with congenital anomalies of the kidney and urinary tract. Kidney Int 2009; 76:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16296/abstract/41\">",
"      Sharp DS, Ross JH, Kay R. Attitudes of pediatric urologists regarding sports participation by children with a solitary kidney. J Urol 2002; 168:1811.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6746 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-1A240FD273-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_58_16296=[""].join("\n");
var outline_f15_58_16296=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EMBRYOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Normal development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Abnormal development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Ultrasound diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Amniotic fluid volume",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Fetal bladder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Fetal kidney",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Fetal adrenal glands",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Renal arteries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Amnioinfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ASSOCIATED ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      OBSTETRICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Bilateral renal agenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Unilateral renal agenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6746\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6746|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/57/27536\" title=\"diagnostic image 1A\">",
"      Prenatal ultrasound of normal fetal kidneys transverse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/3/41008\" title=\"diagnostic image 1B\">",
"      Prenatal ultrasound normal kidneys longitudinal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/42/34464\" title=\"diagnostic image 1C\">",
"      Prenatal ultrasound unilateral kidney adrenal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/14/30959\" title=\"diagnostic image 1D\">",
"      Prenatal ultrasound renal agenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/46/41711\" title=\"diagnostic image 2A\">",
"      Prenatal ultrasound normal renal Doppler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/46/3810\" title=\"diagnostic image 2B\">",
"      Prenatal ultrasound Doppler renal agenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/1/35856\" title=\"diagnostic image 3\">",
"      Prenatal ultrasound bilateral renal agenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/1/7185\" title=\"diagnostic image 4\">",
"      Prenatal ultrasound left renal agenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/13/2257\" title=\"diagnostic image 5\">",
"      Prenatal ultrasound flattened adrenal and renal agenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/13/44240\" title=\"diagnostic image 6\">",
"      Prenatal ultrasound fetal pelvic kidney",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/31/6643\" title=\"diagnostic image 7\">",
"      Prenatal ultrasound of umbilical arteries along the bladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6746|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/2/23588\" title=\"figure 1\">",
"      Etiology renal agenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/60/34759\" title=\"figure 2\">",
"      Embryology of kidney",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/52/28482\" title=\"figure 3\">",
"      Ureteric bud",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/55/7031\" title=\"figure 4\">",
"      Development of a metanephric excretory unit",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5252?source=related_link\">",
"      Amnioinfusion: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43203?source=related_link\">",
"      Amnioinfusion: Technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=related_link\">",
"      Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/55/888?source=related_link\">",
"      Physiology of amniotic fluid volume regulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28409?source=related_link\">",
"      Termination of pregnancy: Second trimester",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/13/36058?source=related_link\">",
"      The preparticipation sports examination in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_58_16297="Gastrointestinal decontamination of poisoned adults";
var content_f15_58_16297=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Gastrointestinal decontamination of poisoned adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/58/16297/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/58/16297/contributors\">",
"     Robert G Hendrickson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/58/16297/contributors\">",
"     Shana Kusin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/58/16297/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/58/16297/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/58/16297/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/58/16297/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/58/16297/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H18993739\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal decontamination refers to the practice of functionally removing an ingested toxin from the GI tract in order to decrease its absorption. Historically, many approaches have been adopted, including gastric evacuation (forced emesis or gastric lavage), intra-gastric binding (most commonly by single or multidose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    ), or speeding transit of toxins to decrease total absorption time (whole bowel irrigation or cathartics). As clinical practice has evolved and understanding of the efficacy, risks, and, benefits of decontamination have grown, many practices have fallen out of favor.",
"   </p>",
"   <p>",
"    This topic provides an overview of the approach to gastrointestinal decontamination in poisoned adults and a review of the evidence supporting the approach described. The management of intoxication with specific agents and general management of the poisoned patient, including children, are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43047?source=see_link\">",
"     \"Initial management of the critically ill adult with an unknown overdose\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=see_link\">",
"     \"Approach to the child with occult toxic exposure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=see_link\">",
"     \"Decontamination of poisoned children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18993746\">",
"    <span class=\"h1\">",
"     APPROACH TO GASTROINTESTINAL DECONTAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;No controlled clinical studies have demonstrated that the",
"    <em>",
"     routine",
"    </em>",
"    use of gastrointestinal (GI) decontamination reduces morbidity and mortality in poisoned patients. However, evidence from human volunteer trials and clinical studies suggest that decontamination may reduce the absorption of toxins in the GI tract and may be helpful in select circumstances",
"    <sup>",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decision to perform GI decontamination is based upon the specific poison(s) ingested, the time from ingestion to presentation, presenting symptoms, and the predicted severity of poisoning. GI decontamination is most likely to benefit patients who:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Present for care soon after ingestion (usually within one to two hours)",
"     </li>",
"     <li>",
"      Have ingested a poison and amount suspected to cause toxicity",
"     </li>",
"     <li>",
"      Do not have clinical factors (eg, somnolence) that make decontamination dangerous",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    GI decontamination should",
"    <strong>",
"     not",
"    </strong>",
"    be performed if the agent and amount ingested are clearly nontoxic, if the agent is considered fully absorbed due to delayed presentation, or if the toxin is not amenable to decontamination.",
"   </p>",
"   <p>",
"    It is common practice for intentional and potentially toxic ingestions to be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (AC) alone. However, in select scenarios other methods of GI decontamination may be useful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18993753\">",
"    <span class=\"h1\">",
"     METHODS OF DECONTAMINATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18993761\">",
"    <span class=\"h2\">",
"     Activated charcoal",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     Activated charcoal",
"    </a>",
"    (AC) is a highly adsorbent powder made from superheated, high surface area, porous particles produced by pyrolysis of organic material. Its extensive surface area is covered with a carbon-based network that also includes functional groups (eg, carbonyl, hydroxyl) that adsorb chemicals within minutes of contact, preventing gastrointestinal absorption and subsequent toxicity. Evidence supporting the use of AC is discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18993776\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;AC is most likely to benefit patients when administered within one hour of poison ingestion, but the potential for benefit when administered later cannot be excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18993783\">",
"    <span class=\"h3\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraindications to the administration of a single-dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (SDAC) include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Depressed mental status without airway protection (risk of aspiration).",
"      <br/>",
"      <br/>",
"      The decision to intubate a poisoned patient is often complicated, but it should be made independently of the decision to give AC. In particular,",
"      <strong>",
"       tracheal intubation should not be performed for the sole purpose of giving AC",
"      </strong>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Late presentation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased risk and severity of aspiration associated with AC use (eg, hydrocarbon ingestion)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Need for endoscopy (eg, significant caustic ingestion)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Toxins poorly adsorbed by AC (eg, metals including iron and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , alkali, mineral acids, alcohols) (",
"      <a class=\"graphic graphic_table graphicRef77553 \" href=\"UTD.htm?4/37/4700\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Presence of intestinal obstruction (absolute contraindication) or concern for decreased peristalsis (relative contraindication)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18993795\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal dose of SDAC is not known, but available data show a dose-response relationship. In vitro studies suggest an AC:toxin ratio of 10:1 to be effective",
"    <sup>",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/4\">",
"     4",
"    </a>",
"    ]. Alternatively, the following dosing regimen is suggested",
"    <sup>",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Children up to one year of age: 10 to 25 g or 0.5 to 1.0",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"     </li>",
"     <li>",
"      Children 1 to 12 years of age: 25 to 50 g or 0.5 to 1.0",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"     </li>",
"     <li>",
"      Adolescents and adults: 25 to 100 g (with 50 g representing the usual adult dose)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18993802\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;AC is available as a powder that is mixed with water to form a slurry. The slurry is gritty and poorly palatable, making administration to children particularly difficult. Flavoring the slurry with juice, chocolate milk, or ice cream may improve compliance but potentially decreases the adsorptive capacity of AC",
"    <sup>",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/5\">",
"     5",
"    </a>",
"    ]. AC is also commercially available as a suspension with thickening agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    , which may help improve palatability and additionally act as a cathartic",
"    <sup>",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18993809\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall rate of AC-associated complications reported in the literature is low",
"    <sup>",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/1\">",
"     1",
"    </a>",
"    ]. Gastrointestinal side effects, including fullness, abdominal pain, nausea, vomiting, constipation, and diarrhea, have been reported, with higher rates occurring if AC is used in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/1\">",
"     1",
"    </a>",
"    ]. According to two randomized trials, aspiration occurs in less than one percent of poisonings and is not increased in patients who receive AC [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Aspiration occurred most often when AC was used in conjunction with gastric emptying techniques that are no longer routinely recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26755739\">",
"    <span class=\"h3\">",
"     Evidence of efficacy and adverse effects",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26755393\">",
"    <span class=\"h4\">",
"     Activated charcoal: Volunteer data",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of data supporting the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (AC) come from in vitro and animal data or volunteer trials. An early study simulating the gastric environment demonstrated that many chemicals adsorb avidly to AC in a dose dependent fashion, but that certain substances &ndash; particularly highly ionic compounds with low molecular weight, mineral acids, and strong bases &ndash; do not bind well [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/10\">",
"     10",
"    </a>",
"    ]. AC has not been shown to adsorb ethanol, even when administered prior to ethanol ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of volunteer trials support the efficacy of AC when it is administered early after ingestion, with absorption decreased by up to 95 percent or more when AC is administered within five minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. When AC is administered one hour after toxin ingestion, systemic absorption is reduced to the range of 50 to 75 percent, depending upon the toxin [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. Despite the results of these trials, it is important to remember that volunteer scenarios may differ markedly from actual poisonings with respect to the timing of presentation, amount of toxin ingested, and presence of other factors, such as food in the stomach or drugs that alter GI transit times.",
"   </p>",
"   <p>",
"    The results of volunteer trials, designed specifically to evaluate the effect of AC when administered later after ingestion, are less compelling. Two volunteer trials failed to find a statistically significant reduction in absorption when AC was administered at two, three, or four hours following ingestion of therapeutic doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. A third trial demonstrated a small but statistically significant reduction in serum acetaminophen levels when AC was given three hours after drug ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/19\">",
"     19",
"    </a>",
"    ]. The subjects in all three volunteer trials received therapeutic range doses of acetaminophen, so the results are difficult to extrapolate to larger ingestions that occur in poisoned patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26755400\">",
"    <span class=\"h4\">",
"     Activated charcoal: Clinical trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized controlled trials of poisoned patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (AC) have failed to demonstrate a consistent impact on clinically important outcomes. However, this may in part be due to methodologic problems in some studies, such as including treatments with AC given several hours after ingestion and treatment of patients with little or no risk of toxicity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trial of 1479 poisoned patients randomly assigned to receive AC or no decontamination reported higher rates of emesis and intubation, as well as a small but statistically significant increase in emergency department length of stay, in patients treated with AC, but overall no significant differences were noted in the clinical course or rates of aspiration between groups [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A trial of 71 patients with an overdose of tricyclic antidepressants (TCA) randomly assigned patients to gastric lavage with or without AC and found no difference in serum drug concentrations between groups [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/21\">",
"       21",
"      </a>",
"      ]. Of note, most patients presented late following ingestion.",
"     </li>",
"     <li>",
"      A trial of 327 patients, who were randomly assigned to receive AC or no decontamination, found no difference in length of stay, vomiting, aspiration, intubation, or mortality between groups [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/8\">",
"       8",
"      </a>",
"      ]. The authors noted that benzodiazepines,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      , and selective serotonin reuptake inhibitors (SSRIs) comprised the majority of toxins, and these drugs would generally not be expected to cause severe toxicity regardless of whether GI decontamination were performed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two observational studies of poisoned patients examined the question of AC efficacy in late-presenting patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective observational series of patients with toxic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      levels who presented more than four hours following ingestion found a lower rate of liver injury among patients given AC in addition to N-acetylcysteine [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/22\">",
"       22",
"      </a>",
"      ]. For patients given AC between four and eight hours after ingestion, the rate of liver injury (AST or ALT &gt;1000",
"      <span class=\"nowrap\">",
"       IU/L)",
"      </span>",
"      was 0 percent versus 12 percent in the group that did not receive AC. Liver injury rates were also lower for those treated 9 to 12 hours after ingestion (3 percent versus 52 percent) and 13 to 16 hours after ingestion (10 percent versus 45 percent).",
"     </li>",
"     <li>",
"      A retrospective series described 981 consecutive patients poisoned with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      who were treated, prior to receiving N-acetylcysteine, with gastric lavage and AC, AC alone, or no decontamination [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/23\">",
"       23",
"      </a>",
"      ]. The authors reported that, in patients presenting within 24 hours with ingestions of 10 g or greater, administration of AC prior to N-acetylcysteine resulted in a lower risk of liver injury (defined AST or ALT greater than 1000",
"      <span class=\"nowrap\">",
"       IU/L)",
"      </span>",
"      compared to treatment with N-acetylcysteine alone (OR 0.36, 95% CI 0.23-0.58) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/23\">",
"       23",
"      </a>",
"      ]. The authors found that this effect predominates when patients present within two hours, but may extend to many who present as long as three hours later.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26755407\">",
"    <span class=\"h4\">",
"     Activated charcoal: Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspiration is the concern most often cited when clinicians choose not to administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (AC). In their joint position paper on single-use AC, the American Academy of Clinical Toxicology and the European Association of Poison Centres and Clinical Toxicologists state that charcoal itself is not responsible for aspiration, but rather administering it improperly (ie, to a patient with an inadequately protected airway; in association with lavage; or instilling it directly into the lung via an improperly placed nasogastric tube) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, when aspiration does occur, poor outcomes cannot clearly be attributed to the charcoal itself rather than the aspiration of acidic gastric contents.",
"   </p>",
"   <p>",
"    Given the widespread use of AC, the overall rate of adverse effects, particularly aspiration, associated with its administration is low. In a randomized clinical trial of self-poisoned adults, AC was found to increase the risk of vomiting (23 percent versus 13 percent in controls) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/9\">",
"     9",
"    </a>",
"    ], but the rate of aspiration was low in both groups (two patients in each group developed aspiration pneumonia out of a total of 1479). A second trial of 327 patients found similar rates of both vomiting (14 and 15 percent, respectively) and aspiration (&lt;1 percent in both groups) in patients treated with AC and those not treated [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/8\">",
"     8",
"    </a>",
"    ].The results of two observational studies suggest that emesis may occur at a higher rate when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    is added to AC [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective chart review of 4562 overdose patients looking for predictors of aspiration found that age, male gender, GCS &lt;15, emesis, seizure, tricyclic antidepressant overdose, and an elapsed time of more than 24 hours between ingestion and presentation were all predictors of aspiration pneumonia, whereas AC administration itself was not [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/26\">",
"     26",
"    </a>",
"    ]. Another retrospective chart review of patients who received AC after intubation found that 2 out of 50, or 4 percent, developed an infiltrate not present prior to intubation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/27\">",
"     27",
"    </a>",
"    ]; the two cases of aspiration pneumonia could not clearly be attributed to charcoal administration.",
"   </p>",
"   <p>",
"    Other less important gastrointestinal side effects have been reported. In a volunteer study, constipation and abdominal fullness occurred at a rate of 46 percent, nausea at 18 percent, and vomiting at 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/19\">",
"     19",
"    </a>",
"    ]. Constipation occurred in 60 percent of subjects in another volunteer study [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18993821\">",
"    <span class=\"h2\">",
"     Multidose activated charcoal",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some instances, patients may benefit from the repeated administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (MDAC). Three distinct mechanisms are thought to account for such benefit:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Interruption of enterohepatic recirculation",
"     </li>",
"     <li>",
"      Facilitation of transluminal diffusion from the body into the bowel lumen (&ldquo;Gut dialysis&rdquo;), followed by excretion",
"     </li>",
"     <li>",
"      Reduced absorption of extended or delayed release formulations",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18993828\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;MDAC may be helpful in life-threatening ingestions of the following medications [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       Carbamazepine",
"      </a>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/19/11577?source=see_link\">",
"       \"Carbamazepine poisoning\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       Dapsone",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"       Phenobarbital",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       Quinine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       Theophylline",
"      </a>",
"      <sup>",
"      </sup>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/16/13578?source=see_link\">",
"       \"Theophylline poisoning\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Volunteer and animal data suggest that MDAC increases elimination of several toxins (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"     nadolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/25/9625?source=see_link\">",
"     piroxicam",
"    </a>",
"    , salicylates), but clinical data are currently insufficient to support the routine use of MDAC in these exposures",
"    <sup>",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18993835\">",
"    <span class=\"h3\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraindications to the use of MDAC are similar to those of SDAC, but also include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Presence of intestinal obstruction (absolute) or concern for decreased peristalsis (relative)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18993842\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;An optimal dosing regimen for MDAC has not been established. In general, after the initial dose, AC should be administered at a rate of at least 12.5",
"    <span class=\"nowrap\">",
"     g/hour,",
"    </span>",
"    or the equivalent, given as divided doses. Examples of acceptable regimens include 50 g administered every four hours, or 25 g every two hours. A volunteer study found no difference in effectiveness of larger doses spread out over time compared to smaller, more frequent doses",
"    <sup>",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18993853\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration is similar to that of AC, but the concurrent use of a cathartic, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    is",
"    <strong>",
"     not",
"    </strong>",
"    recommended. This is of particular importance with young children, in whom the development of diarrhea may lead to dangerous fluid shifts and electrolyte imbalance",
"    <sup>",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18993860\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the complications associated with single-dose AC, constipation and bowel obstruction have been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26755899\">",
"    <span class=\"h3\">",
"     Evidence of efficacy and adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Volunteer trials of MDAC have found significant decreases in the elimination half life of several drugs, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14648?source=see_link\">",
"     aminophylline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , phenylbutazone,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/13,15,28-31\">",
"     13,15,28-31",
"    </a>",
"    ]. However, a randomized controlled trial of 4629 poisoned patients comparing the routine use of MDAC to single-dose AC or no intervention found no difference in rates of intubation, toxin-specific clinical effects, or mortality among groups [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/32\">",
"     32",
"    </a>",
"    ]. The trial was limited by the prolonged time to treatment for many patients and lower than expected mortality in the control group.",
"   </p>",
"   <p>",
"    In contrast, a randomized controlled trial of 401 patients poisoned with yellow oleander-poisoned and treated with either MDAC or a single dose of AC found lower rates of mortality and ICU admission among the MDAC group [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/33\">",
"     33",
"    </a>",
"    ]. This study differs from the larger trial in the narrow scope of toxin studied, shorter time to treatment, and longer administration of MDAC (along with better adherence to regimen).",
"   </p>",
"   <p>",
"    The paucity of data supporting the efficacy of MDAC in actual poisonings and the availability of better treatments for some of the agents studied (eg, antibody (Fab) fragments for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    overdose) have informed the joint position statement of the American Academy of Clinical Toxicology and the European Association of Poison Centres and Clinical Toxicologists, which only supports the use of MDAC in life-threatening ingestions of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complications of MDAC administration are similar to those associated with single-dose AC and are described separately. (See",
"    <a class=\"local\" href=\"#H26755407\">",
"     'Activated charcoal: Adverse effects'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Additional concerns specific to the repeated administration of AC include the development of an ileus or obstruction. There are published reports of patients developing a bowel obstruction requiring surgical intervention and even bowel perforation following repeated administration of AC [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. However, the large randomized trial described above did not report any such complications [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18993876\">",
"    <span class=\"h2\">",
"     Whole bowel irrigation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whole bowel irrigation",
"    <strong>",
"    </strong>",
"    (WBI) refers to the administration of osmotically balanced",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/17/4374?source=see_link\">",
"     polyethylene glycol electrolyte solution",
"    </a>",
"    (PEG-ES) to induce liquid stool and mechanically flush pills, tablets, or drug packets from the GI tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18993883\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;WBI is not routinely recommended, but it may be helpful in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Potentially toxic ingestions of sustained-release or enteric coated pill formulations",
"     </li>",
"     <li>",
"      Significant ingestions of toxins not adsorbed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"       activated charcoal",
"      </a>",
"      (eg, iron tablets, lead-containing foreign bodies)",
"     </li>",
"     <li>",
"      Ingestion of illicit drug packets (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12744?source=see_link\">",
"       \"Internal concealment of drugs of abuse (body packing)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18993890\">",
"    <span class=\"h3\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraindications to WBI include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ileus, bowel obstruction, or intestinal perforation",
"     </li>",
"     <li>",
"      Clinically significant GI hemorrhage",
"     </li>",
"     <li>",
"      Hemodynamic instability (concern for sequestration of bowel and worsening of shock)",
"     </li>",
"     <li>",
"      Intractable emesis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18993897\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no dose-response studies for WBI, but a consensus recommendation regarding dosing is as follows",
"    <sup>",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Children nine months to six years: 500",
"      <span class=\"nowrap\">",
"       mL/hr",
"      </span>",
"     </li>",
"     <li>",
"      Children 6 to 12 years: 1000",
"      <span class=\"nowrap\">",
"       mL/hr",
"      </span>",
"     </li>",
"     <li>",
"      Adolescents and adults: 1500 to 2000",
"      <span class=\"nowrap\">",
"       mL/hr",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    WBI is continued until the rectal effluent is clear. Radiographic studies may be useful in some circumstances (eg, iron ingestion, body packing) to confirm the absence of residual toxin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18993904\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients tolerate poorly the large volume of fluid that must be taken orally to effectively perform WBI. In many cases, nasogastric tube placement is necessary for PEG-ES administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18993911\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a paucity of published data regarding complications associated with WBI. GI complaints including nausea, vomiting, cramping, and bloating are relatively common",
"    <sup>",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients with vomiting and an unprotected airway are at risk of aspiration, but this has not been reported as a direct result of WBI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26756209\">",
"    <span class=\"h3\">",
"     Evidence of efficacy and adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whole bowel irrigation (WBI) may be useful for patients who have ingested extended-release or enteric-coated tablets, particularly when patients present more than two hours after ingestion and therefore are not likely to benefit from charcoal administration. Volunteer data suggest that WBI is effective in some cases, but may interfere with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (AC) when administered concurrently [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One volunteer study examining the effect of WBI on extended release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    absorption as well as the transit time of radiopaque markers found that WBI did not significantly reduce systemic drug absorption but did lead to a clustering of markers in the right hemicolon in the majority of test subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/37\">",
"     37",
"    </a>",
"    ]. The significance of the latter finding remains unclear.",
"   </p>",
"   <p>",
"    There is a dearth of high quality evidence supporting the use of WBI, with case series comprising the majority of studies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/3\">",
"     3",
"    </a>",
"    ]. In one study, statistical analysis of blood concentrations of 71 patients poisoned with extended-release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    found that WBI, when administered with AC, reduced the total absorbed fraction of drug by 29 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18993923\">",
"    <span class=\"h2\">",
"     Gastric lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric lavage",
"    <strong>",
"    </strong>",
"    (GL) refers to the passage of a large bore orogastric tube followed by repetitive instillation and aspiration of small aliquots of fluid in an attempt to aspirate pill fragments or other toxins from within the stomach. Referred to as &ldquo;stomach pumping&rdquo; by the lay public, this formerly widespread modality has been largely abandoned due to unclear benefit (particularly when compared with other readily available and less invasive techniques) and the risk of serious complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18993937\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Association of Poison Centers (AAPC) and the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) have issued a joint statement that gastric lavage should not be employed routinely, if ever, in the management of poisoned patients",
"    <sup>",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/39\">",
"     39",
"    </a>",
"    ]. However, there are rare cases (eg, recent and potentially lethal ingestion) where the procedure may be considered after carefully weighing the well-documented risks against the unclear benefits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18993930\">",
"    <span class=\"h3\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;GL is contraindicated in the following cases:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Unprotected airway",
"     </li>",
"     <li>",
"      Caustic ingestion (due to risk of exacerbating any esophageal or gastric injury)",
"     </li>",
"     <li>",
"      Hydrocarbon ingestion (due to high aspiration risk)",
"     </li>",
"     <li>",
"      Patients at risk of GI hemorrhage or perforation (recent surgery, underlying anatomic abnormality or pathology, coagulopathy)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18993944\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications associated with GL are significant and include the following: aspiration pneumonia, esophageal or gastric perforation, laryngospasm, hypoxia, dysrhythmia, and fluid or electrolyte imbalance [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/39\">",
"     39",
"    </a>",
"    ]. GL may also propel toxins that were to be removed past the pylorus, potentially facilitating systemic absorption and decreasing the effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    <sup>",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26756451\">",
"    <span class=\"h3\">",
"     Evidence of efficacy and adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric lavage (GL), once a mainstay of emergency decontamination of poisoned patients, has been largely abandoned due to the effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (AC).",
"   </p>",
"   <p>",
"    The results of multiple studies call into question the effectiveness of GL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial of self-poisoned patients reported that 52 percent of radio opaque tablets the patients had been asked to swallow immediately prior to GL were retained in the GI tract, while 33 percent were propelled forward into the small bowel [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of poisoned patients, endoscopy performed immediately following gastric emptying revealed that 15 of 17 patients treated with GL (88 percent) had residual intragastric solid [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A volunteer study found that only 45 percent of ingested cobalt was recovered using GL [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When compared directly to AC or when used in conjunction with AC, GL generally does not provide added benefit according to the results of volunteer and clinical trials. Representative studies include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized controlled trial of 808 poisoned patients, symptomatic patients treated with gastric emptying (either ipecac or gastric lavage) had a fourfold increase in intubation rates and a two-fold increase in the rate of ICU admission compared to those receiving AC [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/20\">",
"       20",
"      </a>",
"      ]. GL was associated with a significantly increased risk of aspiration pneumonia.",
"     </li>",
"     <li>",
"      An observational study of 981 consecutive patients poisoned with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      compared outcomes among those treated with AC, AC plus GL, or no decontamination, in addition to N-acetylcysteine, and found no additional benefit from GL beyond that provided by AC alone [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a volunteer study comparing GL administered with AC versus administration of AC alone, no statistically significant differences in reduction of systemic absorption of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      were noted between the two groups [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results notwithstanding, there is evidence that a small subset of patients presenting early (within one hour of ingestion) may benefit from GL. In a randomized controlled trial comparing gastric emptying techniques (syrup of ipecac and GL) with AC, no significant differences were found between groups with respect to clinical deterioration or admission. However, subgroup analysis revealed that patients presenting within one hour of ingestion and treated with GL had a higher rate of clinical improvement than those receiving AC [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/44\">",
"     44",
"    </a>",
"    ]. A second trial using the same protocol produced similar results, but the group treated with gastric emptying included more severe overdoses and when the authors controlled for this difference GL appeared to be of less benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gastric lavage carries significant risks, which, given its questionable clinical benefit, usually outweigh arguments in favor of its use. In a randomized trial, patients treated with GL had higher rates of aspiration (9 percent versus 0 percent) and intubation compared to controls receiving AC [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/20\">",
"     20",
"    </a>",
"    ]. These findings are consistent with numerous published case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/39\">",
"     39",
"    </a>",
"    ]. Esophageal and gastric perforation represents another, albeit less common, risk of GL [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/39,44\">",
"     39,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18993956\">",
"    <span class=\"h2\">",
"     Endoscopy/surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic or surgical removal of poisons may be indicated when a life-threatening toxin has been ingested and cannot be effectively removed by less invasive means. Examples include lethal amounts of heavy metals or pharmacobezoars refractory to whole bowel irrigation. Surgical removal is indicated in patients exhibiting toxicity following ingestion of large cocaine packets (&ldquo;body packers&rdquo;). In most cases, endoscopy is not recommended for the removal of illicit drug packets due to the risk of packet rupture during extraction attempts",
"    <sup>",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12744?source=see_link\">",
"     \"Internal concealment of drugs of abuse (body packing)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11133018\">",
"    <span class=\"h2\">",
"     Outdated treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following modalities of GI decontamination have been used in the past but are",
"    <strong>",
"     no longer routinely recommended",
"    </strong>",
"    :",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18993963\">",
"    <span class=\"h3\">",
"     Syrup of Ipecac",
"    </span>",
"    &nbsp;&mdash;&nbsp;Previously a mainstay of prehospital and emergency department management of toxic ingestions, Syrup of Ipecac (SoI)-facilitated gastric emptying is no longer recommended by the American Academy of Clinical Toxicology (AACT), the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT), or the American Association of Pediatrics (AAP)",
"    <sup>",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. A review of volunteer and clinical studies suggests that SoI is less effective at decreasing systemic absorption than activated charcoal (AC)",
"    <sup>",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/12,49\">",
"     12,49",
"    </a>",
"    ], yields unpredictable and inconsistent results",
"    <sup>",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/41,50,51\">",
"     41,50,51",
"    </a>",
"    ], and has an increased risk of adverse effects including delayed administration of more effective decontamination measures",
"    <sup>",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/24\">",
"     24",
"    </a>",
"    ] and higher rates of aspiration",
"    <sup>",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18993978\">",
"    <span class=\"h3\">",
"     Cathartics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cathartics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39140?source=see_link\">",
"     magnesium citrate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    ) are intended to decrease poison absorption by enhancing rectal evacuation of toxins or the poison-AC complex. The AACT and EAPCCT advise against the use of cathartics as single agent therapy, and the combination of cathartic and AC (eg, AC and sorbitol) should be used sparingly, if at all, and limited to a single dose",
"    <sup>",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16297/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18993761\">",
"     'Activated charcoal'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Adverse effects associated with cathartic use include increased abdominal pain, nausea, vomiting, excessive diarrhea, dehydration, and electrolyte abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18993989\">",
"    <span class=\"h3\">",
"     Dilution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dilution was historically recommended following the ingestion of acidic or alkaline corrosives to decrease the concentration and, thus, the tissue damage from the ingestion. This approach is problematic and we recommend that it not be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18994094\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization&rsquo;s list of international poison centers (",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18994101\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of adults with toxic ingestions have an uncomplicated course and recover fully with supportive care. The use of techniques to reduce absorption of poisons by gastrointestinal (GI) decontamination must be guided by the potential severity of the poisoning, the time from ingestion, and the potential risk to the patient of the interventions considered. In addition, the availability of an effective antidote substantially reduces the importance of decontamination.",
"   </p>",
"   <p>",
"    While various decontamination procedures can reduce blood concentrations of some ingested poisons, there are few data demonstrating that use of these procedures reduces morbidity or mortality. Given these considerations, we suggest the following guidelines for decontamination:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A protected airway (ie, patient is alert with intact airway reflexes or is intubated) is essential prior to initiation of any GI decontamination procedure.",
"     </li>",
"     <li>",
"      Patients may benefit from the administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"       activated charcoal",
"      </a>",
"      (AC) in a single dose of 1",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      (maximum dose 50 g), particularly if given within one to two hours of ingestion.",
"     </li>",
"     <li>",
"      AC should be withheld in situations where clinical benefit is not expected, including:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Nontoxic ingestions",
"     </li>",
"     <li>",
"      Patients who present when poison absorption is considered complete",
"     </li>",
"     <li>",
"      Poisons not bound by AC (",
"      <a class=\"graphic graphic_table graphicRef77553 \" href=\"UTD.htm?4/37/4700\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Patients whose risk of complications (eg, aspiration) is unacceptably high.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A cathartic (eg, 1",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      of 70 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"       sorbitol",
"      </a>",
"      ) may be administered with the initial dose of AC. Cathartics should not be used as monotherapy, and repeated doses are",
"      <strong>",
"       not",
"      </strong>",
"      recommended.",
"     </li>",
"     <li>",
"      Whole bowel irrigation is reserved for patients who have ingested toxic foreign bodies (eg, drug packets), sustained release or enteric-coated drugs, or toxic materials not bound by AC (eg, heavy metals).",
"     </li>",
"     <li>",
"      Gastric lavage is",
"      <strong>",
"       not",
"      </strong>",
"      recommended for routine decontamination. Rarely, gastric lavage may be helpful if the patient has ingested a toxic amount of a poison and the procedure can be performed within one hour of ingestion. When performed, gastric lavage should be followed by AC administration, unless the agent ingested is not adsorbed by AC.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/1\">",
"      Chyka PA, Seger D, Krenzelok EP, et al. Position paper: Single-dose activated charcoal. Clin Toxicol (Phila) 2005; 43:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/2\">",
"      Position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol 1999; 37:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/3\">",
"      Position paper: whole bowel irrigation. J Toxicol Clin Toxicol 2004; 42:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/4\">",
"      Olkkola KT. Effect of charcoal-drug ratio on antidotal efficacy of oral activated charcoal in man. Br J Clin Pharmacol 1985; 19:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/5\">",
"      West L. Innovative approaches to the administration of activated charcoal in pediatric toxic ingestions. Pediatr Nurs 1997; 23:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/6\">",
"      Gwilt PR, Perrier D. Influence of \"thickening\" agents on the antidotal efficacy of activated charcoal. Clin Toxicol 1976; 9:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/7\">",
"      Minocha A, Herold DA, Bruns DE, Spyker DA. Effect of activated charcoal in 70% sorbitol in healthy individuals. J Toxicol Clin Toxicol 1984; 22:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/8\">",
"      Cooper GM, Le Couteur DG, Richardson D, Buckley NA. A randomized clinical trial of activated charcoal for the routine management of oral drug overdose. QJM 2005; 98:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/9\">",
"      Merigian KS, Blaho KE. Single-dose oral activated charcoal in the treatment of the self-poisoned patient: a prospective, randomized, controlled trial. Am J Ther 2002; 9:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/10\">",
"      Decker WJ, Combs HF, Corby DG. Adsorption of drugs and poisons by activated charcoal. Toxicol Appl Pharmacol 1968; 13:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/11\">",
"      Minocha A, Herold DA, Barth JT, et al. Activated charcoal in oral ethanol absorption: lack of effect in humans. J Toxicol Clin Toxicol 1986; 24:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/12\">",
"      Neuvonen PJ, Vartiainen M, Tokola O. Comparison of activated charcoal and ipecac syrup in prevention of drug absorption. Eur J Clin Pharmacol 1983; 24:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/13\">",
"      Neuvonen PJ, Elonen E. Effect of activated charcoal on absorption and elimination of phenobarbitone, carbamazepine and phenylbutazone in man. Eur J Clin Pharmacol 1980; 17:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/14\">",
"      Lapatto-Reiniluoto O, Kivist&ouml; KT, Neuvonen PJ. Activated charcoal alone and followed by whole-bowel irrigation in preventing the absorption of sustained-release drugs. Clin Pharmacol Ther 2001; 70:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/15\">",
"      Crome P, Dawling S, Braithwaite RA, et al. Effect of activated charcoal on absorption of nortriptyline. Lancet 1977; 2:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/16\">",
"      Tenenbein M, Cohen S, Sitar DS. Efficacy of ipecac-induced emesis, orogastric lavage, and activated charcoal for acute drug overdose. Ann Emerg Med 1987; 16:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/17\">",
"      Green R, Grierson R, Sitar DS, Tenenbein M. How long after drug ingestion is activated charcoal still effective? J Toxicol Clin Toxicol 2001; 39:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/18\">",
"      Yeates PJ, Thomas SH. Effectiveness of delayed activated charcoal administration in simulated paracetamol (acetaminophen) overdose. Br J Clin Pharmacol 2000; 49:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/19\">",
"      Sato RL, Wong JJ, Sumida SM, et al. Efficacy of superactivated charcoal administered late (3 hours) after acetaminophen overdose. Am J Emerg Med 2003; 21:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/20\">",
"      Merigian KS, Woodard M, Hedges JR, et al. Prospective evaluation of gastric emptying in the self-poisoned patient. Am J Emerg Med 1990; 8:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/21\">",
"      Hult&eacute;n BA, Adams R, Askenasi R, et al. Activated charcoal in tricyclic antidepressant poisoning. Hum Toxicol 1988; 7:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/22\">",
"      Spiller HA, Winter ML, Klein-Schwartz W, Bangh SA. Efficacy of activated charcoal administered more than four hours after acetaminophen overdose. J Emerg Med 2006; 30:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/23\">",
"      Buckley NA, Whyte IM, O'Connell DL, Dawson AH. Activated charcoal reduces the need for N-acetylcysteine treatment after acetaminophen (paracetamol) overdose. J Toxicol Clin Toxicol 1999; 37:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/24\">",
"      Kornberg AE, Dolgin J. Pediatric ingestions: charcoal alone versus ipecac and charcoal. Ann Emerg Med 1991; 20:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/25\">",
"      Harchelroad F, Cottington E, Krenzelok EP. Gastrointestinal transit times of a charcoal/sorbitol slurry in overdose patients. J Toxicol Clin Toxicol 1989; 27:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/26\">",
"      Isbister GK, Downes F, Sibbritt D, et al. Aspiration pneumonitis in an overdose population: frequency, predictors, and outcomes. Crit Care Med 2004; 32:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/27\">",
"      Moll J, Kerns W 2nd, Tomaszewski C, Rose R. Incidence of aspiration pneumonia in intubated patients receiving activated charcoal. J Emerg Med 1999; 17:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/28\">",
"      Ilkhanipour K, Yealy DM, Krenzelok EP. The comparative efficacy of various multiple-dose activated charcoal regimens. Am J Emerg Med 1992; 10:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/29\">",
"      Mauro LS, Mauro VF, Brown DL, Somani P. Enhancement of phenytoin elimination by multiple-dose activated charcoal. Ann Emerg Med 1987; 16:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/30\">",
"      Park GD, Goldberg MJ, Spector R, et al. The effects of activated charcoal on digoxin and digitoxin clearance. Drug Intell Clin Pharm 1985; 19:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/31\">",
"      Neuvonen PJ, Elonen E, Mattila MJ. Oral activated charcoal and dapsone elimination. Clin Pharmacol Ther 1980; 27:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/32\">",
"      Eddleston M, Juszczak E, Buckley NA, et al. Study protocol: a randomised controlled trial of multiple and single dose activated charcoal for acute self-poisoning. BMC Emerg Med 2007; 7:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/33\">",
"      de Silva HA, Fonseka MM, Pathmeswaran A, et al. Multiple-dose activated charcoal for treatment of yellow oleander poisoning: a single-blind, randomised, placebo-controlled trial. Lancet 2003; 361:1935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/34\">",
"      Atkinson SW, Young Y, Trotter GA. Treatment with activated charcoal complicated by gastrointestinal obstruction requiring surgery. BMJ 1992; 305:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/35\">",
"      Goulbourne KB, Cisek JE. Small-bowel obstruction secondary to activated charcoal and adhesions. Ann Emerg Med 1994; 24:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/36\">",
"      Gomez HF, Brent JA, Munoz DC 4th, et al. Charcoal stercolith with intestinal perforation in a patient treated for amitriptyline ingestion. J Emerg Med 1994; 12:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/37\">",
"      Ly BT, Schneir AB, Clark RF. Effect of whole bowel irrigation on the pharmacokinetics of an acetaminophen formulation and progression of radiopaque markers through the gastrointestinal tract. Ann Emerg Med 2004; 43:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/38\">",
"      Kumar VV, Oscarsson S, Friberg LE, et al. The effect of decontamination procedures on the pharmacokinetics of venlafaxine in overdose. Clin Pharmacol Ther 2009; 86:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/39\">",
"      Vale JA, Kulig K, American Academy of Clinical Toxicology, European Association of Poisons Centres and Clinical Toxicologists. Position paper: gastric lavage. J Toxicol Clin Toxicol 2004; 42:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/40\">",
"      Saetta JP, March S, Gaunt ME, Quinton DN. Gastric emptying procedures in the self-poisoned patient: are we forcing gastric content beyond the pylorus? J R Soc Med 1991; 84:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/41\">",
"      Saetta JP, Quinton DN. Residual gastric content after gastric lavage and ipecacuanha-induced emesis in self-poisoned patients: an endoscopic study. J R Soc Med 1991; 84:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/42\">",
"      Tandberg D, Diven BG, McLeod JW. Ipecac-induced emesis versus gastric lavage: a controlled study in normal adults. Am J Emerg Med 1986; 4:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/43\">",
"      Christophersen AB, Levin D, Hoegberg LC, et al. Activated charcoal alone or after gastric lavage: a simulated large paracetamol intoxication. Br J Clin Pharmacol 2002; 53:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/44\">",
"      Kulig K, Bar-Or D, Cantrill SV, et al. Management of acutely poisoned patients without gastric emptying. Ann Emerg Med 1985; 14:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/45\">",
"      Pond SM, Lewis-Driver DJ, Williams GM, et al. Gastric emptying in acute overdose: a prospective randomised controlled trial. Med J Aust 1995; 163:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/46\">",
"      Trent MS, Kim U. Cocaine packet ingestion. Surgical or medical management? Arch Surg 1987; 122:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/47\">",
"      Position paper: Ipecac syrup. J Toxicol Clin Toxicol 2004; 42:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/48\">",
"      American Academy of Pediatrics Committee on Injury, Violence, and Poison Prevention. Poison treatment in the home. American Academy of Pediatrics Committee on Injury, Violence, and Poison Prevention. Pediatrics 2003; 112:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/49\">",
"      Curtis RA, Barone J, Giacona N. Efficacy of ipecac and activated charcoal/cathartic. Prevention of salicylate absorption in a simulated overdose. Arch Intern Med 1984; 144:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/50\">",
"      Auerbach PS, Osterloh J, Braun O, et al. Efficacy of gastric emptying: gastric lavage versus emesis induced with ipecac. Ann Emerg Med 1986; 15:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/51\">",
"      Tandberg D, Wood DA. Ipecac-induced emesis and gastric lavage are equally unpleasant. Vet Hum Toxicol 1988; 30:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/52\">",
"      Albertson TE, Derlet RW, Foulke GE, et al. Superiority of activated charcoal alone compared with ipecac and activated charcoal in the treatment of acute toxic ingestions. Ann Emerg Med 1989; 18:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16297/abstract/53\">",
"      Position paper: cathartics. J Toxicol Clin Toxicol 2004; 42:243.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 321 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-D8E73D39BC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_58_16297=[""].join("\n");
var outline_f15_58_16297=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18994101\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18993739\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18993746\">",
"      APPROACH TO GASTROINTESTINAL DECONTAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18993753\">",
"      METHODS OF DECONTAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18993761\">",
"      Activated charcoal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18993776\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18993783\">",
"      - Contraindications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18993795\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18993802\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18993809\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26755739\">",
"      - Evidence of efficacy and adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H26755393\">",
"      Activated charcoal: Volunteer data",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H26755400\">",
"      Activated charcoal: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H26755407\">",
"      Activated charcoal: Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18993821\">",
"      Multidose activated charcoal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18993828\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18993835\">",
"      - Contraindications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18993842\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18993853\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18993860\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26755899\">",
"      - Evidence of efficacy and adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18993876\">",
"      Whole bowel irrigation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18993883\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18993890\">",
"      - Contraindications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18993897\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18993904\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18993911\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26756209\">",
"      - Evidence of efficacy and adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18993923\">",
"      Gastric lavage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18993937\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18993930\">",
"      - Contraindications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18993944\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26756451\">",
"      - Evidence of efficacy and adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18993956\">",
"      Endoscopy/surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11133018\">",
"      Outdated treatments",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18993963\">",
"      - Syrup of Ipecac",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18993978\">",
"      - Cathartics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18993989\">",
"      - Dilution",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18994094\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18994101\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/321\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/321|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/37/4700\" title=\"table 1\">",
"      Agents for which activated charcoal is not recommended",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=related_link\">",
"      Approach to the child with occult toxic exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/19/11577?source=related_link\">",
"      Carbamazepine poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=related_link\">",
"      Decontamination of poisoned children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43047?source=related_link\">",
"      Initial management of the critically ill adult with an unknown overdose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12744?source=related_link\">",
"      Internal concealment of drugs of abuse (body packing)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/16/13578?source=related_link\">",
"      Theophylline poisoning",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_58_16298="Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation";
var content_f15_58_16298=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/58/16298/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/58/16298/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/58/16298/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/58/16298/contributors\">",
"     Nelson J Chao, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/58/16298/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/58/16298/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/58/16298/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with malignancy who undergo hematopoietic cell transplantation (HCT) will attain a complete remission. However, many of these patients will have residual disease that is too small to detect using conventional techniques (ie, minimal residual disease) that puts them at risk of eventual relapse. Relapse ultimately occurs in 40 to 75 percent of patients who undergo an autologous HCT and 10 to 40 percent of those who undergo an allogeneic HCT. Discontinuation of immunosuppression followed by immunotherapy with donor lymphocyte infusion (DLI) may be used to treat relapse after allogeneic HCT. Other methods of immunotherapy (eg, interleukin-2, interferon alpha, dendritic cell vaccination) are under investigation for the prevention of or treatment of relapse following autologous or allogeneic HCT.",
"   </p>",
"   <p>",
"    The rationale for using immunotherapy to prevent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treat the reemergence of malignancy is based in part upon the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rates of leukemia relapse are much higher in patients who have received identical twin (syngeneic) transplants compared with HLA-identical sibling transplants administered with identical cytotoxic treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/1\">",
"       1",
"      </a>",
"      ]. This suggests that a graft-versus-tumor (GVT) effect plays a major role in reducing the risk of relapse following an allogeneic HCT. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link&amp;anchor=H4#H4\">",
"       \"Donor selection for hematopoietic cell transplantation\", section on 'Identical twin donors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who develop acute or chronic graft-versus-host disease (GVHD), particularly chronic GVHD, have a lower risk of relapse [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/2,3\">",
"       2,3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The withdrawal of immunosuppression among patients with relapsing chronic myeloid leukemia after HCT may rarely result in cytogenetic remission occurring in association with GVHD [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/4\">",
"       4",
"      </a>",
"      ]. A similar effect has been described in a patient with relapsing chronic lymphocytic leukemia [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The infusion of donor leukocytes into patients who have relapsed following an allogeneic HCT has directly resulted in a GVT effect, especially in CML and certain subsets of lymphoma. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Donor lymphocyte infusions'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The infusion of T cell depleted grafts is associated with a higher incidence of graft failure and disease relapse. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24792?source=see_link&amp;anchor=H9#H9\">",
"       \"Prevention of acute graft-versus-host disease: Trials of T cell depletion\", section on 'T cell dose'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic review discusses the use of immunotherapy to prevent and treat relapse following HCT. The basic principles underlying the pathogenesis of the GVT effect after HCT are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/43/44729?source=see_link\">",
"     \"Biology of the graft-versus-tumor effect following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term \"hematopoietic cell transplantation\" (HCT) will be used throughout this review as a general term to cover transplantation of progenitor cells from any source (eg, bone marrow, peripheral blood, cord blood). Otherwise, the source of such cells will be specified (eg, autologous peripheral blood progenitor cell transplantation). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DONOR LYMPHOCYTE INFUSIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discontinuation of immunosuppression followed by donor lymphocyte infusion (DLI) may be used to treat patients with relapse following an",
"    <strong>",
"     allogeneic",
"    </strong>",
"    HCT. While responses to the rapid tapering of immunosuppression alone have been noted [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/4,5\">",
"     4,5",
"    </a>",
"    ], responses are relatively rare unless followed by DLI.",
"   </p>",
"   <p>",
"    The efficacy of DLI has been pivotal in demonstrating the role of graft-versus-tumor (GVT) reactions in controlling hematologic malignancy. Since the initial reports in the 1980s, a number of studies have documented that reinfusion of unmanipulated leukocytes results in significant clinical responses in relapsed patients, particularly those with chronic myeloid leukemia (CML) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/6\">",
"     6",
"    </a>",
"    ]. Responses have also been noted in lymphoma, acute myeloid leukemia (AML), myelodysplastic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/7\">",
"     7",
"    </a>",
"    ], and multiple myeloma (MM), but are rare in acute lymphoblastic leukemia (ALL) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/8\">",
"     8",
"    </a>",
"    ]. DLI is not without side effects. Approximately 60 percent of patients receiving a DLI will develop graft-versus-host disease (GVHD). The use of DLI should be avoided in patients with ongoing active GVHD and in patients who have converted to host (rather than donor) chimerism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33066?source=see_link&amp;anchor=H24#H24\">",
"     \"Hematopoietic cell transplantation in chronic myeloid leukemia\", section on 'Treatment: donor lymphocyte infusion'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/51/29498?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of relapsed or refractory acute myeloid leukemia\", section on 'Donor lymphocyte infusion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    DLI may also help with engraftment in the setting of mixed chimerism post-HCT. One report described a child with homozygous sickle cell disease who was developing increasing mixed chimerism following allogeneic HCT from an HLA-identical sibling [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/9\">",
"     9",
"    </a>",
"    ]. The use of DLI was associated with easily treated acute GVHD, and resulted in full donor chimerism with reversal of his anemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30775?source=see_link&amp;anchor=H9#H9\">",
"     \"Hematopoietic cell transplantation in sickle cell disease\", section on 'Donor lymphocyte infusion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the mechanism by which DLI results in clinical responses is unclear, it is presumed to be a T cell-mediated process. Further analysis of larger numbers of patients is critical to fully understand the mechanisms involved in this response.",
"   </p>",
"   <p>",
"    Some data suggest that DLI normalizes the T cell receptor (TCR) repertoire and expands the antileukemic cell population. In one study, for example, the TCR repertoire was analyzed before and after DLI among four patients with relapsed chronic myeloid leukemia (CML) and 10 normal controls [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/10\">",
"     10",
"    </a>",
"    ]. Initially, the patients' repertoire was characterized by a large number of oligoclonal and clonal patterns, while all controls had a polyclonal pattern. Following infusion of CD4+ lymphocytes, these abnormal patterns slowly normalized over the ensuing several months; by one year, all four patients had an almost normal TCR repertoire. In each patient, expansion of at least one TCR subfamily coincided with the time of disappearance of Philadelphia chromosome-positive cells.",
"   </p>",
"   <p>",
"    These findings provide evidence of clonal expansion of allogeneic T cells that may be selective mediators of the antileukemic effect. In another study, patients with relapsed CML responding to DLI generated potent antibody responses to CML-associated antigens, suggesting the development of coordinated T- and B-cell immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of donor lymphocyte infusion (DLI) varies with the underlying malignancy, the dose of infused lymphocytes, and the degree of host lymphodepletion. Outcomes are best for patients with chronic phase chronic myeloid leukemia (CML) followed by patients with lymphoma, multiple myeloma, and acute leukemia (mostly acute myeloid leukemia). Initial studies also suggest that the presence of host-derived regulatory T cells decreases the antitumor effect [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/12\">",
"     12",
"    </a>",
"    ]. Patients who respond to DLI will usually demonstrate a clinical response within two to three months, but a full response may take one year or longer [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/13\">",
"     13",
"    </a>",
"    ]. Responses can be durable with reports of responses lasting up to 20 years.",
"   </p>",
"   <p>",
"    Data regarding the efficacy of donor lymphocyte infusions (DLI) come primarily from small case series and two large retrospective studies from Europe and North America:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The European Group for Blood and Marrow Transplantation reported the results with DLI obtained from 84 patients with chronic myeloid leukemia (CML), 23 with acute myeloid leukemia (AML) and 22 with acute lymphoblastic leukemia (ALL) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/14\">",
"       14",
"      </a>",
"      ]. In this retrospective analysis, 73 percent of patients with relapsed CML had a complete remission after DLI. Remissions, whether defined by molecular or hematologic criteria, were durable. Patients with AML and ALL did not respond as well, as only 29 and zero percent developed a complete remission, respectively.",
"      <br/>",
"      <br/>",
"      DLI treatment was associated with substantial toxicity: 41 percent developed clinically significant GVHD; 41 percent suffered from myelosuppression; and 13 percent died of causes other than their underlying malignancy.",
"     </li>",
"     <li>",
"      A second retrospective analysis (from 25 North American programs) reported the outcomes after DLI in 140 allogeneic transplant patients who relapsed [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/15\">",
"       15",
"      </a>",
"      ]. A response rate of 60 percent was observed for patients with CML. The responses were superior in patients with only cytogenetic relapse or for those treated with DLI while in chronic phase, compared with those who had progressed to either accelerated or blast phases. As in the European study, the results were not as favorable among patients with AML or ALL (15 and 18 percent complete response, respectively). Complications included GVHD (60 percent) and pancytopenia (19 percent).",
"     </li>",
"     <li>",
"      Successful responses to DLI have also been described in multiple myeloma [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/15-19\">",
"       15-19",
"      </a>",
"      ]. As an example, a retrospective study of 63 patients with relapsed or refractory myeloma following non-myeloablative allogeneic HCT reported an overall response rate of 38 percent (19 percent complete) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/19\">",
"       19",
"      </a>",
"      ]. Acute and chronic GVHD were seen in 38 and 43 percent, respectively. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/28/36296?source=see_link&amp;anchor=H11#H11\">",
"       \"Allogeneic hematopoietic cell transplantation in multiple myeloma\", section on 'Donor lymphocyte infusion'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The decreased response of relapsed acute leukemia to DLI may be due to the more rapid proliferative capacity of malignant cells, since a full response to DLI often requires months. As a result, some clinicians have advocated the use of chemotherapy to first debulk the disease prior to DLI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/20\">",
"     20",
"    </a>",
"    ]. Other clinicians have advocated the use of DLI in patients with acute leukemia and minimal residual disease following HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/21\">",
"     21",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 57 patients with AML, CML, or myelodysplastic syndrome (MDS) relapsing after allogeneic transplant received cytarabine-based chemotherapy, followed by G-CSF-primed DLI without prophylactic immunosuppression [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/20\">",
"       20",
"      </a>",
"      ]. Toxicity was appreciable, with a 56 percent incidence of GVHD; treatment-related mortality and two-year overall survival rates were 23 and 19 percent, respectively. Multivariate analysis indicated that those with a post-transplant remission of &ge;6 months had a relative odds of remission following this treatment approach of 3.7 (95% CI: 1.1-12). Patients with a complete response or no response to this treatment had one-year survival rates of 51 and 5 percent, respectively.",
"     </li>",
"     <li>",
"      In another study, 814 patients with standard-risk AML, ALL, or MDS who received allogeneic HCT in first or second complete remission were assessed for minimal residual disease (MRD) to determine eligibility for prophylactic DLI [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/21\">",
"       21",
"      </a>",
"      ]. Patients with MRD were eligible for DLI if they had a donor available and had no evidence of active GVHD (56 patients). Patients with MRD who did not have a donor were treated with interleukin-2 (IL-2, 49 patients). When compared with IL-2, DLI resulted in superior rates of disease-free (56 versus 24 percent) and overall (58 versus 28 percent) survival at three years. This compared to rates of disease-free and overall survival at three years of 62 versus 66 percent, respectively, in patients with no evidence of MRD after HCT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Responses to DLI can be remarkably durable. For example, in an analysis of 66 patients with CML who relapsed and received DLI, 67 percent achieved a molecular complete remission (CR) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/22\">",
"     22",
"    </a>",
"    ]. For those patients achieving a molecular CR, 95 percent were alive and in continuous CR at three years following DLI. Similar results have been reported by others [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1037110845\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main complications following DLI are the emergence of graft-versus-host disease and myelosuppression. DLI should be avoided in patients with ongoing active GVHD and in patients who have converted to host (rather than donor) chimerism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Risk of GVHD after DLI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The infusion of unmanipulated donor leukocytes produces graft-versus-host disease (GVHD) in 40 to 60 percent of recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The rate appears to be independent of the underlying disorder, but may increase as the dose of DLI increases. The association between DLI and GVHD is further complicated by the difficulty in knowing when to treat GVHD after it occurs, since the graft-versus-host effect is clearly related to a concurrent graft-versus-tumor (GVT) response [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/15,16,26-28\">",
"     15,16,26-28",
"    </a>",
"    ]. However, some patients have developed a GVT response without GVHD, thereby suggesting that these two effects may be separable in some individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/43/44729?source=see_link&amp;anchor=H18#H18\">",
"     \"Biology of the graft-versus-tumor effect following hematopoietic cell transplantation\", section on 'Possible separation of GVT from GVHD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple approaches have been tried to limit the risk of GVHD following DLI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cell dose &mdash; The number of infused cells has been varied to attempt to find a dose that has effective antileukemic properties but does not cause significant GVHD. In one study of patients with chronic myeloid leukemia (CML) who relapsed following a T-cell depleted transplant, a dose of 1 x 10",
"      <sup>",
"       7",
"      </sup>",
"      CD3+ T",
"      <span class=\"nowrap\">",
"       cells/kg",
"      </span>",
"      resulted in excellent antileukemic efficacy without causing significant GVHD [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/29\">",
"       29",
"      </a>",
"      ]. It is unknown whether this dose has a similar effect in patients who relapse following a non-T cell-depleted transplant. (See",
"      <a class=\"local\" href=\"#H1112077615\">",
"       'Administration'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Depletion of CD8+ T cells or enrichment of CD4+ T cells [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/30,31\">",
"       30,31",
"      </a>",
"      ] &mdash; In one study, defined numbers of CD4+ donor T cells were infused in 40 patients who had relapsed following an allogeneic HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/30\">",
"       30",
"      </a>",
"      ]. GVHD developed in 32 percent of patients who received 0.3 x 10",
"      <sup>",
"       8",
"      </sup>",
"      CD4+",
"      <span class=\"nowrap\">",
"       cells/kg",
"      </span>",
"      compared with 55 percent of those who received at least 1 x 10",
"      <sup>",
"       8",
"      </sup>",
"      CD4+",
"      <span class=\"nowrap\">",
"       cells/kg.",
"      </span>",
"      The disease response was excellent, particularly among those who received the cell infusions for relapse of CML when treated in early chronic phase (78 percent molecular response rate). In addition, 48 percent of the responding patients never developed GVHD.",
"     </li>",
"     <li>",
"      Infusion of modified leukocytes &mdash; Attempts have been made to modify the donor leukocytes to make them susceptible to certain drugs, thereby permitting them to be eradicated upon the development of GVHD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In one study, donor lymphocytes were transfected with the herpes simplex virus thymidine kinase (HSV-TK) gene, which renders cells sensitive to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/32\">",
"       32",
"      </a>",
"      ]. Eight patients who had either relapsed or developed an EBV-associated lymphoma were treated. Antitumor responses were noted in five individuals. Three patients subsequently developed GVHD which could be controlled with ganciclovir. Immunologic responses to the transgenes (ie, HSV-TK) may limit the utility of this approach [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/33\">",
"       33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In another study, donor T cells were genetically altered to contain a fusion caspase 9 protein that could induce apoptosis upon exposure to a synthetic dimerizing drug [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/34\">",
"       34",
"      </a>",
"      ]. Five patients who had undergone HCT for relapsed acute leukemia were treated with the genetically modified T cells. The dimerizing drug was administered to four patients who developed GVHD, which resulted in elimination of 90 percent of the modified T cells within 30 minutes and resolution of the GVHD within 48 hours. An advantage of this strategy is the rapid response and use of a dimerizing agent that is not a therapeutic drug (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      ) as in the case of HSV-TK induced T cells above.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Host lymphodepletion &mdash; Lymphodepletion of the host prior to DLI, performed in an effort to promote in vivo expansion and immune activation of the infused lymphocytes, resulted in significantly",
"      <strong>",
"       more",
"      </strong>",
"      acute GVHD with greater GVHD lethality [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ex vivo expansion of antigen-specific T cells &mdash; Experimental mouse models have demonstrated that infusion of antigen-specific T cells may eradicate residual tumor with minimal or no GVHD [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]. Methods of generating substantial numbers of antigen-specific T cells ex vivo that are capable of establishing a reservoir of functional antigen-specific T cell in vivo are exciting but need further study in humans [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/38\">",
"       38",
"      </a>",
"      ]. Natural killer cells and cytokine-induced killer cells do not appear to cause GVHD [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H1037110556\">",
"       'Expanded and activated T cells'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Other complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The other major complications of DLI are myelosuppression and, occasionally, aplasia. Aplasia has been primarily observed in patients with little or no evidence of donor hematopoiesis (as defined by the presence of donor CD34+ cells) at the time of DLI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/41\">",
"     41",
"    </a>",
"    ]. Therefore, prior to the use of DLI, chimerism studies should be performed. If the recipient has converted to host (rather than donor) chimerism, DLI should not be used or only with extreme caution as it may result in significant pancytopenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1112077615\">",
"    <span class=\"h2\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ideal dose and timing of DLI is not known and clinical practice varies.",
"   </p>",
"   <p>",
"    Donor mononuclear cells are collected by apheresis from the related or unrelated donor that provided the original hematopoietic stem cell graft. Outside of a clinical trial, these cells are infused into the recipient without prior manipulation. Published studies have reported doses ranging from 0.01 x 10",
"    <sup>",
"     8",
"    </sup>",
"    T",
"    <span class=\"nowrap\">",
"     cells/kg",
"    </span>",
"    to 8.8 x 10",
"    <sup>",
"     8",
"    </sup>",
"    T",
"    <span class=\"nowrap\">",
"     cells/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/13\">",
"     13",
"    </a>",
"    ]. Cell doses less than 1 x 10",
"    <sup>",
"     8",
"    </sup>",
"    T",
"    <span class=\"nowrap\">",
"     cells/kg",
"    </span>",
"    appear to be suboptimal and doses above 4.5 x 10",
"    <sup>",
"     8",
"    </sup>",
"    T",
"    <span class=\"nowrap\">",
"     cells/kg",
"    </span>",
"    do not appear to improve response and may result in higher rates of GVHD. As such, doses between 3 x 10",
"    <sup>",
"     7",
"    </sup>",
"    T",
"    <span class=\"nowrap\">",
"     cells/kg",
"    </span>",
"    and 4.5 x 10",
"    <sup>",
"     8",
"    </sup>",
"    T",
"    <span class=\"nowrap\">",
"     cells/kg",
"    </span>",
"    appear reasonable. When determining the dose to be used, the clinician should take into consideration the underlying hematologic malignancy and the doses used in trials of DLI in patients with that malignancy. If there is no clinical response by three months post-DLI, a second DLI infusion may be considered. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Risk of GVHD after DLI'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    It is unclear whether a DLI should be administered upon the identification of molecular relapse or whether the clinician should wait for the emergence of a hematologic relapse. Theoretically, DLI may be more effective when there is less disease burden to eradicate. To address this issue, some clinicians have advocated the use of chemotherapy to first debulk the disease prior to DLI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/20\">",
"     20",
"    </a>",
"    ]. Another approach may be to administer DLI to patients with relapse detected by highly sensitive molecular probes, a condition predictive of eventual clinical relapse (particularly if persistently positive and found more than six months after transplantation) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/42\">",
"     42",
"    </a>",
"    ]. In this setting, one approach would be to use low dose DLI (ie, 10",
"    <sup>",
"     7",
"    </sup>",
"    <span class=\"nowrap\">",
"     cells/kg),",
"    </span>",
"    which has been associated with reduced risk of GVHD. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Risk of GVHD after DLI'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12073?source=see_link&amp;anchor=H16#H16\">",
"     \"Remission criteria in acute myeloid leukemia and monitoring for residual disease\", section on 'Relapsed disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41225?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of the treatment of chronic myeloid leukemia\", section on 'Monitoring response'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1037110883\">",
"    <span class=\"h2\">",
"     Manipulated grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various techniques have been used to manipulate the donor lymphocyte graft in an effort to increase the lymphocyte specificity to eradicate tumor while minimizing effects on the host. As yet, these techniques are considered experimental and require further study in humans before they can be widely applied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1037110556\">",
"    <span class=\"h3\">",
"     Expanded and activated T cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methods of generating substantial numbers of antigen-specific T cells that are capable of providing a graft-versus-tumor response and minimal graft-versus-host disease are exciting, but experimental [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/43-49\">",
"     43-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    T cells can be activated with stimulation through the T cell receptor followed by the addition of cytokines such as IL-2 or co-stimulation with anti-CD28. Using anti-CD3, IFN-gamma and IL-2 results primarily in the activation and expansion of CD8 T cells capable of recognizing and killing tumor cell targets through an NKG2D mediated mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/43\">",
"     43",
"    </a>",
"    ]. These cells, termed cytokine induced killer (CIK) cells can be expanded from patients with malignancies and shown to kill autologous tumor targets [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. A phase I trial using this approach has been performed in patients with lymphoma who have relapsed following autologous HCT, demonstrating that the approach is technically feasible and well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/46\">",
"     46",
"    </a>",
"    ]. Studies following both autologous and allogeneic HCT are ongoing.",
"   </p>",
"   <p>",
"    Co-stimulatory T cells activated with",
"    <span class=\"nowrap\">",
"     anti-CD3/CD28",
"    </span>",
"    beads results in the activation and expansion primarily of CD4+ T cells. These cells have been extensively studied in vitro and in animal models.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, adoptive transfer of the co-stimulated T cells was technically feasible, well tolerated and associated with favorable outcomes following autologous HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second study in 50 patients with multiple myeloma undergoing autologous HCT, such treatment was well tolerated with no effect on hematopoietic recovery [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/48\">",
"       48",
"      </a>",
"      ]. However, a T-cell \"engraftment syndrome\" clinically and histopathologically indistinguishable from GVHD was noted in one-sixth of the patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A similar study was performed in 18 patients relapsing after allogeneic HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/50\">",
"     50",
"    </a>",
"    ]. For those patients with active disease, chemotherapy was given prior to the infusion of the cellular therapy. Patients first received conventional DLI followed 12 days later by",
"    <span class=\"nowrap\">",
"     CD3/CD28",
"    </span>",
"    activated DLI (aDLI) in a dose ranging from 10",
"    <sup>",
"     6",
"    </sup>",
"    to 10",
"    <sup>",
"     8",
"    </sup>",
"    cells. Seven patients developed acute GVHD and four patients developed chronic GVHD. Eight patients achieved CR (44 percent), including four patients who remain alive and free of disease a median of 23 months following the use of aDLI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1037110587\">",
"    <span class=\"h3\">",
"     Cytotoxic T lymphocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exquisite specificity of cytotoxic T lymphocytes (CTLs) has led investigators to attempt to isolate cells with significant antitumor activity (",
"    <a class=\"graphic graphic_table graphicRef52815 \" href=\"UTD.htm?20/60/21451\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef76786 \" href=\"UTD.htm?15/4/15435\">",
"     table 2",
"    </a>",
"    ). The technical feasibility and clinical effectiveness of infused CTLs remains to be established; this approach is the subject of ongoing clinical research. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The potential clinical efficacy of infused CTLs has been demonstrated in pilot studies directed against defined viral targets, such as cytomegalovirus and Epstein-Barr virus (EBV). These studies demonstrated that CTLs can be isolated, expanded, and used with clinical efficacy in vivo [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/51\">",
"       51",
"      </a>",
"      ]. In addition, CTLs that are active against EBV-infected cells derived from the donor have been used to treat patients who have EBV-associated lymphomas or are risk for such disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/52\">",
"       52",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/43/44729?source=see_link\">",
"       \"Biology of the graft-versus-tumor effect following hematopoietic cell transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Since EBV is frequently associated with Hodgkin lymphoma, this approach has been applied to patients with this disorder who have relapsed following autologous HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/53\">",
"       53",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"       \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A number of groups have attempted to develop cloned CTLs active against leukemic cells. In one study, for example, irradiated tumor cells from a patient with AML were used as stimulator cells, while the responder CTLs were derived from the peripheral blood of the HLA-matched sibling. Several CTL lines were generated that specifically lysed these leukemic cells in vitro [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/54\">",
"       54",
"      </a>",
"      ]. The antigenic structures on the malignant cells were not identified.",
"     </li>",
"     <li>",
"      The exploitation of differences between donor and recipient with respect to minor histocompatibility antigens, structures recognized by CTLs, has been an area of intense research. In one report, CD8+ and CD4+ CTL clones that recognized the minor histocompatibility antigens HA-1 and HA-2 were isolated and characterized [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/55\">",
"       55",
"      </a>",
"      ]. These clones generally did not differentially recognize leukemic and nonleukemic cells; however, there was a differential GVT effect that may have been related to differences in susceptibility to lysis.",
"     </li>",
"     <li>",
"      Several groups have introduced novel receptors into T cells to redirect these cells to specific tumor targets such as CD19 for CLL, CD20 for B cell non-Hodgkin lymphoma and CD19 for ALL [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/56-58\">",
"       56-58",
"      </a>",
"      ]. These adoptively transferred T cells have not persisted for very long and a number of groups are exploring strategies to improve persistence of the cells. One approach has been to utilize sub-populations of T cells for modification, such as central memory T cells (chimeric antigen receptor T cells, CAR-T cells) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/59-64\">",
"       59-64",
"      </a>",
"      ]. As an example, two intriguing reports described three patients with relapsed or refractory CLL who received autologous T cells modified with a lentiviral vector expressing chimeric antigen receptor with specificity for CD19, coupled with CD137 and CD3-zeta signalling domains after a preparatory regimen [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/59,63\">",
"       59,63",
"      </a>",
"      ]. All three patients demonstrated a tumor response, which persisted in one for at least 10 months. Toxicity included severe tumor lysis syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1037111299\">",
"    <span class=\"h1\">",
"     GRANULOCYTE COLONY STIMULATING FACTOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small case series of treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) following relapse of leukemia after allogeneic HCT initially reported that a subset of patients achieved cytogenetic remission of leukemia and reestablishment of donor origin hematopoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/65\">",
"     65",
"    </a>",
"    ]. This and other studies reported a worsening of graft-versus-host disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]. The mechanism whereby G-CSF induces both remission as well as GVHD is not clear. Since responses are relatively rare and the risk of GVHD may be increased, this approach has not been further investigated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1037110280\">",
"    <span class=\"h1\">",
"     INTERLEUKIN-2",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of the cytokine interleukin-2 (IL-2) has been investigated as a method of potentially improving responses to autologous HCT. Interest in the use of IL-2 after autologous HCT was initially supported by the observation that IL-2 production is impaired following autologous HCT, but that peripheral blood cells isolated from patients who have undergone autologous HCT are still able to respond to this cytokine [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/68\">",
"     68",
"    </a>",
"    ]. IL-2 has been administered in the post-HCT setting in an effort to enhance the antitumor activity of hematopoietic cells. Currently, IL-2 therapy is experimental and should therefore be employed only in the context of a clinical trial.",
"   </p>",
"   <p>",
"    A number of phase I and II clinical trials evaluating the use of recombinant IL-2 to treat patients with or without relapse of malignancy following HCT have been performed. Impressive disease-free survival has been reported in some, but not all, studies of patients with acute myeloid leukemia (AML) and non-Hodgkin lymphoma (NHL) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/69-71\">",
"     69-71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase II study from the City of Hope National Medical Center followed 56 patients with acute myeloid leukemia (AML) in first complete remission treated with IL-2 at a dose of 9 x 10",
"      <sup>",
"       6",
"      </sup>",
"      <span class=\"nowrap\">",
"       units/meter(2)",
"      </span>",
"      per day for four days, followed by 10 days of IL-2 at a dose of 1.6 x 10",
"      <sup>",
"       6",
"      </sup>",
"      <span class=\"nowrap\">",
"       units/meter(2)",
"      </span>",
"      per day following recovery from autologous transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/72\">",
"       72",
"      </a>",
"      ]. This treatment was reasonably well tolerated, with 68 percent of the patients receiving the intended doses. At a median follow-up of 39 months, patients who received HCT and IL-2 had superior disease-free survival (74 versus 68 percent).",
"     </li>",
"     <li>",
"      In another series, 56 patients with NHL and Hodgkin lymphoma (HL) were treated with a combination of IL-2 (3 to 6",
"      <span class=\"nowrap\">",
"       IU/m2",
"      </span>",
"      per day) and interferon alfa (IFNa, three million units per day) for five days per week over a period of four weeks following HCT or peripheral blood stem cell transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/71\">",
"       71",
"      </a>",
"      ]. Although toxicity was significant (86 percent developed grade II to III level toxicity), adverse effects were tolerated and largely resolved following termination of IL-2 and IFNa therapy. The patients treated with IL-2 plus IFNa had, compared with the historical controls, a significantly higher rate of survival at 48 months (90 versus 46 percent) and a higher rate of complete remission (80 percent at a median follow-up of 34 months compared with 53 percent of historically treated patients at a median follow-up of 23 months). This approach is currently under evaluation in a randomized clinical trial.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, not all studies have found a survival benefit with IL-2. In a study of adults with acute lymphocytic leukemia (ALL) who underwent autologous HCT, 60 patients were randomized to therapy with or without IL-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/73\">",
"     73",
"    </a>",
"    ]. The three-year probability of complete remission was the same in the two groups (approximately 28 percent). A randomized trial conducted through the Southwest Oncology Group (SWOG) comparing IL-2 with no further therapy following autologous HCT for patients with non-Hodgkin lymphoma did not show benefit for the administration of this cytokine in the dose and schedule utilized [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is possible that these discordant results are related to the underlying disease, dose,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    schedule of the administration of IL-2. These data underscore the concept that mechanisms of GVT may be disease-specific, requiring the evaluation of effectiveness in various diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1037111163\">",
"    <span class=\"h1\">",
"     INTERFERON ALFA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferon alfa (IFNa) is another type of immunotherapy that has been used most commonly for patients with chronic myeloid leukemia (CML) in whom treatment is begun early following a cytogenetic relapse after allogeneic HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. In one study of 14 such patients, IFNa was given daily (1 to 3 million",
"    <span class=\"nowrap\">",
"     units/m2",
"    </span>",
"    per day) until cytogenetic remission was obtained, at which time the dose was lowered for maintenance therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/75\">",
"     75",
"    </a>",
"    ]. Eight patients (57 percent) have remained in complete remission for periods ranging from at least 10 to 54 months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27111?source=see_link\">",
"     \"Interferon alpha for the treatment of chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to promising results with the use of tyrosine kinase inhibitors for the treatment of CML, it is unclear what the role of IFNa is in the setting of early relapsed CML. Some have used IFNa [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/77\">",
"     77",
"    </a>",
"    ] or IL-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/78\">",
"     78",
"    </a>",
"    ] and DLI for those individuals not responding to DLI alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20762?source=see_link\">",
"     \"Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ANTIGEN-PULSED DENDRITIC CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial studies of vaccination using dendritic cells (DCs) have demonstrated promise, but further study is needed before this approach can be offered to the greater population. DCs are macrophage-like antigen presenting cells that play a major role in the induction of an immune-mediated response. DCs can be isolated by a variety of methods:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They can be obtained from the peripheral blood, particularly following treatment with certain cytokines, such as Flt3-ligand.",
"     </li>",
"     <li>",
"      They can be expanded in culture from CD34+ progenitor cells in the presence of cytokines, including granulocyte-macrophage colony-stimulating factor, IL-4, tumor necrosis factor, Flt3-ligand, and CD40 ligand (L).",
"     </li>",
"     <li>",
"      They can be obtained by culturing B cells in the presence of CD40L, thereby resulting in the dramatic expansion of cells capable of antigen presentation which express the required costimulatory molecules [",
"      <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ability to successfully isolate and expand DCs (or professional antigen presenting cells), which express all of the molecules required for a productive immunologic reaction, permits investigators to introduce experimental antigens into these cells, possibly inducing an effective immune response to a malignancy. The in vivo application of DCs has been successfully explored in murine model systems.",
"   </p>",
"   <p>",
"    Clinical trials have been reported using DCs pulsed with tumor-specific idiotype proteins in patients with follicular lymphomas and multiple myeloma not undergoing transplant. As an example, a report of four patients with follicular non-Hodgkin lymphoma treated with DCs pulsed with tumor-associated idiotype protein, followed by subcutaneous injection of the soluble antigen reported in vitro antitumor cellular responses, significant reductions in tumor mass were noted in two patients, and resolution of molecular disease in a third patient [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Responses to DC vaccination have been seen in a minority of patients with multiple myeloma who have undergone autologous transplantation, but a survival advantage has not yet been demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/81\">",
"     81",
"    </a>",
"    ]. As an example, one study included 20 patients with multiple myeloma who underwent reduced intensity conditioning allogeneic HCT with a partial T cell depleted graft followed by preemptive donor lymphocyte infusion and DC vaccination in six patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/82\">",
"     82",
"    </a>",
"    ]. None of the patients who received DC vaccination developed graft-versus-host disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/47/31482?source=see_link&amp;anchor=H18#H18\">",
"     \"Autologous hematopoietic cell transplantation in multiple myeloma\", section on 'Dendritic cell vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the appeal of this technique, technical and theoretical problems need to be addressed. These include the requirement for cell culturing, individualized therapy, HLA restriction of the peptide antigens, the best choice of DCs, method of expansion and activation, source of antigen (peptide, whole protein, tumor cell extract, genetic transfection), route of administration, and the immunologic competence of the recipient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     HLA MISMATCHED HEMATOPOIETIC CELL TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most centers, a complete match at the HLA-A, HLA-B (both class I) and HLA-DR loci (class II) is required for that individual to be used as a transplant donor, since mismatches at these loci are associated with a higher risk of severe GVHD and death, despite the possible induction of a graft-versus-tumor (GVT) effect.",
"   </p>",
"   <p>",
"    However, preliminary evidence in a small number of patients suggests that, using a nonmyeloablative conditioning regimen, with or without the use of donor lymphocyte infusion, transplantation across HLA barriers may result in mixed hemopoietic chimeras that have potent graft-versus-tumor effects without the induction of severe GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. In one study of five patients with refractory non-Hodgkin lymphoma, the use of such a strategy was associated with complete and partial clinical remission at 460 and 103 days after HCT in two patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/83\">",
"     83",
"    </a>",
"    ]; neither patient developed graft-versus-host disease (GVHD). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link&amp;anchor=H7#H7\">",
"     \"Donor selection for hematopoietic cell transplantation\", section on 'Mismatched related donors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another approach has been to use myeloablative conditioning and haploidentical donors. In these transplants it was reasoned that some donor recipient pairs may be mismatched at class I HLA resulting in the usual loss of inhibition of natural killer cells, which are typically controlled through binding of class I molecules and killer inhibitory receptors (KIR). In these studies it was found that NK cells are some of the first immunological cells to recover following this type of transplantation and those patients who had the opportunity for alloreactivity due to the HLA disparity of the donor and recipient had a markedly reduced risk of disease recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/85\">",
"     85",
"    </a>",
"    ]. This beneficial impact of potentially alloreactive NK cells has not been seen in all studies, however [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The concept of NK cell alloreactivity and the finding that NK cells do not cause GVHD (due to yet unexplained reasons) led to the approach of adoptive therapy with NK cells across HLA barriers. Such a trial has been initiated with haploidentical NK cells in patients with cancer. Interestingly, some patients with AML responded and the use of these cells did not result in either significant toxicity or GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?15/58/16298/abstract/87\">",
"     87",
"    </a>",
"    ]. Further studies using this innovative approach are warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of patients with malignancy who undergo hematopoietic cell transplantation (HCT) will attain a complete remission, but relapse will occur in 40 to 75 percent of patients who undergo an autologous HCT and 10 to 40 percent of those who undergo an allogeneic HCT. Immunotherapy takes advantage of the innate graft-versus-tumor effect following allogeneic HCT to prevent or treat relapse following HCT. The preemptive use of immunotherapy remains experimental. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Discontinuation of immunosuppression followed by unmanipulated donor lymphocyte infusion (DLI) may be used to treat patients with relapse following an allogeneic HCT. Response varies with hematologic malignancy being highest with chronic myeloid leukemia. Responses have also been noted in lymphoma, acute myeloid leukemia, and multiple myeloma, but are rare in acute lymphoblastic leukemia. A clinical response is usually seen within two to three months, but a full response may take one year or longer. Responses can be durable, lasting up to 20 years. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main complications following DLI are the emergence of graft-versus-host disease (GVHD) and myelosuppression. DLI should be avoided in patients with ongoing active GVHD and in patients who have converted to host (rather than donor) chimerism. (See",
"      <a class=\"local\" href=\"#H1037110845\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ideal dose and timing of DLI is not known and clinical practice varies. Doses between 3 x 10",
"      <sup>",
"       7",
"      </sup>",
"      T",
"      <span class=\"nowrap\">",
"       cells/kg",
"      </span>",
"      and 4.5 x 10",
"      <sup>",
"       8",
"      </sup>",
"      T",
"      <span class=\"nowrap\">",
"       cells/kg",
"      </span>",
"      appear reasonable. If there is no clinical response by three months post-DLI, a second DLI infusion may be considered. DLI may be most effective at the first sign of relapse. (See",
"      <a class=\"local\" href=\"#H1112077615\">",
"       'Administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Various techniques have been used to manipulate the donor lymphocyte graft in an effort to increase the lymphocyte specificity to eradicate tumor while minimizing effects on the host. As yet, these techniques are considered experimental and require further study in humans before they can be widely applied. (See",
"      <a class=\"local\" href=\"#H1037110883\">",
"       'Manipulated grafts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other experimental methods of immunotherapy include the use of granulocyte colony stimulating factor, interleukin-2, interferon alfa, antigen-pulsed dendritic cell vaccination, and HLA mismatched HCT. (See",
"      <a class=\"local\" href=\"#H1037111299\">",
"       'Granulocyte colony stimulating factor'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1037110280\">",
"       'Interleukin-2'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1037111163\">",
"       'Interferon alfa'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'HLA mismatched hematopoietic cell transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/1\">",
"      Gale RP, Horowitz MM, Ash RC, et al. Identical-twin bone marrow transplants for leukemia. Ann Intern Med 1994; 120:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/2\">",
"      Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 300:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/3\">",
"      Weiden PL, Sullivan KM, Flournoy N, et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/4\">",
"      Elmaagacli AH, Beelen DW, Trenn G, et al. Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 23:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/5\">",
"      Mehta J, Powles R, Singhal S, et al. Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: possible role of graft-versus-leukemia. Bone Marrow Transplant 1996; 17:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/6\">",
"      Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004; 103:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/7\">",
"      Depil S, Deconinck E, Milpied N, et al. Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome. Bone Marrow Transplant 2004; 33:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/8\">",
"      MacKinnon S. Who may benefit from donor leucocyte infusions after allogeneic stem cell transplantation? Br J Haematol 2000; 110:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/9\">",
"      Baron F, Dresse MF, Beguin Y. Donor lymphocyte infusion to eradicate recurrent host hematopoiesis after allogeneic BMT for sickle cell disease. Transfusion 2000; 40:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/10\">",
"      Claret EJ, Alyea EP, Orsini E, et al. Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion. J Clin Invest 1997; 100:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/11\">",
"      Wu CJ, Yang XF, McLaughlin S, et al. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest 2000; 106:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/12\">",
"      Baba J, Watanabe S, Saida Y, et al. Depletion of radio-resistant regulatory T cells enhances antitumor immunity during recovery from lymphopenia. Blood 2012; 120:2417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/13\">",
"      Deol A, Lum LG. Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited. Cancer Treat Rev 2010; 36:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/14\">",
"      Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86:2041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/15\">",
"      Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/16\">",
"      Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997; 90:4206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/17\">",
"      Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000; 18:3031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/18\">",
"      Salama M, Nevill T, Marcellus D, et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 2000; 26:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/19\">",
"      van de Donk NW, Kr&ouml;ger N, Hegenbart U, et al. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2006; 37:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/20\">",
"      Levine JE, Braun T, Penza SL, et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 2002; 20:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/21\">",
"      Yan CH, Liu DH, Liu KY, et al. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood 2012; 119:3256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/22\">",
"      Dazzi F, Szydlo RM, Cross NC, et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000; 96:2712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/23\">",
"      Russell NH, Byrne JL, Faulkner RD, et al. Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant 2005; 36:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/24\">",
"      Porter DL, Collins RH Jr, Hardy C, et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000; 95:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/25\">",
"      Shiobara S, Nakao S, Ueda M, et al. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome. Bone Marrow Transplant 2000; 26:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/26\">",
"      Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008; 112:4371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/27\">",
"      Barrett AJ. Understanding and harnessing the graft-versus-leukaemia effect. Br J Haematol 2008; 142:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/28\">",
"      Martino R, Caballero MD, P&eacute;rez-Sim&oacute;n JA, et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 2002; 100:2243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/29\">",
"      Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/30\">",
"      Alyea EP, Soiffer RJ, Canning C, et al. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998; 91:3671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/31\">",
"      Giralt S, Hester J, Huh Y, et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995; 86:4337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/32\">",
"      Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997; 276:1719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/33\">",
"      Berger C, Flowers ME, Warren EH, Riddell SR. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 2006; 107:2294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/34\">",
"      Di Stasi A, Tey SK, Dotti G, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011; 365:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/35\">",
"      Miller JS, Weisdorf DJ, Burns LJ, et al. Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone. Blood 2007; 110:2761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/36\">",
"      Fontaine P, Roy-Proulx G, Knafo L, et al. Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease. Nat Med 2001; 7:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/37\">",
"      Meunier MC, Delisle JS, Bergeron J, et al. T cells targeted against a single minor histocompatibility antigen can cure solid tumors. Nat Med 2005; 11:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/38\">",
"      Wang X, Berger C, Wong CW, et al. Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice. Blood 2011; 117:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/39\">",
"      Cooley S, McCullar V, Wangen R, et al. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 2005; 106:4370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/40\">",
"      Introna M, Borleri G, Conti E, et al. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica 2007; 92:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/41\">",
"      Keil F, Haas OA, Fritsch G, et al. Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: lack of residual donor hematopoiesis predicts aplasia. Blood 1997; 89:3113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/42\">",
"      Radich JP, Gehly G, Gooley T, et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995; 85:2632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/43\">",
"      Verneris MR, Karami M, Baker J, et al. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 2004; 103:3065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/44\">",
"      Alvarnas JC, Linn YC, Hope EG, Negrin RS. Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2001; 7:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/45\">",
"      Linn YC, Lau LC, Hui KM. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol 2002; 116:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/46\">",
"      Leemhuis T, Wells S, Scheffold C, et al. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005; 11:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/47\">",
"      Laport GG, Levine BL, Stadtmauer EA, et al. Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood 2003; 102:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/48\">",
"      Rapoport AP, Stadtmauer EA, Aqui N, et al. Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells. Clin Cancer Res 2009; 15:4499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/49\">",
"      Bornh&auml;user M, Thiede C, Platzbecker U, et al. Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia. Blood 2011; 117:7174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/50\">",
"      Porter DL, Levine BL, Bunin N, et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood 2006; 107:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/51\">",
"      Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/52\">",
"      Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995; 345:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/53\">",
"      Bollard CM, Aguilar L, Straathof KC, et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med 2004; 200:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/54\">",
"      Faber LM, van Luxemburg-Heijs SA, Willemze R, Falkenburg JH. Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J Exp Med 1992; 176:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/55\">",
"      Faber LM, van der Hoeven J, Goulmy E, et al. Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Clin Invest 1995; 96:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/56\">",
"      Cooper LJ, Al-Kadhimi Z, Serrano LM, et al. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood 2005; 105:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/57\">",
"      Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008; 112:2261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/58\">",
"      Brentjens RJ, Davila ML, Riviere I, et al. CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia. Sci Transl Med 2013; 5:177ra38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/59\">",
"      Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/60\">",
"      Brentjens RJ, Rivi&egrave;re I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011; 118:4817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/61\">",
"      Koehler P, Schmidt P, Hombach AA, et al. Engineered T cells for the adoptive therapy of B-cell chronic lymphocytic leukaemia. Adv Hematol 2012; 2012:595060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/62\">",
"      Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012; 119:2709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/63\">",
"      Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3:95ra73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/64\">",
"      Porter DL, Kalos M, Zheng Z, et al. Chimeric Antigen Receptor Therapy for B-cell Malignancies. J Cancer 2011; 2:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/65\">",
"      Giralt S, Escudier S, Kantarjian H, et al. Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med 1993; 329:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/66\">",
"      Law L, Tuscano J, Wun T, et al. Filgrastim treatment of acute myelogenous leukemia (M7) relapse after allogeneic peripheral stem cell transplantation resulting in both graft-versus-leukemia effect with cytogenetic remission and chronic graft-versus-host disease manifesting as polyserositis and subsequent bronchiolitis obliterans with organizing pneumonia. Int J Hematol 2002; 76:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/67\">",
"      Worth LL, Mullen CA, Choroszy M, et al. Treatment of leukemia relapse with recombinant granulocyte-macrophage colony stimulating factor (rhGM-CSF) following unrelated umbilical cord blood transplant: Induction of graft-vs.-leukemia. Pediatr Transplant 2002; 6:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/68\">",
"      Welte K, Ciobanu N, Moore MA, et al. Defective interleukin 2 production in patients after bone marrow transplantation and in vitro restoration of defective T lymphocyte proliferation by highly purified interleukin 2. Blood 1984; 64:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/69\">",
"      Benyunes MC, Massumoto C, York A, et al. Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 1993; 12:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/70\">",
"      Hamon MD, Prentice HG, Gottlieb DJ, et al. Immunotherapy with interleukin 2 after ABMT in AML. Bone Marrow Transplant 1993; 11:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/71\">",
"      Nagler A, Ackerstein A, Or R, et al. Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients postautologous marrow or stem cell transplantation. Blood 1997; 89:3951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/72\">",
"      Stein AS, O'Donnell MR, Slovak ML, et al. Interleukin-2 after autologous stem-cell transplantation for adult patients with acute myeloid leukemia in first complete remission. J Clin Oncol 2003; 21:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/73\">",
"      Attal M, Blaise D, Marit G, et al. Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group. Blood 1995; 86:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/74\">",
"      Thompson JA, Fisher RI, Leblanc M, et al. Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438). Blood 2008; 111:4048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/75\">",
"      Higano CS, Chielens D, Raskind W, et al. Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation. Blood 1997; 90:2549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/76\">",
"      Arcese W, Mauro FR, Alimena G, et al. Interferon therapy for Ph1 positive CML patients relapsing after T cell-depleted allogeneic bone marrow transplantation. Bone Marrow Transplant 1990; 5:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/77\">",
"      Leda M, Ladon D, Pieczonka A, et al. Donor lymphocyte infusion followed by interferon-alpha plus low dose cyclosporine A for modulation of donor CD3 cells activity with monitoring of minimal residual disease and cellular chimerism in a patient with first hematologic relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation. Leuk Res 2001; 25:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/78\">",
"      Slavin S, Naparstek E, Nagler A, et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87:2195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/79\">",
"      Schultze JL, Michalak S, Seamon MJ, et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 1997; 100:2757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/80\">",
"      Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/81\">",
"      Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study. Blood 1999; 93:2411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/82\">",
"      Levenga H, Schaap N, Maas F, et al. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma. Biol Blood Marrow Transplant 2010; 16:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/83\">",
"      Sykes M, Preffer F, McAfee S, et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 1999; 353:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/84\">",
"      Dey BR, McAfee S, Colby C, et al. Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol 2005; 128:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/85\">",
"      Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295:2097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/86\">",
"      Davies SM, Ruggieri L, DeFor T, et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 2002; 100:3825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/58/16298/abstract/87\">",
"      Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105:3051.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3552 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-189A616C48-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_58_16298=[""].join("\n");
var outline_f15_58_16298=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DONOR LYMPHOCYTE INFUSIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1037110845\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Risk of GVHD after DLI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Other complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1112077615\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1037110883\">",
"      Manipulated grafts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1037110556\">",
"      - Expanded and activated T cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1037110587\">",
"      - Cytotoxic T lymphocytes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1037111299\">",
"      GRANULOCYTE COLONY STIMULATING FACTOR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1037110280\">",
"      INTERLEUKIN-2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1037111163\">",
"      INTERFERON ALFA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ANTIGEN-PULSED DENDRITIC CELLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      HLA MISMATCHED HEMATOPOIETIC CELL TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/3552\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/3552|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/60/21451\" title=\"table 1\">",
"      Effector cell populations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/4/15435\" title=\"table 2\">",
"      Cytotoxic T cell targets",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/28/36296?source=related_link\">",
"      Allogeneic hematopoietic cell transplantation in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/47/31482?source=related_link\">",
"      Autologous hematopoietic cell transplantation in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/43/44729?source=related_link\">",
"      Biology of the graft-versus-tumor effect following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=related_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33066?source=related_link\">",
"      Hematopoietic cell transplantation in chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30775?source=related_link\">",
"      Hematopoietic cell transplantation in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27111?source=related_link\">",
"      Interferon alpha for the treatment of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41225?source=related_link\">",
"      Overview of the treatment of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24792?source=related_link\">",
"      Prevention of acute graft-versus-host disease: Trials of T cell depletion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12073?source=related_link\">",
"      Remission criteria in acute myeloid leukemia and monitoring for residual disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20762?source=related_link\">",
"      Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/51/29498?source=related_link\">",
"      Treatment of relapsed or refractory acute myeloid leukemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_58_16299="Silicosis occupations";
var content_f15_58_16299=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Occupations associated with silicosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Underground coal mining",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Surface coal mining",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hard rock mining",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tunneling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Quarrying and stone cutting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foundry work",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Masonry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blast furnaces",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Steelworks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rolling and finishing mills",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sand blasting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Construction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Production or use of silica flour",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glass manufacturing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cement and concrete production",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ceramics production",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_58_16299=[""].join("\n");
var outline_f15_58_16299=null;
var title_f15_58_16300="Antigenic subtypes of influenza";
var content_f15_58_16300=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F52181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F52181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antigenic subtypes of influenza A virus associated with pandemics or epidemics",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Year",
"       </td>",
"       <td class=\"subtitle1\">",
"        Subtype",
"       </td>",
"       <td class=\"subtitle1\">",
"        Severity of outbreak",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1889-90",
"       </td>",
"       <td>",
"        H2N8*",
"       </td>",
"       <td>",
"        Severe pandemic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1900-03",
"       </td>",
"       <td>",
"        H3N8*",
"       </td>",
"       <td>",
"        Moderate epidemic, probable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1918-19",
"       </td>",
"       <td>",
"        H1N1, formerly HswN1",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Severe pandemic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1933-35",
"       </td>",
"       <td>",
"        H1N1, formerly H0N1",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Mild epidemic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1946-47",
"       </td>",
"       <td>",
"        H1N1",
"       </td>",
"       <td>",
"        Mild epidemic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1957-58",
"       </td>",
"       <td>",
"        H2N2",
"       </td>",
"       <td>",
"        Severe pandemic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1968-69",
"       </td>",
"       <td>",
"        H3N2",
"       </td>",
"       <td>",
"        Moderate pandemic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1977-78",
"       </td>",
"       <td>",
"        H1N1",
"       </td>",
"       <td>",
"        Mild pandemic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2009-10",
"       </td>",
"       <td>",
"        H1N1",
"       </td>",
"       <td>",
"        Mild to moderate pandemic",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * As determined by retrospective serologic survey of individuals alive during those years.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Hemagglutinins formerly designated as Hsw and H0 are now classified as variants of H1.",
"      <br>",
"       &Delta; During the 2009-2010 H1N1 influenza A pandemic, mortality was relatively high among individuals &lt;65 years of age and relatively low among those &ge;65 years of age. (Armstrong GL, Brammer L, Finelli L. Timely assessment of the severity of the 2009 H1N1 influenza pandemic. Clin Infect Dis 2011; 52 [Suppl 1]:S83.)",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data adapted from: Dolin R. Influenza. In: Harrison's Principles of Internal Medicine, 17th ed, Braunwald E, Fauci AS, Kasper DL, et al (Eds), McGraw Hill Book Company. New York 2008. p.1127.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_58_16300=[""].join("\n");
var outline_f15_58_16300=null;
var title_f15_58_16301="Specimens for anaerobic culture";
var content_f15_58_16301=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Specimens appropriate for anaerobic culture",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Specimen and collection method",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normally sterile body fluids",
"       </td>",
"       <td>",
"        Includes blood, pleural fluid, peritoneal fluid, bile, cerebrospinal fluid.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abscess contents",
"       </td>",
"       <td>",
"        Needle aspirates are preferred.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wound*",
"       </td>",
"       <td>",
"        Exudate, preferably collected by syringe aspiration using care to decontaminate the adjacent surface.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Pulmonary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pleural fluid",
"       </td>",
"       <td>",
"        Antecedent antibiotics will reduce yield.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Transtracheal aspirate*",
"       </td>",
"       <td>",
"        The only likely specimen source now is pleural fluid.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Transthoracic needle aspirate",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Thoracotomy specimen",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bronchoscopic aspirate*",
"       </td>",
"       <td>",
"        Requires",
"double-lumen catheter brush with distal occluding plug or",
"bronchoalveolar lavage, each combined with quantitative culture.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tracheostomy aspirate*",
"       </td>",
"       <td>",
"        Validity is not well established; one-third of patients",
"without evidence of infection yield anaerobes, and quantitative",
"cultures may be required.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Urinary tract",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"2\">",
"        Suprapubic aspirate",
"       </td>",
"       <td>",
"        Rare source of anaerobic infections.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suspect when positive Gram stain and negative culture.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Female genital tract",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Culdocentesis",
"       </td>",
"       <td>",
"        Experience is varied, seldom done now.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Specimens obtained above pelvic reflection at surgery or laparoscopy",
"       </td>",
"       <td>",
"        Seldom done.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Transabdominal needle aspirates of uterus",
"       </td>",
"       <td>",
"        Seldom done.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intrauterine brush using double catheter with a distal occluding plug*",
"       </td>",
"       <td>",
"        Requires quantitative culture; seldom done.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Intraabdominal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aspirates, biopsy specimens",
"       </td>",
"       <td>",
"        Specimen must be devoid of gastrointestinal flora.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Small bowel aspirate",
"       </td>",
"       <td>",
"        Quantitative culture is necessary to detect bacterial overgrowth syndromes.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Oral-dental",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aspirate of closed spaces",
"       </td>",
"       <td>",
"        Collected from endodontal canal and preferably transported in conditions that preserve hydration and anaerobiosis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Paper point specimen",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Paranasal sinuses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aspirate using catheter or syringe*",
"       </td>",
"       <td>",
"        Plastic catheter inserted into depths of sinus track is preferred.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Middle-ear aspirate",
"       </td>",
"       <td>",
"        Optimal specimens are obtained with intact tympanic membrane.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Soft tissue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aspirate of closed spaces, eg, abscesses",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Biopsies using 3-mm dermal punch*",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Because contamination with normal flora is common, broth cultures are inappropriate; interpretation is facilitated with quantitative or semiquantitative culture.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_58_16301=[""].join("\n");
var outline_f15_58_16301=null;
var title_f15_58_16302="Contents: Urinary tract infections";
var content_f15_58_16302=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?0/41/670\">",
"       Nephrology and Hypertension",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Urinary tract infections",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Urinary tract infections",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Asymptomatic bacteriuria",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/19/42295\">",
"           Approach to the adult with asymptomatic bacteriuria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/30/34278\">",
"           Emphysematous urinary tract infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/40/43657\">",
"           Urinary tract infections and asymptomatic bacteriuria in pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cystitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/47/10999\">",
"           Acute complicated cystitis and pyelonephritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/15/13561\">",
"           Acute uncomplicated cystitis and pyelonephritis in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/7/15479\">",
"           Acute uncomplicated cystitis, pyelonephritis, and asymptomatic bacteriuria in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/30/34278\">",
"           Emphysematous urinary tract infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/24/5514\">",
"           Recurrent urinary tract infection in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/24/44422\">",
"           Urinary tract infection associated with urethral catheters",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/40/43657\">",
"           Urinary tract infections and asymptomatic bacteriuria in pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Diagnosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/54/39777\">",
"           Clinical microbiology review: Genitourinary infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/41/24214\">",
"           Urine sampling and culture in the diagnosis of urinary tract infection in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/42/4776\">",
"           Acute bacterial prostatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/49/15128\">",
"           Candida infections of the bladder and kidneys",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/60/23496\">",
"           Chronic bacterial prostatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/51/14134\">",
"           Renal and perinephric abscess",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pathogenesis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/46/16102\">",
"           Bacterial adherence and other virulence factors for urinary tract infection",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pyelonephritis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/36/12868\">",
"           Asymptomatic bacteriuria in patients with diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/30/34278\">",
"           Emphysematous urinary tract infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/62/41961\">",
"           Management of vesicoureteral reflux",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/54/40802\">",
"           Pathogenesis and clinical manifestations of struvite stones",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/10/3242\">",
"           Presentation, diagnosis, and clinical course of vesicoureteral reflux",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/24/5514\">",
"           Recurrent urinary tract infection in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/40/43657\">",
"           Urinary tract infections and asymptomatic bacteriuria in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/26/16804\">",
"           Xanthogranulomatous pyelonephritis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Renal and systemic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/43/14005\">",
"           Renal disease in tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/44/4807\">",
"           Urinary tract infection in autosomal dominant polycystic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/6/20579\">",
"           Urinary tract infection in renal transplant recipients",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-667873D472-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f15_58_16302=[""].join("\n");
var outline_f15_58_16302=null;
var title_f15_58_16303="2002 TNM breast cancer";
var content_f15_58_16303=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F73355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F73355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    2002 TNM staging classification for breast cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Primary tumor (T)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TX",
"       </td>",
"       <td colspan=\"3\">",
"        Primary tumor cannot be assessed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T0",
"       </td>",
"       <td colspan=\"3\">",
"        No evidence of primary tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Tis",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"3\">",
"        Carcinoma in situ",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Tis (DCIS)",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Intraductal carcinoma in situ",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Tis (LCIS)",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Lobular carcinoma in situ",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Tis (Paget)",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Paget disease of the nipple with no tumor; tumor-associated Paget disease is classified according to the size of the primary tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        T1",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"3\">",
"        Tumor 2 cm or less in greatest dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T1mic",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Microinvasion 0.1 cm or less in greatest dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T1a",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Tumor more than 0.1 but not more than 0.5 cm in greatest dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T1b",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Tumor more than 0.5 cm but not more than 1 cm in greatest dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T1c",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Tumor more than 1 cm but not more than 2 cm in greatest dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T2",
"       </td>",
"       <td colspan=\"3\">",
"        Tumor more than 2 cm but not more than 5 cm in greatest dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T3",
"       </td>",
"       <td colspan=\"3\">",
"        Tumor more than 5 cm in greatest dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        T4*",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"3\">",
"        Tumor of any size with direct extension to (a) chest wall or (b) skin, only as described below:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T4a",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Extension to chest wall",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T4b",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Edema (including peau d'orange) or ulceration of the breast skin, or satellite skin nodules confined to the same breast",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T4c",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Both (T4a and T4b)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T4d",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Inflammatory carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Regional lymph nodes (N)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Clinical classification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        NX",
"       </td>",
"       <td colspan=\"3\">",
"        Regional lymph nodes cannot be assessed (eg, previously removed)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        N0",
"       </td>",
"       <td colspan=\"3\">",
"        No regional lymph node metastases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        N1",
"       </td>",
"       <td colspan=\"3\">",
"        Metastasis to movable ipsilateral axillary lymph node(s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        N2",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"3\">",
"        Metastasis to ipsilateral axillary lymph node(s) fixed or matted, or in clinically apparent ipsilateral internal mammary nodes in the absence of evident axillary node metastases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        N2a",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Metastasis to ipsilateral axillary lymph node(s) fixed to one another (matted) or to other structures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        N2b",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Metastasis only in clinically apparent (as detected by imaging studies [excluding lymphoscintigraphy] or by clinical examination or grossly visible pathologically) ipsilateral internal mammary nodes in the absence of evident axillary node metastases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        N3",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"3\">",
"        Metastasis to ipsilateral infraclavicular lymph node(s) with or without clinically evident axillary lymph nodes, or in clinically apparent ipsilateral internal mammary lymph node(s) and in the presence of clinically evident axillary lymph node metastases, or metastasis in ipsilateral supraclavicular lymph nodes with or without axillary or internal mammary nodal involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        N3a",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Metastasis to ipsilateral infraclavicular lymph node(s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        N3b",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Metastasis to ipsilateral internal mammary lymph node(s) and clinically apparent axillary lymph nodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        N3c",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Metastasis in ipsilateral supraclavicular lymph nodes with or without axillary or internal mammary nodal involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Pathologic classification",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        pNX",
"       </td>",
"       <td colspan=\"3\">",
"        Regional lymph nodes cannot be assessed (eg, previously removed, or not removed for pathologic study)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        pN0",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"3\">",
"        No regional lymph node metastasis; no additional examination for isolated tumor cells (ITCs, defined as single tumor cells or small clusters not greater than 0.2 mm, usually detected only by immunohistochemical or molecular methods but which may be verified on hematoxylin and eosin (H&amp;E) stains. ITCs do not usually show evidence of malignant activity [eg, proliferation or stromal reaction])",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        pN0(i-)",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        No histologic nodal metastases, and negative by immunohistochemistry (IHC)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        pN0(i+)",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        No histologic nodal metastases but positive by IHC, with no cluster greater than 0.2 mm in diameter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        pN0(mol-)",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        No histologic nodal metastases and negative molecular findings (by reverse transcriptase polymerase chain reaction, RT-PCR)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        pN0(mol+)",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        No histologic nodal metastases, but positive molecular findings (by RT-PCR)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        pN1",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"3\">",
"        Metastasis in 1 to 3 ipsilateral axillary lymph node(s) and/or in internal mammary nodes with microscopic disease detected by SLND but not clinically apparent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        pN1mi",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Micrometastasis (greater than 0.2 mm, none greater than 2.0 mm)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        pN1a",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Metastasis in 1 to 3 axillary lymph nodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        pN1b",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Metastasis to internal mammary lymph nodes with microscopic disease detected by SLND but not clinically apparent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        pN1c",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Metastasis in 1 to 3 ipsilateral axillary lymph node(s)",
"        <strong>",
"         and",
"        </strong>",
"        in internal mammary nodes with microscopic disease detected by SLND but not clinically apparent. If associated with more than 3 positive axillary nodes, the internal mammary nodes are classified as N3b to reflect increased tumor burden.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        pN2",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"3\">",
"        Metastasis in 4 to 9 axillary lymph nodes or in clinically apparent internal mammary lymph nodes in the",
"        <strong>",
"         absence",
"        </strong>",
"        of axillary lymph nodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        pN2a",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Metastases in 4 to 9 axillary lymph nodes (at least one tumor deposit &gt;2 mm)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        pN2b",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Metastasis in clinically apparent internal mammary lymph nodes in the absence of axillary lymph nodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        pN3",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"3\">",
"        Metastasis in 10 or more axillary lymph nodes, or in infraclavicular lymph nodes, or in clinically apparent ipsilateral internal mammary lymph nodes in the",
"        <strong>",
"         presence",
"        </strong>",
"        of one or more positive axillary nodes; or in more than three axillary lymph nodes with clinically negative microscopic metastasis in internal mammary lymph nodes; or in ipsilateral supraclavicular lymph node(s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        pN3a",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Metastasis in 10 or more axillary lymph nodes (at least one tumor deposit greater than 2.0 mm), or metastasis to the infraclavicular lymph nodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        pN3b",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Metastasis in clinically apparent ipsilateral internal mammary lymph nodes in the",
"        <strong>",
"         presence",
"        </strong>",
"        of one or more positive axillary nodes; or in more than three axillary lymph nodes with microscopic metastasis in internal mammary lymph nodes detected by SLND but not clinically apparent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        pN3c",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"3\">",
"        Metastasis in ipsilateral supraclavicular lymph node(s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Distant metastasis (M)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MX",
"       </td>",
"       <td colspan=\"3\">",
"        Distant metastasis cannot be assessed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M0",
"       </td>",
"       <td colspan=\"3\">",
"        No distant metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M1",
"       </td>",
"       <td colspan=\"3\">",
"        Distant metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Stage groupings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage 0",
"       </td>",
"       <td>",
"        Tis",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage I",
"       </td>",
"       <td>",
"        T1 (including T1mic)",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Stage IIA",
"       </td>",
"       <td>",
"        T0",
"       </td>",
"       <td>",
"        N1",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T1 (including T1mic)",
"       </td>",
"       <td>",
"        N1",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T2",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Stage IIB",
"       </td>",
"       <td>",
"        T2",
"       </td>",
"       <td>",
"        N1",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T3",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Stage IIIA",
"       </td>",
"       <td>",
"        T0",
"       </td>",
"       <td>",
"        N2",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T1 (including T1mic)",
"       </td>",
"       <td>",
"        N2",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T2",
"       </td>",
"       <td>",
"        N2",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T3",
"       </td>",
"       <td>",
"        N1",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T3",
"       </td>",
"       <td>",
"        N2",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IIIB",
"       </td>",
"       <td>",
"        T4",
"       </td>",
"       <td>",
"        N0-2",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IIIC",
"       </td>",
"       <td>",
"        Any T",
"       </td>",
"       <td>",
"        N3",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IV",
"       </td>",
"       <td>",
"        Any T",
"       </td>",
"       <td>",
"        Any N",
"       </td>",
"       <td>",
"        M1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Dimpling of the skin, nipple retraction, or any other skin change except those described for T4b and T4d may occur in T1-3 tumors without changing the classification.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Classification is based upon axillary lymph node dissection (ALND) with or without sentinel lymph node dissection (SLND). Classification based solely on SLND without ALND should be designated (sn) [eg, pN0(i+)(sn)].",
"    </div>",
"    <div class=\"reference\">",
"     AJCC Cancer Staging Manual, Sixth Edition (2002) published by Springer-Verlag New York, Inc. Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_58_16303=[""].join("\n");
var outline_f15_58_16303=null;
